










' ' {; 
Characterisation of Fibrinogen and 
Fibrin Proteolysis by the N eutrophil 
Membrane 
by 
Richard Kirsch MBChB 
A thesis submitted for the degree Doctor of Philosophy (Medicine) 




















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
m1 b IO k,, I f2.. S 
~1 ~144,1" 
Dedication 
To my family 
111 
Acknowledgements 
I would like to express my sincere appreciation to all who have 
contributed to the production of this thesis. In particular I would like 
to thank the following people. 
Professor Enid Shephard, who has given so generously of her time 
and expertise in supervising this thesis. Her dedication to her work 
and to her students has been an inspiration to me and to many others 
who have come before me. 
My father, who allowed me to work in his laboratory, and who has 
been such a wonderful role model both as a doctor and a scientist. 
His kindness, wisdom and eternal optimism guided me safely over 
the many obstacles of laboratory life. 
Vivienne Woodbume, my first my teacher, friend and co-worker in 
the lab, whose commitment and contribution to this project over the 
years has been enormous. Her laboratory and technical expertise and 
attention to detail led many improvements in the design of 
experimental procedures used in this study. This thesis also belongs 
to her. 
The members of UCT Electron microscope unit (EMU) who have 
helped me in so many ways. I am, in particular, indebted to 
Mohamed Jaffer for the enormous contribution that he made to this 
project as an electron microscopist par excellence, problem-solver, 
advisor and friend. I cannot thank him enough for all the time and 
energy he has spent helping me. I am also very grateful to Trevor 
Sewell, the head of the EMU, for taking such an active interest in my 
project, for treating me like a member of his unit (where I felt I had a 
second home), and for allowing me full access to his· unit including 
the use of his office! I am also grateful to William Williams, Miranda 
Waldron and Dane Gemeke for the help that they have given me. 
Joel Dave, my good friend, who has travelled the same road sharing 
the ups and downs of laboratory life along the way. He spent many 
IV 
months helping me with. the molecular biology side of my project, 
which he did with great patience and enthusiasm despite a busy 
schedule. His friendship and support has meant a great deal to me 
over the years. 
Peter Meissner for the many ways in which he helped me with my 
thesis and for constantly reminding me of the lighter side of the 
laboratory. Nothing has ever been too much trouble for Pete and I am 
grateful for his generosity, friendship and the early morning coffee 
visits whilst I was writing up! 
Mr Wells for running the laboratory so smoothly and for patiently 
fixing everything that I broke during my first year in the laboratory. 
His calm manner and his ability and to solve any problem made him 
the backbone our laboratory. 
Brent Jennings for patiently helping me when I ran into computer 
problems and for his friendship over the years. 
Lesley Frith and Val Hancock for keeping me supplied with purified 
human fibrinogen. 
Anne Corrigall, Ed Sturrock, Lutz Thilo, Mario Ehlers and Pauline 
Hall who, despite busy schedules, gave generously of their time and 
expertise, in advising me on various aspects of my project. 
Fikile Daki who, in addition to keeping me supplied with clean 
glassware and a spotless working environment, took the time to 
become my friend and to teach me Xhosa. Nangamso Madiba! 
The many people in the laboratory who have contributed to this 
thesis through useful discussions, technical assistance or the donation . 
of blood. In particular I am grateful to Susan Adams, Helen Botes, 
Vanessa Burch, Sandra Davids, Lester Davids, Brandon Davidson, 
Heather Epstein, Trevor Finch, Richard Hift, Sharon Kelly, Anwar 
Mall, Leslie Martin, Lavinia Petersen, Faiza Pearce, Mbulelo Maneli, 
Mogamat Samuels, Kwanele Siziba and Wendy Spearman. 
V 
Lastly, on a personal level, I would like to express my deep gratitude 
to my family. My parents have "lived" this thesis with me offering 
constant support and encouragement along the way, and never losing 
faith in me. Whilst writing up this thesis I was inspired by the 
beautiful Xhosa textbooks that my mother has written, from which I 
got many ideas on layout and design. I am also grateful to my 
brothers David and Derek who have been pillars of support over the 
years, as well as to my grandmother, my mother-in-law Pepsi, and 
my brother- and sister-in-law David and Debbi for all the 
encouragement they have given me. Thanks to Pepsi for generously 
supplying the paper on which this thesis is printed. Finally, I would 
like to thank Tanya, my wife, for the many sacrifices that she has 
made to enable me to undertake this project. This would not have 
been possible without her love, patience, support and understanding, 
for which I am deeply grateful. This thesis is dedicated to my family. 
VI 








The Neutrophil - Literature Review 
Neutrophil maturation 
















Membrane serine proteases 


























65-70 kDa protease 




Intercellular adhesion molecules 
Neutrophil-endothelial cell interaction 
Neutrophil-extracellular matrix interaction 
Neutrophil interaction with fibrinogen 
References 
Chapter Three 
Fibrinogen - Literature Review 
Structure 
Biosynthesis and regulation 
The fibrinogen gene 
Fibrinogen biosynthesis 
Regulation of fibrinogen synthesis 
Fibrin formation 
Thrombin cleavage of fibrinogen 
Non-covalent polymerisation 
Covalent crosslinking 
Plasmin mediated fibrin( ogen)olysis 
Plasminogen activators 
Plasminogen and plasmin 
Fibrin(ogen) degradation 


































































activity of the neutrophil membrane 127 
Study design 127 
Methods 128 
Results 
The effect of the specific elastase inhibitor 
Me0-Suc-(Ala)z-Pro-Val-CH2Cl 131 
Comparison of the fibrinogen degradation products 
generated by conditioned medium to those generated 
byHNE 134 
The contribution of cathepsin G to the fibrinogen 
degrading activity of the conditioned medium 13 7 
lX 
Comparison of the fibrinogen degradation products 
generated by the conditioned medium to those 
generated by granule proteases 140 
Identification of the apparent molecular mass of 
the membrane associated proteolytic activity 143 
Discussion 14 7 
Summary and conclusions 158 
References 15 8 
Chapter Six 
The localisation of neutrophil associated 




Immunoelectron microscopy 168 
Co localisation of fibrinogen and biotinylated 
bovine serum albumin (BSA) 172 
Uptake of [1251]-labelled fibrinogen and BSA 173 
Release of internalised fibrinogen 175 
Divalent cations and the uptake of fibrinogen 
and BSA 177 
Temperature dependence of the uptake of 
fibrinogen and BSA 179 
Neutrophil association with extensively degraded 
fibrinogen 181 
The effect of BSA on fibrinogen uptake 182 
Discussion 183 










Immunoelectron microscopy 202 
The effect of PMA on neutrophil mediated clot lysis 204 
The role of granule proteases in fibrin dissolution 209 
Discussion 212 
Summary and conclusions 217 
References 217 
Chapter Eight 
Summary and conclusions 
Appendices 
Appendix 1 - Chemicals and reagents 
Appendix 2 - Abbreviations 







Recent studies have identified a novel 600 kDa neutrophil 
membrane associated protease which degrades fibrinogen, fibrin and 
C-reactive protein (CRP) during incubation of these ligands with 
phorbol 12-myristate 13-acetate (PMA, 5-10 ng/ml) stimulated 
neutrophils. This proteolysis is predominantly an extracellular event 
which occurs through a ligand dependent release of this protease 
from the neutrophil. Degradation products arising from this 
proteolysis not only become neutrophil associated but influence a 
number of important processes occurring in inflammation and 
coagulation. The aim of the present 'study was to purify and further 
characterize this protease and investigate the location of the 
neutrophil associated fibrinogen and fibrin degradation products. 
Whilst enzyme purification procedures were unsuccessful, several 
observations made during these attempts suggested that the 
neutrophil membrane associated proteolytic activity displayed similar 
characteristics to proteases of the azurophil granule. The proteolytic 
activity of the membrane was concluded from inhibitor profiles, 
zymography, and the apparent molecular mass values and 
hydrophobicity of the fibrinogen degradation products that it 
generated, to be the composite action of the azurophil granule 
proteases, human neutrophil elastase, cathepsin G and possibly 
proteinase 3. Electron microscopy analysis of PMA stimulated 
neutrophils incorporated within fibrin clots revealed morphological 
changes suggestive of neutrophil degranulation, and the proteolytic 
activity released by these cells was shown to be identical to that of 
azurophil granule proteases with respect to the apparent molecular 
mass values of the fibrin products that it generated. Immunoelectron 
microscopy revealed minimal internalization of fibrin like material 
during this process suggesting that neutrophil mediated fibrinolysis 
under these conditions is predominantly an extracellular event. 
Immunoelectron microscopy was used to localise fibrinogen 
degradation products previously reported to be associated with the 
neutrophil following incubation with fibrinogen. This revealed 
xii 
neutrophil associated fibrinogen products to be intracellular. 
Internalisation appears to be the result of pinocytosis which is 
stimulated in the presence of PMA. Although internalisation may be 
enhanced by an initial interaction of fibrinogen with the neutrophil 
membrane, a large proportion of uptake occurs via the fluid phase. 
Both intact and degraded forms of fibrinogen can associate with the 
neutrophil. Internalised material is rapidly degraded intracellularly 
into low molecular weight products which are partially released into 
the surrounding medium. This intracellular degradation, however, 
contributes minimally to the overall degradation of fibrinogen by 
neutrophils; the major pathway is extracellular. 
The demonstration in this· study, that the previously identified 
fibrinogen- fibrin- and CRP-degrading activity of the neutrophil 
membrane is due to azurophil granule proteases co-incides with 
numerous recent reports suggesting that membrane bound forms of 
these proteases, due to their ability to evade naturally occurring 
protease inhibitors, are the biologically relevant forms of these 
proteases. The membrane expression of azurophil granule proteases 
has recently been shown to be under the control of a variety of 
inflammatory mediators. Thus, neutrophil mediated degradation of 
fibrinogen, fibrin and CRP in vivo may be tightly controlled by the 







Mammalian survival depends upon an innate immune system that 
can respond rapidly to infection without prior exposure to invading 
pathogens. Polymorphonuclear leukocytes (neutrophils) are central to 
this innate immune system and represent the first line of defence 
against bacterial infection. 1•3 Beyond their role as phagocytic cells, 
neutrophils can influence a variety of other biological processes. 
Their intimate association with fibrin thrombi has long been 
recognised,4"6 and it has become increasingly apparent that the 
coagulation and inflammation pathways are intimately linked. 7'8 
Leukocytes can regulate the coagulation pathway9•15 whilst 
coagulation proteins can modify the inflammatory response. 16"21 
During inflammation, neutrophils accumulate in affected tissues 
where they engulf invading pathogens and remove necrotic debris. 
This activates a number of potent mechanisms capable of destroying 
internalised microbes which are subsequently digested by proteolytic 
enzymes of the neutrophil granules. 1•3 The local release of 
inflammatory mediators may stimulate monocytes as well as 
endothelial cells to express tissue factor on their cell surfaces. 22 
Tissue factor triggers the coagulation cascade which culminates in 
the conversion of prothrombin to thrombin.23 Thrombin cleaves 
fibrinogen, the essential ingredient of the fibrin clot, which then 
polymerises to form the insoluble gel-like matrix, fibrin.24 Fibrin 
deposition is thus a frequent accompaniment of the acute 
inflammatory response and is thought to be important in the process 
of tissue repair.25 Neutrophils have also been found in intimate 
association with fibrin within the vascular compartment. 4"6 
Leukocytes frequently accumulate in complex thrombi, formed by 
fibrin and platelets, showing preferential accumulation relative to 
their concentration in the bloodstream.4 The ability of leukocytes to 
degrade fibrin clots has been noted since the turn of the century,26,27 
and it has been suggested that neutrophils may provide an alternative 
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fibrinolytic pathway to that mediated by plasmin.9 The ability of 
neutrophils to degrade fibrinogen and fibrin has been attributed to 
two proteases residing in the azurophil granules of neutrophils, 
namely human neutrophil elastase (HNE) and cathepsin G. 10,11,28,29 
Cleavage of fibrinogen by these proteases renders it non-clottable, 
and generates degradation products . with potent anticoagulant 
properties.9' 10 Such proteolysis may allow the neutrophil to regulate 
fibrin deposition at sites of inflammation. 
Whilst neutrophils are capable of influencing the coagulation system, 
so too may coagulation proteins modify the neutrophil inflammatory 
response. Neutrophils adherent to immobilised fibrinogen exhibit a 
much greater response to inflammatory stimuli than non-adherent 
neutrophils. 16,17,30 This interaction is regulated by a family of 
adhesion receptors, known as integrins, of which the B2- and B3-
integrin subfamilies can recognise specific peptide sequences on the 
fibrinogen molecule.31 "35 Ligation of these receptors by immobilised 
fibrinogen can signal for important neutrophil functions such as 
phagocytosis, respiratory burst and degranulation. 16' 17'30,36 In addition 
fibrin( ogen) products released during coagulation and fibrinolysis 
have been shown to influence neutrophil function. Plasmin- and 
HNE-derived fibrin degradation products, as well as the thrombin 
cleaved fibrinopeptide B, are chemotactic for neutrophils.20,21 ,37 On 
the other hand, plasmin derived fragments of fibrinogen have been 
reported to inhibit neutrophil respiratory burst, chemotaxis and 
adhesion. 18' 19 
The present study was stimulated by the identification of a neutrophil 
membrane protease capable of degrading fibrinogen and solubilising 
fibrin clots. 13' 14 This protease was shown by size exclusion 
chromatography to be 600 kDa in size and to be composed of at least 
4 subunits when subjected to SDS-PAGE.38 While stimulation of 
neutrophils with a low dose of PMA led to a partial release of this 
protease into the extracellular medium, incubation of intact 
neutrophils with substrates for this enzyme induced a time dependent 
egress of this proteolytic activity from the membrane. 13' 14,38 The 
proteolysis of fibrinogen and fibrin by this membrane associated 
protease was shown to have several important effects on both the 
coagulation and inflammatory responses. Proteolysis of fibrinogen 
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rendered it non-clottable through cleavage between amino acids 21 and 
22 of the N-terminus of the Aa chain and amino acids 394 and 395 
from the N-terminus of the y-chain.13 Several of the low molecular 
weight products generated during fibrinogen proteolysis were shown 
to associate with P2-integrin receptors modulating subsequent 
adhesive interactions.39 The ability of this membrane protease to 
degrade fibrin clots led to the suggestion that neutrophil mediated 
fibrinolysis is not dependent on degranulation. 14 The low molecular 
weight fibrin peptides generated during this process were shown to 
inhibit thrombin induced platelet aggregation, whilst the higher 
molecular weight products could partially overcome platelet induced 
resistance of fibrin to plasminolysis.40 In addition to its effects on 
fibrinogen, this protease was also shown to degrade C-reactive 
protein (CRP)38 generating several biologically active peptides 
capable of modulating a number of important pro-inflammatory 
neutrophil responses.4144 This novel membrane associated protease 
thus appeared to be associated with a number of processes influencing 
both the inflammatory and coagulation pathways (see figure 1). 
Fibrinogenolysis 
c::, ~ - --
c::, c::, c::, ~ - - --
c:::J c::::i - - -
Renders fibrinogen non-clottable 
Fibrinogen peptides 
• I • . t .. . . . 
• 0 •• ·e· . . .. ·.~·· ... 




.. i .. ·. :·o· == 
Inhibit platelet function 
Fibrinolysis 
... ........ :•:•: ····· ... 
Solubilises fibrin clots 
CRP peptides 
.. : i . ·.·. 
0 0 0 0 ·e· . .·.~· ... 
Inhibit neutrophil function 
Figure 1: The 600 kDa membrane associated protease has been reported to have 
numerous biological functions which result from its proteolysis of fibrinogen, fibrin 
and C-reactive protein. 
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Whilst this protease had been partially characterised with respect to 
its molecular weight, its inhibitor profile and its pattern of substrate 
d d . 13 14 38 . b 'fi d fr d h egra at1on, ' ' 1t was yet to e pun 1e om cru e extracts. T us 
many of its structural and catalytic properties remained to be 
elucidated. 
The present study aimed to purify and further characterise the 600 kDa 
membrane associated protease. In addition this study sought to 
confirm the association of neutrophil derived fibrinogen degradation 
products with P2-integrin receptors on the neutrophil surface. 
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Chapter Two 
The Neutrophil 
N eutrophils represent the first line of defence against microbial 
pathogens and are important mediators of the inflammatory response. 
They are the most prevalent of the circulating leukocytes, comprising 
approximately 55-60% of white cells in peripheral blood; 
lymphocytes, monocytes, basophils and eosinophils make up the 
remainder (figure 1 ). 1 The latter two groups, together with the 
neutrophils constitute a population of leukocytes known as 
granulocytes - so named because of the abundance of granules in 
their cytoplasm - of which neutrophils comprise over 90%. 1 
As a phagocytic cell the phylogeny of the neutrophil long precedes 
the emergence of the lymphocyte, suggesting its fundamental 
importance in host defence.2 To fulfil its role as a phagocyte, the 
neutrophil is equipped with an armoury of antimicrobial machinery 
which enables it to migrate to sites of inflammation, engulf invading 
micro-organisms and liberate an array of toxic oxygen metabolites 
and potent proteases 
aimed at the destruct-
ion of internalised 
material. 3-6 Despite the 
long held perception of 
the neutrophil as a 
purely mechanical 
phagocytic cell, it is 
rapidly emerging as a 
highly sophisticated 
inflammatory cell and 
an important regulator 
of the acute inflamm-
atory response. 
PERIPHERAL BLOOD LEUKOCYTES 
/ 
I GRANULOCYTES I 
/ ! "" G@®(i)~ 
NEUTROPHIL EOSINOPHIL BASOPHIL MONOCYTE LYMPHOCYTE 
(54-62%) (1-3%) (0--0.75%) (3-7%) (25-33%) 
Figure 1: Peripheral blood leukocytes. The 
granulocyte population consists of neutrophils, 
eosinophils and basophils. The proportion of each 
group in the peripheral blood is indicated. 
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Neutrophil maturation 
Neutrophils evolve from pluripotent stem cells.7 The myeloblast is 
the first recognisable precursor cell and, following the acquisition of 
azurophil granules, it evolves into the promyelocyte. The 
promyelocyte divides to form the myelocyte, in which the specific 
granules are synthesised. 8 During the final stages of maturation there 
is no cell division and the cell passes through the metamyelocyte 
stage and on to the band cell with a sausage shaped nucleus. As the 
band cell matures the nucleus assumes a lobulated configuration. 1 
Myeloblast Promyelocyte Myelocyte Metamyelocyte Band cell Neutrophil 
Figure 2: The neutrophil precursors. Progression towards maturity is characterised 
by he progressive acquisition of the various granule subsets. 
Neutrophils are produced in the bone marrow at a rate of 
approximately 70 million/minute.9 After maturation, the neutrophil 
usually spends up to 5 days within the bone marrow prior to release 
in to the circulation where it has a lifespan of approximately 2-3 
days.6'9 Under normal conditions, about 90% of the neutrophil pool is 
in the bone marrow, 2-3% in the circulation and the rest in the tissues.1 
An overview of neutrophil function 
In performing its phagocytic function, the neutrophil is involved in a 
series of events, starting with its migration into affected tissues and 
culminating in the internalisation and destruction of foreign particulate 
The Neutrophil 
matter (see figure 3). This process is broadly divided into five steps 





5. Kill 4. Phagocytosis 
Figure 3: A schematic representation of the five basic steps involved in 
the neutrophil response to inflammation, beginning with migration from 
the vasculature and culminating in destruction of ingested material. 
1. Adherence 
The first step in the acute 
inflammatory response is the 
attachment of the neutrophil to the 
endothelial cell (EC) surface. 10 
Tissue injury results in the release of 
a variety of inflammatory mediators 
which are capable of promoting 
neutrophil adhesion to EC by 
enhancing the avidity of neutrophil 
surface adhesion molecules for EC 
ligands. At the same time, 
inflammatory mediators also induce 
the expression EC adhesion 
molecules which further support 
neutrophil adhesion. 11 The molecular 
1 (C) 
• ~ L-selectin 








Figure 4: Molecules involved 
in neutrophil-EC interactions 
9 
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basis of neutrophil-EC adhesion is discussed in detail in a later 
section, and is therefore eluded to only briefly here. The initial 
interaction of the neutrophil with the endothelium, known as 
tethering, is mediated by a family of adhesion molecules known as 
selectins which are found both on the EC (E- and P-selectin) and on 
the neutrophil (L-selectin) (Figure 4). Tethering precedes firm 
adhesion which results in arrest of the cell and is mediated by 
interactions between P2-integrins (CD11/CD18 family) and EC 
counter-receptors, including intercellular adhesion molecules 1 and 2 
(ICAM 1 and 2). 11 
2. Transmigration 
After strong adhesion to ECs, neutrophils migrate into tissues under 
the influence of promigratory factors (figure 5). Many of the 
cytokines that trigger strong adhesion may also act as chemotactic 
factors, e.g. interleukin 8 (IL-8). The increased vascular permeability 
at sites of inflammation allows the migration of neutrophils from the 
vasculature. It has been suggested that the transience of both P-
selectin expression and P2-integrin mediated adhesion provides the 
reversibility required for the migration of neutrophils across ECs. 11 
3. Chemotaxis 
Once the neutrophil has traversed 
the endothelium it must migrate to 
the site of inflammation. It does so 
by the process of chemotaxis which 
involves directed movement across 
a concentration gradient of 
chemoattractant molecules (figure 
5). 5 A variety of chemotactic agents 
are involved in neutrophil migration 
towards the inflammatory site and 
these may be derived from the plasma 
( e.g. C5a, kallikrein, fibrinopeptide 
B), from inflammatory cells (e.g IL-8, 
~~~~~ 
gradient . ... . : . · / .: . : 
:::: ::~ ::.:_._:_._:._: 
:,1,!Lf\ /J/,),\ ,),!LLL:i:: ........ ... .. ......... .. .. ............. , ..... ..... ,. . .................. ......... .. ..... .. ............ ..... .. ...... ,, .................... ... .... .. ... ... ...... .. ..... .. .... ... .... .................... ....... ....... . 
Figure 5: Directed migration of 
neutrophils across a chemotactic 
gradient allows for their accum-
ulation at inflammatory sites. 
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leukotriene B4, platelet activating factor) or micro-organisms (e.g. 
FMLP [N-formyl-methionyl-leucyl-phenylalanine ]). 12 Chemotaxis is 
initiated by the binding of chemoattractants to neutrophil surface 
receptors, with the subsequent activation of signal transduction 
events which induce dramatic rearrangements of the cytoskeleton, 
facilitating directed migration. 13•14 
4. Phagocytosis 
Having arrived at the inflammatory 
focus, neutrophils ingest foreign 
particulate matter or cellular 
debris by a process known as 
phagocytosis.6•13 This process can 
be divided into three distinct steps 
(figure 6): 
(i) The fust involves the attachment 
of the particle to the cell surface. 
This process is facilitated by the 
coating of particles with serum 
opsonins , most commonly 
complement fragments or IgG, 
which are recognised by receptors 
on the cell surface (IgG by IgG-Fc 
receptors, and C3b and C3bi by 
complement (C3) receptors CRl 
and CR3 respectively).6 
(ii) Binding is followed by particle 
engulfment which is characterised 
by a flow redistribution of the 
plasma membrane to surround the 
particle with finger-like protrusions 
known as pseudopodia. Fusion of 
the pseudopodia around the particle 
yields a membrane bound organelle 











Figure 6: The 3 steps of phagocytosis 
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(iii) In the final step of the process, phagosomes are transformed into 
functional phagolysosomes through the aquisition of acid hydrolases 
and ion pumps (required for the acidification of the endosomal 
compartment) via fusion with lysosomes. 16•17 
5. Neutrophil killing 
The ingestion of foreign particles sets into motion the potent 
microbicidal machinery of the neutrophil. Concomitant with 
phagocytosis there is a burst of oxygen consumption and activation 
of the hexose monophosphate shunt which generates NADPH (figure 
7).6 NADPH oxidase is assembled on the phagosomal (and plasma) 
membranes, into an active complex together with flavoproteins and 
cytochrome b. This complex generates reactive oxygen intermediates 
such as superoxide anion (02) through the oxidation of NADPH 
(figure 7). Superoxide anion is converted to hydrogen peroxide 
(H202) either by spontaneous dismutation or through the action of 
superoxide dismutase. 5 Myeloperoxidase, liberated from the 
azurophil granules, catalyses the conversion of H20 2 to toxic 
intermediates such as hypochlorous acid (HOCl). HOCl is an 
extremely powerful oxidant with potent microbicidal potential due to 









H20 2 + 2 0 2 
Figure 7: A schematic 
representation of the 
metabolic events related 
to the neutrophil respiratory 
burst. The cytochrome 
b558"FAD-NADPH oxidase 
system is assembled on 
the membrane of the 
phagolysosome. This 
facilitates the generation 
of oxygen radicals which 
are converted to the toxic 
hypochlorous acid by 
myeloperoxidase released 
from azurophil granules. 
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Acidification of the phagolysosome assists in neutrophil destruction 
of internalised micro-organisms. Some microbes are killed by a low 
pH, and a number of neutrophilic antimicrobial systems function best 
at low pH. 5 Acidification occurs via the acquisition, from the 
lysosomes, of acid hydrolases, as well as the appropriate ion pumps 
and channels required for accumulation of hydrogen ions within the 
phagocytic compartment. 5 
Neutrophil granules contain a vast store of bactericidal proteins and 
peptides, including bacterial permeability increasing protein (BPI), 
defensins, azurocidin, and many others, which can destroy ingested 
microrganisms.3 Neutrophil granules also contain a number of potent 
proteases, including elastase, cathepsin G and proteinase 3, which 
contribute both toward bactericidal activity and digestion of 
microbial debris.19 
Neutrophil granules 
Neutrophil granules are intimately involved in both neutrophil 
proteolytic as well as adhesive processes, the two subjects of the 
experimental section of this thesis. A considerable portion of this 
review will therefore be devoted to this very important group of 
organelles. 
Over the last 15 years the perception of neutrophil granules has 
changed dramatically. Long viewed as simple bags of proteolytic or 
bactericidal proteins destined for release into the phagosome or the 
extracellular millieu, neutrophil granules have become increasingly 
recognised as the essential machinery which enables the neutrophil to 
adapt rapidly, and fundamentally, to changes in its environment. The 
incorporation of granule proteins into the external membrane of the 
neutrophil following fusion of granules with the plasma membrane 
allows the neutrophil to rapidly change the profile of proteins 
expressed on its surface.20•21 Depending on the granule population 
released, neutrophils may undergo upregulation of specific functions 
h dh · · h · · b 22-24 sue as a erence, m1grat1on, p agocytos1s or respiratory urst. 
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The neutrophil granules have emerged as an extremely heterogeneous 
group of organelles. The simplest classification includes four groups 
of neutrophil granules distinguished on the basis of their protein 
content, size and density (figure 8). These include the azurophil 
(primary), specific (secondary) and gelatinase (tertiary) granules as 




















Figure 8: Neutrophil granules differ in their size, density and protein content 
reflecting the stage of neutrophil maturation at which they are formed. 
Following synthesis of granule proteins, the packaging of granules in 
the Golgi apparatus involves condensation of protein within 
cystemae and release of Golgi derived coated vesicles which 
ultimately lose their coats and fuse to form immature granules. 
Further condensation occurs during maturation of granules. 8•25 In 
view of the considerable heterogeneity of neutrophil granules, it 
would appear that sorting of the various proteins into different 
granules requires a highly sophisticated mechanism. Such a 
mechanism is not in fact required, as all granule proteins that are 
synthesised at a particular point in time are packaged into the same 
granules. Thus the basis for granule heterogeneity lies in the 
The Neutrophil 15 
differences in gene expression and protein synthesis associated with 
the different stages of the neutrophil maturation cycle.26•27 Indeed, it 
has long been known that the different neutrophil granules arise at 
specific stages of neutrophil development. Azurophil (primary) 
granules are the first to appear in the cytoplasm during the neutrophil 
maturation process, at the promyelocyte stage. Next follow the 
specific (secondary) granules which are formed at the 
myelocyte/metamyelocyte stage and this is accompanied by a 
cessation in the production of azurophil granules. 8 This is followed 
by the gelatinase (tertiary) granules which develop at the 
metamyelocyte/band cell stage. 28 The secretory vesicles are the last to 
arise in the cytoplasm and first appear in band cells and segmented 
cells.2 
The various granule subsets show marked differences in their 
propensity for mobilisation following neutrophil activation. The 
order of mobilisation correlates negatively with the size and density 
of the granules. Secretory vesicles represent the most easily 
mobilisable set of granules followed by the gelatinase, specific and 
lastly azurophil granules.29"31 In addition to membrane constituents, 
neutrophil granules also contain a variety of proteins and peptides of 
major importance within their interiors. These include a number of 
proteases and antimicrobial proteins and peptides involved in 
neutrophil migration and destruction of invading micro-organisms.2·3 
Because the different categories of neutrophil granule reflect 
differences in gene expression and synthesis of granule proteins over 
time, rather than post-synthesis sorting mechanisms, rhere is 
considerable overlap between the various groups with respect to 
granule contents. 27 Thus, rather than comprising completely separate 
groups, neutrophil granules form a continuum from azurophil 
through to gelatinase granules, with a number of proteins being 
shared between the groups.32•33 However, for practical purposes, 
granules can be divided into four major categories, each of which is 
reviewed separately below. 
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1. Azurophil granules 
Azurophil granules are the stores of most proteolytic and bactericidal 
proteins. Being the first to appear during neutrophil maturation they 
are also known as primary granules. Azurophil granules were 
initially distinguished from other granules on the basis of their 
affinity for the basic dye azure A (which stains acid mucopoly-
saccharide ), 34 and later on the basis of their myeloperoxidase content 
which is not present in' other granules. 8'35 Azurophil granules are 
generally regarded as being spherical and oval in contrast to specific 
granules which tend to be more elongated and irregular.8 The 
azurophil granules contain myeloperoxidase, 36 the serine proteases 
elastase,37 cathepsin G,38 and proteinase 3,39 acid hydrolases,40 and a 
variety of microbicidal proteins including lysozyme,41 defensins,42 
azurocidin,43 and bactericidal/permeability increasing protein.44 Until 
recently, azurophil granules have generally been considered to be 
analogous to lysosomes,. since they are membrane bound organelles 
that contain acid hydrolases that 
have not yet entered into a 
digestive event. 40,41,45 However, 
recent studies have revealed that 
the classic lysosomal membrane 
markers, lysosome associated 
membrane protein (LAMP) 1 and 
2, are not present in · the 
membranes of azurophil 
granules.46 This has led to the 
suggestion that these granules do 
not in fact represent true 
lysosomes, but behave more like 
regulated storage vesicles which 
are mobilised to the phagosome 
during ingestion of micro-
organisms.47 The membranes of 
azurophil granules do not contain 
any receptors or other functional 
proteins involved m the 
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interaction of neutrophils with their environment.2 Although CD63 
and CD68 have been identified on azurophil granule membranes, 
their significance, if any, is unclear.48'49 Of all the granule subsets, 
azurophil granules have the lowest propensity for mobilisation.31 It 
has thus been suggested these granules may play less of a role 
extracellularly than other classes of neutrophil granules,31 and that 
their major role may only be executed after disintegration of the cell.2 
However, secretion of azurophil granules does occur to some 
extent, 50 and a number of recent studies have demonstrated the 
presence of elastase and cathepsin G bound to the cell surface of 
activated neutrophils.51•54 Moreover, neutrophils have also been 
shown to express the azurophil granule microbicidal factor BPI on 
their surfaces. 55 It thus appears that regulated release of azurophil 
granules, albeit it at relatively low levels, may allow the constituents 
of these granules to perform important functions extracellularly. 
2. Specific granules 
The specific granules are the 
second subset of neutrophil 
granules to develop during 
neutrophil maturation and hence 
are referred to as secondary 
granules. Specific granules tend 
to be more irregular and 
elongated in shape. 8 These 
granules are distinguished by 
their content of lactoferrin and 
vitamin B12-binding protein, 
which are unique to this subset of 
organelles. 56 In contrast to 
azurophil granules, the membranes 
of specific granules serve as 
important reservoirs of receptors 
and other proteins and, following 
their translocation to the 
neutrophil membrane, these 
constituents boost the capacity of 
Specific granule constituents* 
Membrane: 
• Cytochrome b558 
• Mac 1 (CD11b) 
• Laminin receptor 
• Fibronectin receptor 
• Vitronectin receptor 
• Thrombospondin receptor 
• FMLP-receptor 
• Tumour necrosis factor receptor 
• G-protein a-subunit 




• Vitamin 812 binding protein 
• Collagenase 
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the neutrophil to perform various functions. Since these granules 
represent the major store of flavocytochrome b55g, an essential 
component of NADPH, they contribute significantly towards the 
respiratory burst. 57·58 In addition they contain a variety of adhesion 
receptors (including Mac-1,59 and the ·laminin-, fibronectin- and 
vitronectin receptors23) which add to the contributions made by the 
more easily mobilisable gelatinase and secretory granules (see later). 
Specific granules are also important reservoirs of receptors for 
FMLP60·61 and tumour necrosis factor (TNF).62 
With respect to matrix proteins, specific granules are dominated by 
lactoferrin,2 whose precise function remains unknown, although it 
has been reported to possess microbicidal activity.3 Another 
constituent of the matrix worth mentioning is collagenase,63 due to its 
potential to facilitate neutrophil migration through tissues, 64 and to 
cause tissue destruction when uncontrolled. 18 The matrix also 
contains a variety of other proteins including lysozyme,41 urokinase 
plasminogen activator (u-PA),65 gelatinase,28 and vitamin B12 binding 
proteins. 66 
3. Gelatinase granules 
Gelatinase (tertiary) granules 
are the third subset of 
neutrophil granules to 
develop during neutrophil 
maturation, with maximal 
synthesis occurring during 
metamyelocyte/band cell 
stage. 28 Like specific granules, 
gelatinase granules are 
peroxidase negative but differ 
from the former in that they 
lack lactoferrin.32 These 
granules, which are lighter 
and smaller than specific 
granules, store the bulk of 
neutrophil gelatinase, although 
Gelatinase granule constituents* 
Membrane: 
• Mac 1 (CD11 b) 
• Cytochrome b558 
• FMLP-receptor 
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some gelatinase is also stored in .the specific granules.32 Gelatinase 
granules are mobilised more readily than specific granules in 
response to inflammatory mediators.29•31•67 Although the membrane 
of gelatinase granules appears to be similar to that of specific 
granules,68 mobilisation of gelatinase granules during neutrophil 
activation does not make a major contribution to the neutrophil 
membrane because these granules are small and relatively few.32 The 
significance of mobilisation of gelatinase granules, therefore, does 
not appear to be their contribution to membrane proteins, but rather 
the release of gelatinase, which due to the highly concentrated state 
in which it is stored, occurs in substantial amounts.2 As type IV 
collagen (of basement membranes) and type V collagen (of 
interstitial tissues) are major substrates of gelatinase,69-71 it is likely 
that exocytosis of gelatinase granules plays an important role in the 
migration of neutrophils through basement membranes and into the 
underlying tissue. 72•73 
4. Secretory vesicles 
The observation that a variety of receptors, including Mac-1, can 
become incorporated into the plasma membrane without the 
associated exocytosis of cytoplasmic granules, led to a search for an 
alternative mobilisable source of these receptors. This resulted in the 
discovery of the secretory vesicle, the most rapidly mobilisable 
intracellular structure in neutrophils.21 •74-76 The membranes of 
secretory vesicles are 
particularly rich in a variety of 
important receptors and 
proteins, including Mac-1, 77 the 
FMLP receptor,78 the u-PA 
receptor, 79 as well as 
cytochrome bsss,77 and CRt.80 
The only known intravesicular 
constituent of secretory vesicles 
is plasma; thus albumin 
currently serves as a marker of 
these vesicles. 81 This implies 
that secretory vesicles are 
Secretory vesicle constituents* 
Membrane: 
• Alkaline phosphatase 
• Mac 1 (CD11b) 
• Cytochrome b5ss 
• CR1 
• FMLP-receptor 
• Urokinase plasminogen activator 
receptor 
Matrix: 
• Plasma proteins 
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endocytic in origin. Secretory vesicles are, however, distinct from 
the endocytic vesicles of constitutive pinocytosis and, once 
mobilised, are not reassembled.81-83 
The extreme sensitivity with which the neutrophil responds to 
inflammatory stimuli by mobilising secretory vesicles suggests that 
these vesicles play a primary role in the initiation of the neutrophil 
inflammatory response. The secretory vesicles are thought to be 
mobilised when the neutrophil establishes primary rolling contact 
with the endothelium. The mobilisation of these vesicles may be 
mediated by signalling through selectins, 84·85 or by inflammatory 
mediators liberated from the endothelium. 86·87 Incorporation of these 
vesicles into the plasma membrane endows the neutrophil with a 
variety of receptors (in particular ~2-integrins and FMLP receptors) 
which render the neutrophil highly responsive to inflammatory 
stimuli and primed for migration into tissues.88-90 
Thus, the heterogeneity of the neutrophil cytoplasmic granules, 
together with their differential rates of mobilisation, provides the 
neutrophil with the ability to rapidly adapt to changes in its 
environment in a highly regulated manner. This is summarised below 
with the aid of figure 9. Whilst mobilisation of the secretory vesicles 
appears to initiate the increased neutrophil adhesiveness required for 
attachment to the endothelium, subsequent release of gelatinase 
granules facilitates neutrophil migration through tissues through the 
ability of gelatinase to degrade collagen. The specific granules are 
next to be released with the subsequent translocation cytochrome b5s8 
to the neutrophil membrane, which is vital for the assembly and 
activation of the NADPH-oxidase-cytochrome bss8 complex and the 
subsequent respiratory burst. These granules also bolster the supply 
of various adhesion receptors important in phagocytosis. Finally, 
following internalisation of the foreign particle, azurophil granules 
release a variety of antimicrobial proteins and proteases into the 













Figure 9: The role of cytoplasmic granules in the neutrophil inflammatory response. 
(1) Circulating neutrophils become tethered to activated endothelium primarily via 
selectins, both on the neutrophil and the endothelium. Ligation of L-selectin may 
signal for the release of secretory vesicles. (2) The incorporation of secretory 
vesicles into the plasma membrane increases the surface expression of 
CD11b!CD18 (Mac-1) enhancing the potential for firm adhesion to the endothelium. 
(3) Exocytosis of gelatinase from gelatinase granules as well as elastase from 
azurophil granules may facilitate the degradation of the basement membrane and 
thus assist in transmigration into the extravascular space. (4) The expression of 
receptors for chemotactic molecules such as FMLP (released from secretory vesicles 
and specific and gelatinase granules facilitates directed migration towards the 
inflammatory focus. (5) Mobilisation of specific granules to the neutrophil surface may 
enhance the phagocytic potential of the neutrophil via the increased expression of 
Mac-1 on the plasma membrane. Fusion of specific and azurophil granules with the 
phagosome supplies cytochrome bssa and myeloperoxidase respectively, which allow 
for the generation of toxic oxygen metabolites. The release of bactericidal agents and 
potent digestive proteases facilitates the intracellular digestion of internalised 
particles. 
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Neutrophil proteases 
Proteases of the neutrophil granule 
I. Serine proteases 
Human neutrophil elastase (HNE), cathepsin G, proteinase 3 and 
azurocidin belong to a family of multifunctional haematopoietic 
serine proteases, often referred to as serprocidins. In addition to their 
broad spectrum proteolytic activity, these powerful proteases are also 
endowed with microbicidal properties. 19'91 The serprocidins are 
structurally related cationic glycoproteins of similar size (25-29 
kDa). 19 Within this group, azurocidin is exceptional in that it is a 
sterile enzyme, lacking proteolytic activity due to mutations in 2 out 
of 3 residues in the presumed catalytic triad of the protein.92'93 
Multiple and sometimes overlapping functions are a characteristic of 
this family of proteases. 19 They exhibit a broad spectrum of 
proteolytic activity and have been shown to modulate a wide variety 
of important cellular processes (see below). Their microbicidal 
activity may involve both proteolytic and non-proteolytic 
mechanisms.3' 19 The serprocidins are broadly cytotoxic to Gram-
negative and positive bacteria, fungi, protozoa as well as mammalian 
cells.3 They may act alone or in combination with other antimicrobial 
agents. They may play an additional role in host defences by 
converting cytotoxins from active to inactive forms. 19 
The serine proteases of the azurophil granule are structural relatives 
of the granzymes of the granules of cytotoxic T cells, as well as 
certain mast cell proteases (see figure 10).94 The genes of HNE, 
proteinase 3 and azurocidin are organised in a single locus on 
chromosome 19,95 whilst the gene for cathepsin G is located, together 
with those for two cathepsin G-like proteases of cytotoxic T-
lymphocytes, in a single cluster on chromosome 14.96 There is strong 
evidence to suggest that these proteases have arisen from a single 
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Figure 10: The haematopoietic serine proteases are a closely related family of 
proteases stored in the cytoplasmic granules of a variety of haematopoietic cells. 
' The synthesis of the serprocidins occurs during the promyelocyte 
stage of neutrophil maturation.98 Co-translational removal of a signal 
peptide yields a zymogen containing a 2-amino-acid propeptide 
aminoterminally, which prevents premature activation of the protease 
during intracellular transport. 56 Subsequent removal of the 
prodomain in the pregranular or granular compartments yields the 
mature and active enzyme.98 Each member of this family is discussed 
in turn below. 
1. Human neutrophil elastase 
Human neutrophil elastase (HNE) is a potent, broad-specificity serine 
protease of considerable (patho )physiological importance. When 
·appropriately controlled, its proteolytic activity regulates a variety of 
important biological processes; however, when inappropriate or 
prolonged, HNE mediated proteolysis may result in extensive tissue 
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damage and a variety of disabling and destructive diseases including 
emphysema, glomerulonephritis and rheumatoid arthritis.99"103 
HNE is a single chain, cationic 30 kDa glycoprotein, 218 amino acids 
in length. 104 As with other serine proteases, HNE activity is 
dependent on the catalytic triad His41-Aspss-Ser173 centred at the 
HNE reactive site. 104·105 When a substrate is introduced into the 
active site pocket, the transfer of a proton within the triad converts 
the Seri 73 into a highly reactive nucleophile which is capable of 
disrupting the peptide bond within the target substrate. 105 HNE is 
classified as an elastase because it belongs to a small group of 
proteases which can degrade insoluble elastin, a highly crosslinked 
rubber-like macromolecule which provides structural integrity and 
flexibility to connective tissue matrices. 106 However, despite the 
specificity of its name, neutrophil elastase can also destroy most 
other matrix proteins (including fibronectin, fibrinogen, collagen 
types III, IV and VI, and proteoglycans) as well as coagulation 
factors, immunoglobulins and complement components.53·107·108 
The ability ofHNE to degrade extracellular matrix proteins has led to 
the suggestion that it may play an important role in neutrophil 
migration, both from the vasculature and through the tissues, by 
digesting proteins in the cell's path. 18 Indeed, recent evidence 
indicates that neutrophil migration across confluent EC monolayers 
in vitro is HNE dependent. 109 This is supported by in vivo 
observations that leukocyte emigration across venular endothelium 
into interstitium, during experimentally induced inflammation, is 
markedly diminished in the presence of HNE inhibitors. 110-112 
Moreover, the recent finding that HNE binds specifically to the 
adhesion receptor Mac-1, and is essential for reversal of integrin 
mediated attachment of neutrophils to the extracellular matrix, has 
suggested an additional mechanism whereby this protease may 
promote neutrophil emigration. 113 HNE also has also been shown to 
upregulate the expression of the P-subunit of the CD 11/CD 18 
integrin complex and, to a lesser extent, CD 11 b on the neutrophil 
surface. 111 This upregulation has been shown to promote neutrophil 
migration but not adhesion at inflammatory sites, although the 
mechanism for this remains unclear. 111 
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HNE is a multifunctional protease which is involved in a variety of 
biological processes beyond ,its role in connective tissue proteolysis 
(see figure 11). 
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Figure 11: A schematic representation of the multiple effects that human 
neutrophil elastase may have on the function of a variety of cell types. In 
addition HNE may have a variety of indirect effects as a result of proteolysis of a 
variety of plasma proteins. 
HNE mediated proteolysis can influence neutrophil function in 
several ways. It can promote the influx of neutrophils into sites of 
inflammation by inducing release of granulocyte macrophage colony 
stimulation factor (GM-CSF), IL-6 and IL-8 from epithelial cells, 114· 
116 by cleaving a 1-antiproteinase inhibitor to generate a chemotactic 
fragment, 117 and by stimulating the release of leukotriene B4 (LTB4) 
from mononuclear phagocytes. 118 HNE has also been shown to 
augment superoxide generation in response to various stimuli, and 
this may significantly enhance neutrophil microbicidal activity, as 
well as the potential for host tissue injury. 119 HNE has been shown to 
exhibit bactericidal activity in vitro, 120·121 which is not necessarily 
dependent on its proteolytic activity. 121 The physiological 
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significance of these in vitro observations has recently been 
confirmed by in vivo studies, using mice rendered HNE deficient by 
targeted mutagenesis of the HNE gene. 122 Mice deficient in HNE 
showed markedly higher morbidity and mortality rates following 
intraperitoneal inoculation with Gram negative bacteria (klebsiella 
pneumonia and escherichia coli) but not Gram positive bacteria 
(staphylococcus aureus) than normal mice. This appeared to be due 
to impaired intraphagosomal killing of ingested Gram negative 
bacteria. 122 
HNE has also been shown to modulate the function of a variety of 
other cell types. It is known to prime macrophage superoxide 
production, 123 modify platelet aggregation, 124 and to stimulate B-
lymphocyte proliferation. 125 It has also been shown to induce the 
secretion of platelet activating factor (P AF) by EC, 126 L TB4 by 
macrophages, 118 a variety of cytokines by epithelial cells, 114"116 and to 
shed TNF receptors from phagocytes. 127 It has recently been reported 
that HNE can degrade the EC adhesion receptor, ICAM-1 and it has 
been suggested that in this way HNE might downregulate ICAM-1 
mediated adhesion to neutrophils to EC. 128 However, another recent 
study reports upregulation of ICAM-1 expression by HNE (as 
determined both immunologically and by mRNA levels). 129 Taken 
together these studies raise the possibility of a negative feedback 
mechanism activated by the proteolysis ofICAM-1. 
Several pro-inflammatory mediators as well as plasma proteins may 
be proteolytically modified by HNE, often with important 
physiological consequences. In this regard, HNE has been shown to 
generate IL-2 peptides which inhibit adherence of T-lymphocytes to 
the extracellular matrix. 130 HNE has also been shown to cleave IL-8 
into a more active form, 131 to inactivate both TNFa and B, 132' 133 and 
to generate complement components. 134' 135 Proteolysis of clotting 
proteins by HNE is discussed in the following chapter (pages 81-84). · 
Until recently the biological relevance of HNE mediated proteolysis 
has been questioned, due to the relatively small quantities of HNE 
that are released from the neutrophil in response to biologically 
relevant stimuli,2' 136 and the high concentration of HNE inhibitors in 
the extracellular space. 137 (Whilst the most important of these 
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inhibitors is a 1-antiproteinase, formerly a 1-antitrypsin, HNE is also 
susceptible to other inhibitors including ai-macroglobulin in the 
plasma and antileukocyte protease (ALP) in the mucosa). 137,138 
Although the extracellular space is replete with high affinity HNE 
inhibitors, HNE in the immediate pericellular environment has been 
shown to retain its catalytic activity. 139-142 Numerous studies have 
investigated the factors responsible for this phenomenon, and a 
number of potential mechanisms have been identified: 
It has been shown that reactive oxygen species produced by the 
MPO/H20 2/halide system are capable of oxidatively inactivating a1-
proteinase inhibitor. 143 Neutrophil and macrophage metallo-
proteinases have also been shown to inactivate a1-proteinase 
inhibitor. 144'145 Thus, proteolysis in the microenvironment 
surrounding the cell may be facilitated by local inactivation of 
proteinase inhibitors. 
Another potential mechanism whereby HNE may be allowed to 
evade extracelllular inhibitors is through the creation of a 
microenvironment which excludes proteinase inhibitors. Neutrophils 
have been shown to form protected extracellular compartments 
between their plasma membranes and protein ( e.g. fibrinogen, 
fibronectin and elastin) coated surfaces; these protected 
compartments can exclude most of the macromolecular components 
of plasma, including most naturally occurring proteinase inhibitors, 
thereby allowing continued proteolysis of the extracellular 
matrix. l39,t4t,I46-I48 
More recently HNE has been shown to evade inhibition by binding to 
the neutrophil surface.51-53 Surface bound HNE retains its catalytic 
activity and is substantially resistant to inhibition by naturally 
occurring protease inhibitors.51-53 Whilst resting neutrophils have 
been shown to express a significant level of HNE on their 
membranes, 52,54,t 13 this is greatly increased following neutrophil 
activation with the phorbol ester PMA, or the chemoattractants, 
fMLP or IL-8.51-54 Priming of neutrophils with TNFa or PAF, prior 
to stimulation with these chemoattractants markedly enhances this 
response. 53 The fact that HNE expression is under the control of 
biologically relevant effector molecules suggests that the inducible 
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expression of membrane bound HNE may play an important role in 
the neutrophil inflammatory response. 53 
A comparison of protease-inhibitor and protease-substrate 
interactions, may help to explain the preservation of catalytic activity 
of surface bound proteases in the presence of naturally occurring 
protease inhibitors.51 The complex formed between a proteinase and 
its inhibitor requires a very precise conformation and only one bond 
in the inhibitor molecule is subjected to cleavage. This contrasts with 
substrate hydrolysis where multiple bonds in the substrate molecule 
are accessible for cleavage. Thus steric hindrances would have a far 
greater effect on inhibitors attempting to interact with the active site 
of membrane bound proteases than substrates.51 
There are numerous examples of membrane ( or biological surface) 
associated proteinases that remain functional whilst demonstrating 
relative resistance to naturally occurring inhibitors. One such 
example includes urokinase plasminogen activator (u-PA), which 
converts the zymogen plasminogen to the active enzyme plasmin. 
Interestingly, plasmin also displays substantial resistance to its 
natural inhibitor, (a.2-antiplasmin) when membrane bound. 149,150 
Several instances where proteases (including HNE) become resistant 
to their natural inhibitors when bound to fibrin, are described in the 
following chapter. 
In addition to conferring resistance to inhibition, the binding of HNE 
to the neutrophil membrane also helps to focus its activity in the 
immediate pericellular environment and to prevent its diffusion from 
the vicinity of the neutrophil. This allows HNE mediated proteolysis 
to be both highly localised and tightly regulated. 53 The neutrophil 
membrane has been reported to contain receptors that are specific for 
HNE, 151 and more recently, HNE has been shown to bind specifically 
to Mac-I coated surfaces. 113 It has, however, been suggested that the 
association of this protease with the neutrophil membrane is largely 
non-specific, and due to the interaction between negative charges on 
the neutrophil surface (sialic acid residues) and positive charges on 
HNE.51 This is supported by the recent observations that cationic 
proteins abrogate the agonist induced upregulation of HNE 
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expression on the neutrophil surface, and that HNE can be eluted off 
the neutrophil surface by solutions of increasing ionic strength. 53 
Recent studies therefore suggest that membrane-bound HNE is an 
important biological form of this protease, allowing its catalytic 
activity to be preserved in the presence of naturally occurring 
proteinase inhibitors, and to be localised to the immediate 
pericellular environment. 
2. Cathepsin G 
Cathepsin G is a 29 kDa glycoprotein which, like HNE, is a cationic 
serine protease of relatively broad substrate specificity. It is often 
referred to as a chymotrypsin-like enzyme because. it hydrolyses 
peptide bonds after leucine, methionine and phenylalanine 
residues. 152 Relative to HNE, cathepsin G is considered to be a rather 
inefficient proteinase, degrading a number of substrates more slowly 
than HNE. 152·153 Whilst its natural inhibitor is a 1-antichymotrypsin,
51 
cathepsin G is also very susceptible to a1-antiproteinase. 154 Like 
HNE, cathepsin G is also able to evade the action of naturally 
occurring proteinase inhibitors through its ability to bind to the 
neutrophil membrane,51 ·52 and binding appears to be mediated via a 
similar charge related mechanism. 51 
Cathepsin G is a multifunctional protease which shares a number of 
functions with HNE. These include the upregulation of the neutrophil 
respiratory burst, 119 the stimulation of B-cell proliferation, 125 the 
modification of cytokines such as IL-8 131 and the degradation of a 
variety of extracellular matrix proteins including fibronectin, 
fibrinogen, immunoglobulins · and various complement 
components. 155"158 In addition, cathepsin G possesses microbicidal 
activity which is more potent than that of HNE. 19 · 
Cathepsin G also has a number of unique actions, including 
chemotactic activity for nionocytes and neutrophils, 159 the activation 
of HNE, 160 and the induction of platelet activation and 
aggregation. 161-163 The latter effect is substantially enhanced in the 
presence ofHNE. 124·163 · 
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Recent studies have shown that certain synthetic peptides derived 
from C-reactive protein (CRP) can act as inhibitors of both HNE and 
cathepsin G. 164' 165 As CRP is a known substrate for a recently 
identified neutrophil membrane associated protease (see page 34), it 
is possible that neutrophil mediated proteolysis of CRP, through the 
generation of inhibitory peptides, might regulate the proteolytic 
activity ofHNE and cathepsin G. 
3. Proteinase 3 
Proteinase 3 (PR3) was the third serine protease to be identified in 
azurophil granule. 166 This 29 kDa glycoprotein is a major constituent 
of the azurophil granule, being present in amounts comparable to that 
of HNE.43,167 PR3 shows a preference for peptide bonds involving 
small aliphatic amino acids such as alanine, serine and valine. 168 
PR3 has extensive NH2-terminal homology with HNE and cathepsin 
G d h . . . h 1 . h HNE 168 169 I . , an s ows extensive acflve site omo ogy wit . ' t is 
thus not surprising that these proteases are very similar in function. 
Like HNE and cathepsin G, PR3 is capable of degrading elastin as 
well as a wide variety of connective tissue proteins, including 
fibronectin, laminin, vitronectin, and collagen type IV. 168 This 
suggests that PR3 also has the potential to cause extensive tissue 
destruction. Indeed, this has been demonstrated in animal models, 
where the capacity of PR3 to cause emphysema was shown to be 
similar to that ofHNE. 165 
PR3 may also perform a number of important biological functions, 
including the modulation of cathepsin G induced platelet 
activation171 and the proteolytic modification oflL-8 into more active 
forms. 131 In addition, it has potent microbicidal activity against 
bacteria and fungi.43' 170 Whilst PR3 is inhibited by a 1-antiproteinase 
as well as a 2-macroglobulin, it is not sensitive to either a,-
antichymotrypsin or antileukoproteinase. 168 
The link between PR3 and Wegener's granulomatosis (a severe, 
destructive disease characterised by necrotising vasculitis and 
granuloma formation) has generated substantial interest in this 
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protease. Wegener' s granulomatosis is associated with the presence 
of circulating antibodies against PR3. 173'174 Whilst the detection of 
antibodies in the serum of patients assists in the diagnosis of this 
disease, the precise role of these antibodies in the pathogenesis of 
Wegener's granulomatosis is not entirely clear. 174 
Like HNE and cathepsin G, PR3 has also been shown to bind to the 
neutrophil membrane following release by activated neutrophils. 172 
4. Azurocidin 
Although a member of the family of hematopoeitic serine proteases, 
azurocidin is a "sterile" enzyme which lacks proteolytic activity due 
to mutations in 2 of 3 residues in the presumed catalytic triad of the 
protein; the histidine (His41) is replaced by a serine residue and the 
serine (Serm) is replaced by a glycine residue, whilst the aspartate 
(Asps9) is conserved. 92'93 The functional gene for aiurocidin is 
grouped in a cluster of elastase like genes within a 50 kb region on 
chromosome 19. 175 
This 29 kDa glycoprotein is relatively abundant in azurophil 
granules,176 and despite its lack of catalytic activity, azurocidin has 
been shown to have other important properties. It is a potent 
antibiotic against Gram negative bacteria and a major contributor to 
the overall antimicrobial activity of the neutrophil azurophil granule 
in vitro.43 ,170 Azurocidin also appears to function as a strong 
chemotactic agent for monocytes and neutrophils. 159'177 Its poor 
solubility at neutral pH under non-denaturing conditions has led to 
the suggestion that may be associated with the granule membrane. 176 
II. Neutrophil matrix metalloproteinases 
Matrix metalloproteinases (MMP) are a highly homologous family of 
zinc and calcium dependent endopeptidases, which play an important 
I . h d d . f II I . . 11s 119 Th ro e m t e egra ation o extrace u ar matnx protems. ' e 
MMP gene family includes gelatinases (MMP-2 and MMP-9), 
collagenases (MMP-1, MMP-8), stromelysins (MMP-3, MMP-10, 
MMP-11), PUMP-I (MMP-7) and membrane type MMP (MT-
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MMP). 180-183 The neutrophil contains two MMPs, namely neutrophil 
gelatinase (MMP-9) and neutrophil collagenase (MMP-8). These 
proteases are secreted as zymogens which may be activated by 
oxygen metabolites or proteolytic processing, 18 and under certain 
conditions, by autocatalytic cleavage. 181 •182 
1. Neutrophil gelatinase 
Neutrophil gelatinase (MMP-9) is a 92 kDa protein found in the 
specific (secondary) and gelatinase (tertiary) neutrophil granules.2 
Whereas gelatinase in the specific granules is present in relatively 
low concentrations and partially complexed to a 25 kDa protein 
NGAL (neutrophil gelatinase associated lipocalin), gelatinase in the 
tertiary granules is stored in high concentrations in its free form.2 
Gelatinase is initially mobilised from the tertiary granules by 
chemotactic signals during neutrophil recruitment,31 •67 and is secreted 
as a latent pro-enzyme, which is activated by oxygen metabolites or 
proteases, including HNE and cathepsin G. 18•54•184 
Neutrophil gelatinase is able to degrade the major components of the 
endothelial basement membranes and extracellular matrix, namely 
native or denatured type IV collagen/gelatin, laminin, and 
fibronectin. 185 Numerous reports suggest that gelatinase plays an 
important role in neutrophil migration.72•73•186 It has recently been 
shown that, following release, gelatinase can bind to the neutrophil 
membrane where it becomes activated by membrane bound HNE and 
cathepsin G.54 This may have important implications for the 
regulation of neutrophil migration through connective tissue. 
2. Neutrophil collagenase 
Collagenase is a 75 kDa protease which preferentially degrades 
native type I collagen.180•185 Neutrophil procollagenase is stored as a 
glycosylated protein within the specific granules of the 
neutrophil. 187•188 Inflammatory mediators induce the release of 
procollagenase189 which can then be activated by the neutrophil, in a 
similar manner to that described for gelatinase. The activated 
protease plays a key role in connective tissue turnover due to its 
ability to degrade collagen in the extracellular matrix. 
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Serine proteases of the neutrophil membrane 
Over the last decade, there have been numerous reports of serine 
protease activity associated with the. neutrophil membrane. This 
review considers three neutral serine proteases which have been 
reported to date. 
1. 300 kDa protease 
Pontremoli et al190 reported a novel 300 kDa membrane which was 
distinguished from serine proteases of the neutrophil azurophil 
granule on the basis of its molecular weight, inhibitor profiles and 
substrate specificities.190 Stimulation with low dose PMA (1 Ong/ml) 
induced release of this protease into the extracellular medium. This 
concentration of PMA was reported to cause only a minor discharge 
of secondary granules and no release of azurophil granules ( as 
indicated by the absence of azurophil granule markers B-
glucuronidase and N-acetylglucosaminidase). The release the 300 
kDa protease from the neutrophil was ATP dependent and associated 
with phosphorylation of membrane proteins. 191 This protease, located 
at sites of interaction of the neutrophil membrane and 
cytoskeleton, 192 was reported to have cytolytic activity190 and to . 
downregulate protein kinase C activity. 192 
2. 65-70 kDa protease 
King et al193 identified a membrane associated serine protease which 
was immunoprecipitated by an -antibody which recognises 
chymotrypsin. Although this "chymotrypsin-like" protease was 
originally reported to have a molecular weight of 150-180 kDa, 
immunoaffinity chromatography later revealed it to be 65-70 kDa in 
size. 194 It was suggested that this discrepancy in size was due to the 
propensity for these molecules to form dimers or trimers under the 
original experimental conditions. 194 The authors pointed to previous 
studies which noted a tendency for membrane proteins to aggregate 
after solubilisation unless maintained in conditions of high 
osmolarity. 195' 196 Interestingly, the proteolytic activity of this protease 
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was noted to be very similar to that of cathepsin G with respect to its 
inhibitor profile, its optimal pH, its affinity for substrates containing 
aromatic amino acids, and its requirement for calcium as a co-factor. 
However, it was suggested that it was unlikely that the detected 
proteinase activity was due to contamination with cathepsin G as the 
starting membrane preparation was free of other azurophil granule 
markers. 196 The recent observations, however, that the highly cationic 
azurophil granule serine proteases can bind to the neutrophil 
membrane by a charge related mechanism, brings into question the 
validity of using markers such as myeloperoxidase (MPO) or P-
glucuronidase to exclude the involvement of granule enzymes. 
During preparative procedures which involve cell lysis, the liberated 
cationic serine proteases may have a high propensity for binding to 
the membrane fraction, which is not neccessarily shared by the 
commonly used markers such as MPO and p-glucuronidase. Thus, it 
is possible that membrane preparations shown to be free of azurophil 
granule markers, may in fact be contaminated with azurophil granule 
serine proteases. 
3. 600 kDa protease 
A 600 kDa neutral serine protease of the neutrophil membrane has 
recently been reported to degrade C-reactive protein (CRP). 197 This 
protease was found to be associated with the neutrophil membrane 
and cytoskeleton fractions, and was partially released in response to 
stimulation with a dose of PMA (1 Ong/ml) which has been reported 
not to induce the release of azurophil granules. 190,197 The proteolytic 
activity of the neutrophil membrane and cytoskeleton fractions, as 
well the conditioned medium from PMA stimulated neutrophils, was 
shown by size exclusion chromatography to elute in a single peak 
corresponding to a molecular weight of 600 kDa. When each of these 
three fractions were subjected to SDS/P AGE, the proteolytic activity 
in each fraction, responsible for degrading CRP, was reported to 
migrate as four discrete bands to positions corresponding to apparent 
molecular mass values of 200 kDa, 316 kDa, 398 kDa and 501 kDa. 
It was suggested that these represented proteolytically active subunits 
of the 600 kDa protein. 197 
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Each fraction (membrane, cytoskeleton and PMA stimulated 
conditioned medium) was reported to generate CRP degradation 
products with identical apparent molecular mass values. These 
products were reported to differ in molecular mass from those 
produced by the action of azurophil granule (lysosomal) proteases on 
CRP. The CRP degrading activity of both the cytoskeleton and 
membrane fractions was reported to be completely inhibited by 
PMSF implying that this enzyme was a serine protease. 197 
These same neutrophil fractions were subsequently reported to 
possess fibrinogen and fibrin degrading activity. 198·199 Once again, 
when subjected to SDS/P AGE, the proteolytic activity in each 
fraction, responsible for degrading fibrin( ogen), was reported to 
migrate as four discrete bands to positions corresponding to apparent 
molecular mass values of 200 kDa, 316 kDa, 398 kDa and 501 
kDa. 198·199 This suggested that the same protease degraded CRP, 
fibrinogen and fibrin. This protease was reported to generate 
fibrin( ogen) degradation products with distinctly different molecular 
mass values from those produced by plasmin, neutrophil lysosomal 
enzymes and purified HNE. 198·199 Inhibitor profiles also suggested 
that this protease was distinct from known neutrophil proteases. Two 
specific chloromethyl ketone inhibitors of HNE (namely Suc-(Ala)3-
CH2Cl and Suc-(Ala)2-Val-CH2Cl) were reported to have no effect 
on fibrinogenolysis by these neutrophil preparations, whilst a third, 
Me0-Suc-(Ala)2-Pro-Val- CH2Cl, was reported to be only partially 
inhibitory (50% at 20 hours). Likewise, a specific inhibitor of 
cathepsin G, Suc-(Ala)iPro-PheCH2Cl, was reported to be non-
inhibitory.198 As with CRP, fibrin(ogen) degrading activity was very 
sensitive to inhibition by PMSF (phenylmethylsulphonyl fluoride) · 
and a.1-antitrypsin, but resistant to a number of cysteine and 
metalloproteinase inhibitors. This protease was reported to cleave a 
peptide from the N-terminus of the Aa. chain of fibrinogen (the Aa. 
1-21 peptide), previously thought to be produced exclusively by 
HNE.19s 
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Neutrophil adhesion 
The ability of cells to adhere to one another and to proteins in the 
extracellular matrix is central to a variety of important biological 
processes, including cell differentiation, migration, wound healing, 
tumour invasion, and cellular responses to, inflammation. 200 In the 
neutrophil, adhesive interactions are regulated by three distinctive 
families of adhesion receptors, namely the integrins, the selectins and 
the immunoglobulin superfamily. Each class of receptor will be 
reviewed in turn after which their collective roles in the adhesion 
process will be considered with particular reference to neutrophil-
endothelial cell interactions and neutrophil-extracel/ular matrix 
interactions. 
1. lntegrin receptors 
Integrins are a ubiquitous family of highly differentiated adhesion 
molecules which direct the processes of cell-cell communication as 
well as cellular interaction with the extracellular matrix.201 These 
membrane glycoproteins also serve as transmembrane links between 
the extracellular environment and the cytoskeleton of the cell,202•203 
and are thus able to act as signal transducers modulating important 
cellular functions. 200,204 As such they are intimately involved in many 
complex processes beyond adhesion including haemostasis, cell 
maturation and embryogenesis.200,205 
In addition, integrins are able to 
modulate a variety of important 
leukocyte inflammatory responses 
such as cytokine production,206 
phagocytosis and the respiratory 
burst.207•208 Integrins are 
heterodimeri c transmembrane 
proteins composed of non-
covalently linked a- and P-subunits 
(Figure 12). These subunits are the 
products of two different genes, 
Figure 12: A schematic represent-
ation of the two subunits of the 
heterodimeric integrin receptors. 
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and the expression of both subunits is required for receptor 
function.209 To date the integrin superfamily is known to contain 16 
different a-subunits and 8 different J3-subunits. These can pair in 
various combinations to form one of 22 different of aJ3-dimer 
permutations.200 Integrins are divided into subclasses according to 
their J3-subunit, and at least 8 subclasses (J3 1-J3s intergrins) are known 
to exist. 
N eutrophils express three subclasses of integrin receptors, namely J3 1, 
J32, and J33-integrins. The J32-integrin subclass is unique to leukocytes 
and the expression of this subset is far higher than the other two 
subclasses.210 These receptors, also known as the leukocyte integrin 
family, will be the major focus of the review which follows. Beta-1-
integrins, also known as very late antigens (VLAs ), are the most 
widely distributed class of integrin receptors in mammalian cells;211 
in neutrophils a2P1, a3f31, a4f31, asf31 and a6f31 are expressed.210 The 
J33-integrin family of receptors, also known as cytoadhesins, include 
the leukocyte response integrin (LRI), the vitronectin receptor as well 
as the platelet receptor, GPIIb/IIIa.205,212 
Electron microscopy has revealed integrins to be asymmetric 
structures consisting of a mushroom-like extracellular region (formed 
by the NH2-terminal regions of the a and J3 subunits) and two 
flexible cytoplasmic tails (formed by the C-termini of these 
subunits).213 The extracellular domains of the a and J3 subunits 
associate with each other to form the ligand binding pocket,211 whilst 
the cytoplasmic domains are thought to be linked to the cytoskeleton 
through intermediary linker proteins such as talin and a actinin.214 
This arrangement is believed to facilitate the translation of the 
extracellular signal, induced by ligand binding, to an intracellular 
event via reorganisation of the cytoskeleton. Integrins can bind to a 
variety of ligands including extracellular matrix (ECM) proteins,215 
cell surface immunoglobulin superfamily receptors,216 and certain 
plasma proteins.217 ECM ligands for integrins include fibronectin, 
fibrinogen, laminin, collagens, entactin, tenascin, thrombospondin 
and vitronectin.202,218,219 Certain integrin receptors can bind more 
than one ECM, whilst certain ECM proteins can bind more than one 
integrin receptor. This results in considerable overlap and redundancy 
in integrin-ligand interactions. 
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Divalent cations regulate the- binding of integrins to the majority of 
their ligands,220,221 and integrin mediated cell adhesion, as well as 
ligand binding to purified receptor, is dependent on millimolar 
concentrations of calcium. 222•224 Inactivated integrins usually have a 
low affinity for ligand; however, upon activation via appropriate 
signals, integrins can participate in high affinity binding.200,220 This 
unique function allows for the modulation of cell adhesive properties 
without quantitative upregulation of integrin expression on the cell 
surface. 11 ,200,225 Integrin receptors frequently recognise their ligands 
via the tripeptide amino acid sequence Arg-Gly-Asp (RGD),202 
although lh-integrins are able to recognise a variety of other peptide 
sequences as well. 
Leukocyte integrins 
The j32-integrins are by far the most abundant and important subset of 
integrin receptors on the neutrophil,210 and are thus the major focus 
of the review which follows. 
Beta-2-integrins, frequently referred to as leukocyte integrins, 
comprise a group of closely related heterodimeric molecules which 
can regulate the leukocyte inflammatory response. 220 These 
glycoproteins share a common j3 (CD18) subunit, and are 
distinguished by their a (CDl 1)-subunits, namely CDlla, CDllb, 
CDllc, CDlld.226•227 The four heterodimers are thus referred to as 
CDlla/CD18 (or lymphocyte function associated antigen [LFA]-1), 
CDllb/CD18 (or Mac-I), CD1 lc/CD18 (or p150,95) and 
CD 11 d/CD 18 ( a 0 j32). The important role played by the leukocyte 
integrins in the inflammatory response is highlighted by the severe 
and recurrent infections suffered by patients who lack these 
receptors.• The expression of each j32-integrin subset varies with the 
the different leukocyte subpopulations. CD 11 a/CD 18, whilst present 
to some extent on all leukocytes, is primarily expressed on lymphoid 
cells. On the other hand CD 11 b/CD 18 is enriched on cells of the 
myeloid lineage whilst CD 11 c/CD 18 and CD 11 d/CD 18 are most 
• Leukocyte adhesion deficiency (LAD) is a syndrome associated with a deficiency 
ofleukocyte ~rintegrins due to a mutation in the gene encoding CDIS.226•228 
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strongly expressed on monocytes and macrophages. 220 All subclasses 
are expressed, to varying degrees, on neutrophils. 
The polypeptide chains comprising the a. and P-subunits are type 1 
membrane proteins. The a-subunits comprise a short cytoplasmic 
tail, a transmembrane domain and a large extracellular domain of 
approximately 1000 amino acids. (see figure 13). This extracellular 
domain contains 7 tandem repeats of 60 amino acids which contain 
divalent cation binding site. 200 Within these repeats is an intervening 
I-domain, of approximately 200 amino acids, which contains the 
ligand binding sites critical for P2-integrin receptor function.229 The 
cytoplasmic tail of the a-subunit contains a conserved basic sequence 
near the transmembrane region, GFFKR, which is thought to play an 
important role in maintaining neutrophils in an inactive state in the 
absence of stimuli. 230 The extracellular domain of the P-subunit 
contains a region of approximately 200 amino acids which shows 
similarities to the I domain of the a-subunit, and just proximal to the 
membrane, a region comprising four cysteine rich motifs. Like the a.-
subunit, the P-subunit also has a short cytoplasmic tail. 200,210,220 
Diva lent cation 
binding domains 
(V-VII) 
CD11 NH, 1 11 , , • 111 IV v VI VII 
Homologous repeats (I-VII) 
Lipid bilayer 
COOH 
.CD18 NH2 !.___~~~~~~II ... ID ..... IDl ..... 6!'1..._~~~lcooH 
Cystelne rich 11 
domains 
Figure 13: A schematic representation of the structure of the Printegrins. The 
CD11 (a-chain) contains the ligand binding I-domain as well as divalent cation 
binding domains. The CD18 (ft-chain) is non-covalently associated with the a-
chain to fonn the functional Printegrin receptor. 
The adhesiveness of leukocyte integrins is not constitutive but 
dependent upon receptor activation. 225·231 Recent evidence suggests 
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that 132-integrins may be activated either directly, via ligand binding 
to integrin receptors, or indirectly, as a consequence of ligand 
binding to non-integrin molecules.220 Whilst the mechanisms behind 
direct activation are still relatively poorly understood, indirect 
activation has been far more extensively studied and several known 
mediators exist. These include various inflammatory mediators such 
as TNF, IL-8, C5a, P AF and FMLP as well as non-physiological 
activators, such as the phorbol ester, phorbol-3-myristate-4-acetate 
(PMA).11·225 It has been suggested that the binding of these mediators 
sets in motion a cascade of signalling events which ultimately leads 
to phosphorylation of serine/threonine residues in cytoplasmic tail of 
CD18, thereby activating the receptor.220 Despite intensive research 
in this area, a more complete understanding of the mechanisms 
behind of integrin activation remains to be achieved.220 The four 132-
integrin subsets are reviewed in turn below. 
1. CD11a/CD18 (LFA-1) 
This integrin receptor, also known as lymphocyte function associated 
antigen- I (LF A-1) is expressed on all leukocytes, but is primarily 
associated with lymphocytes.226 CD1 la/CD18 mediates leukocyte 
adhesion to endothelial cells, 11 and supports T lymphocyte helper and 
killer function.232 Ligation of CD11a/CD18 by ICAM-1 has recently 
been reported to signal for neutrophil phagocytosis.233 
2. CD11b/CD18 (Mac-1) 
CD1lb/CD18, often referred to as Mac-1 or CR3, is enriched on 
granulocytes. It is arguably the most important and versatile adhesion 
receptor on the neutrophil, and is intimately involved in a number of 
fundamental cellular processes. Mac-1 plays an important role in 
neutrophil adhesion to, and transmigration across the 
endothelium.234·235 It also mediates neutrophil homotypic 
aggregation, 236·237 chemotaxis, 236 phagocytosis, 238-240 and adherence 
to serum coated substrates.236 These Mac-1 dependent adhesive 
interactions result from its ability to bind to a variety of cellular and 
soluble ligands including C3bi,241 ·242 intercellular adhesion molecule 
1 (ICAM-1),225·234 fibrinogen,243·244 factor X,245 and L-selectin.246 
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The I domain of Mac-1 has been shown to be critical for the 
recognition of most of its ligands.229 
Mac-1 does not bind to its ligands until a specific stimulus has been 
delivered. The increased avidity which follows Mac-1 activation has 
recently been attributed to the expression of an activation specific 
neoepitope on a small subset of Mac-1 receptors (10-30%).225 
Monoclonal antibodies directed against this epitope have been shown 
to inhibit neutrophil adhesion to ICAM-1 and fibrinogen by over 
90%.225 
3. CD11c/CD18 (p150,95) 
The expression of CD 11 c/CD 18 is mainly restricted to neutrophils 
and monocyte/macrophages, although it has been identified on some 
lymphocytes, and is a marker of hairy cell leukaemia.247-249 In 
contrast to CD11a/CD18 and CD11b/CD18, the functional role of 
CD 11 c/CD 18 is not clearly understood. Like the other leukocyte 
integrins, this receptor is involved in neutrophil adherence to 
endothelium,249·250 binds to fibrinogen251 and C3bi opsonised 
particles, 252 and more recently has been identified as a 
transmembrane signalling receptor for lipopolysaccharide (LPS).253 
4. CD11d/CD18 
The most recently identified member of the P2-integrin family is 
CD11d/CD18.227 The CDlld subunit resembles CDllb and CDllc 
more closely than CD 11 a. It differs in its distribution from the other 
leukocyte integrins in that it is expressed on granulocytes and 
macrophages in the splenic red pulp, on lipid laden macrophages in 
aortic fatty streaks and to a lesser extent on peripheral blood 
leukocytes.221 The only known ligand for this receptor identified to 
date appears to be ICAM-3 which is constitutively expressed on 
resting leukocytes. 221 
Leukocyte response integrin (LRI) 
Leukocyte response integrin (LRI), which shows strong homology to 
members of the p3-integrin subfamily, is one of the more recently 
characterised neutrophil integrin receptors.205·254 Unlike members of 
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the ~2-integrin subfamily, this receptor does not require prior 
activation in order to bind to its ligands. It is intimately associated 
with a 50 kDa protein, known as integrin associated protein (IAP) 
and together they form a signal transduction unit for the activation of 
phagocytes.255·256 Several proteins cqntaining ROD-sequences have 
been reported to transduce signals for neutrophil activation via LRI 
and IAP. These include entactin, fibrinogen, fibronectin, von 
Willebrand's factor, vitronectin and collagen type IV.205 As the 
binding of the ROD-sequence to LRI has been shown to serve as a 
signal for both chemotaxis257 and· phagocytosis, 205 it has been 
suggested that this receptor may play an important role in the 
neutrophil inflammatory response. 
2. Selectins 
The selectins are a family of three integral membrane glycoproteins. 
Each member of this family has an amino terminal lectin domain, an 
epidermal growth factor (EOF)-like sequence, a transmembrane 
domain, and a short cytoplasmic tail (see figure 14).258'259 The lectin 
and EOF-like domains are critically involved in adhesion.259·260 
These domains bind to sialylated glycoproteins on the surface of 
target cells.259 L-selectin is found on the surface of leukocytes and E-
selectin on endothelial cells (EC), whilst P-selectin was initially 
identified on platelets and 
later on EC.259 Tethering 
interactions between 
selectins and their ligands 
( sialylated glycoproteins) 
on the neutrophils and 
EC) cause neutrophils to 
slow down and roll along 
the vessel wall.261 ·262 
Selectins are ideally 
suited to this tethering 
role owing. to their long 
molecular structure that 




Figure 14: A schematic representation of 
selectin structure indicating the amino terminal 
lectin domain, EGF repeat, the complement 
regulatory-like molecules the transmemb~ne 
domain and the cytoplasmic tail. 
,, ' 
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and allows them· to I capture passing leukocytes that express the 
appropriate receptor. 262 Selectin mediated adhesion is strong enough 
to induce rolling along the vessel wall but not so strong as to stop 
leukocytes completely.262 This does however allow neutrophils to be 
exposed to potential integrin activating agents such as chemokines, 
formylated bacterial peptides ( e.g. FMLP) and complement 
fragments. 210 Recent studies suggest that, in addition to their 
adhesive functions, selectins may directly signal cell responses. 
Neutrophils adherent to E-selectin on IL-1 prestimulated EC, or to 
preparations of recombinant E-selectin adsorbed to a plastic surface, 
are reported to increase the adhesiveness of Mac-1.263·264 In addition 
it has recently been reported that crosslinking of L-selectin signals 
for the upregulation ofMac-1 dependent adhesion.265 
The various selectins differ from one another in their pattern of 
expression. L-selectin is constitutively expressed on most leukocytes, 
and upregulation occurs through the rapid enhancement of the avidity 
of L-selectin for its counter receptors.266 L-selectin is rapidly shed 
· from the plasma membrane during the process of neutrophil 
activation following proteolytic cleavage near its transmembrane 
region. 266·267 E-selectin is not constitutively expressed by the EC but 
is actively synthesised following EC activation with various 
chemokines.268 P-selectin, which is stored in EC secretory granules, 
is rapidly translocated to the plasma membrane following EC 
stimulation with thrombin or histamine.262 Thereafter it is rapidly re-
intemalised, resulting in its transient expression which parallels 
neutrophil adhesion to activated EC. The transience of P-selectin· 
expression provides a mechanism to temporally regulate such 
adhesive interactions. 269·270 
3. lntercellular adhesion molecules (ICAM) 
Intercellular adhesion molecules (ICAM) are the EC counter-
receptors for activated leukocyte ~2-integrins, and as such play an 
integral role in neutrophil-EC interactions. ICAMs belong to a 
broader family of adhesion receptors, known as the immunoglobulin 
superfamily, so named due to the repeated immunoglobulin-like 
regions in their extracellular domains (Figure 15). There are three 
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members of the ICAM family, namely ICAM-1, -2 and -3. ICAM-1 
and 2 are involved in neutrophil-EC interactions, and these two 
transmembrane glycoproteins are closely related in terms of structure 
and function. 271 Whilst ICAM-1 contains 5 extracellular 
immunoglobulin (lg)-like domains, ICAM-2 contains only two. The 
two lg domains of ICAM-2 show strong homology with the two 
amino-terminal domains of ICAM-1 (which are known to mediate 
ligand binding), and this may explain their partially overlapping 
functions. 272,273 ICAM-2 is constitutively expressed on EC, and 
therefore mediates binding to resting endothelium. In contrast, 
ICAM-1 expression, which is very low in resting cells, is markedly 
upregulated following EC · 
activation and is therefore 
involved in neutrophil 
binding to inflamed 
endothelium. 259,271 ICAM-1 
is recognised by both 
CDlla/CD18 and CD1 lb/ 
CD18, whereas ICAM-2 is 
recognised only by 
CD1 la/CD18.271 ,274 Ligation 
of CD1la/CD18 and 
CDllb/CD18 by ICAM-1 
has recently been shown to 
upregulate the release of 
HNE by the neutrophil with 








Figure 15: A schematic representation 
of /CAM 1 and 2, showing the extracell-
ular immunoglobulin like domains. 
Neutrophil-endothelial cell interaction 
An early and requisite step in the acute inflammatory response is the 
migration of neutrophils from the circulation into sites of 
inflammation. This requires that the circulating neutrophil makes 
contact with the endothelium, slows down, becomes adherent and 
finally migrates through the blood vessel. 
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The adhesion cascade is initiated by tethering interactions between 
neutrophils and EC which cause circulating neutrophils to slow 
down. This is mediated by selectins both on the neutrophil and on 
EC, which interact with sialylated carbohydrate residues on target 
cells. This results in a degree of adhesion that is sufficient to induce 
neutrophil rolling on the vessel wall but not strong enough to halt 
them completely.261 '262 This transient interaction allows neutrophils 
to become exposed to various factors on the EC surface that activate 
neutrophil expression of P2-integrins. Two such factors include IL-8 
and PAP, which may be produced by activated EC or underlying 
inflammatory cells. 11'276'277 The immobilisation of these proadhesive 
cytokines on the EC surface may localise leukocyte activation to 
areas of endothelium overlying inflammatory sites, and prevent the 
removal of cytokines in passing blood. Other potential trigger factors 
for P2-integrin activation include bacterial wall components (eg. 
FMLP and LPS), complement products,211 and selectins 
themselves.263-265 These factors signal for both quantitative 
upregulation of P2-integrin expression as well as a qualitative 
alteration of the receptors constitutively present in the plasma 
membrane. 11 The latter appears to be the primary mechanism 
whereby neutrophil adherence to the endothelium is increased, as 
suggested by two series of observations. Firstly, maximal adherence 
of activated neutrophils to EC has been shown to precede the 
maximal recruitment CD11b/CD18 to the surface, and secondly, the 
adhesive interaction reverses during a period when increased 
numbers of this heterodimer are present on the neutrophil surface. 11 
This functional upregulation has recently been attributed to an 
activation specific epitope on CD1 lb/CD18 (see page 41).225 
Similarly, CD1 la/CD18 has also been shown to undergo functional 
upregulation, which is mediated via alterations of the cytoplasmic 
domain of its P-chain.278'279 This is important since this receptor does 
not appear to undergo quantitative upregulation following neutrophil 
activation.280 The binding of P2-integrins to their counter-receptors, 
ICAM-1 and ICAM-2, on EC mediates strong adhesion between 
neutrophils and the endothelium. 11,271 
Strong adhesion is a transient phenomenon, and following weakening 
of integrin mediated adhesion, neutrophils migrate · into the 
interstitium.220 Of all the steps involved in neutrophil migration to 
extravascular sites of inflammation, transendothelial migration is the 
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least understood.2 11 It has been suggested that reciprocal interactions 
between CD31 and av~3 (which are present on both neutrophils and 
EC) may facilitate this process, although the precise mechanisms 
involved remain unclear.211 Recent studies suggest that neutrophil 
elastase (HNE) may play an important role in transmigration, not 
only through its ability to digest the basement membrane, but also 
hr gh . b'l. 1 . . fr th . b tr t 112 116 t ou its a 1 1ty to re ease mtegrms om eir su s a es. · 
Tissue -
Molecules 
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Figure 16: The sequential steps in the adhesion of neutrophils to activated 
endothelium. The circulating neutrophi/ is tethered and brought into contact with 
the EC wall by selectin mediated interactions. Tethering allows for the exposure of 
neutrophils to cytokines released by underlying inflammatory cells and expressed 
on the EC surface. Cytokines trigger the expression and upregulation of integrin 
receptors which facilitate strong adhesion of neutrophils to EC. The transience of 
this interaction allows for the subsequent migration of neutrophils into the 
underlying tissue under the influence of chemoattractants released by underlying 
inflammatory cells or invading micro-organisms. 
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Neutrophil-extracellular matrix interactions 
Having traversed the endothelium, the neutrophil must next migrate 
through the extracellular matrix (ECM) to the site of tissue damage. 
The ECM is a relatively stable structural matrix which underlies 
epithelia and endothelia and surrounds connective tissue cells. It is 
composed of collagens, glycoproteins, proteoglycans, elastin and 
associated molecules such as fibronectin, vitronectin, fibrinogen, and 
laminin. Once regarded solely as an extracellular scaffold for the 
maintenance of tissue architecture, the ECM is now recognised as a 
highly interactive substratum capable of modulating cellular function. 
The interaction between neutrophils and the ECM may have a 
profound influence of the neutrophil inflammatory response. 
Whilst fibrinogen is the major ECM protein recognised by P2-
integrins, 211 the p I and p3-integrins recognise a wide variety of 
ligands containing the tripeptide sequence Arg-Gly-Asp (R-G-D), 
including fibrinogen, fibronectin, thrombospondin, vitronectin, 
entactin and collagen type I and IV.2II,254 Integrin receptors provide 
the link between the extracellular environment and the cytoskeleton, 
with ligation of these receptors signalling for important cellular 
functions. 
_ When neutrophils adhere, via P2-integrin receptors, to ECM protein 
coated surfaces, they undergo a number of functional changes -
adherent neutrophils become far more reactive to inflammatory 
stimuli than those in suspension.207,208 The influence of P2-integrin 
mediated adherence on neutrophil function was first noted with 
respect to the respiratory burst. Whilst neutrophils in suspension 
were shown to be poorly responsive to stimulation with low dose 
TNFa and p, those adherent to the ECM respond with a full scale 
respiratory burst.207 The P2-integrin dependence of this phenomenon 
was suggested by two sets of observations. Firstly, neutrophils from 
patients with leukocyte adhesion deficiency (LAD), whose 
leukocytes are deficient in CD18, were found not to undergo a 
normal cytokine induced respiratory burst on ECM coated surfaces. 
Secondly, neutrophils adherent to surface-bound anti-CD I 8 antibody 
were noted to respond with a respiratory burst similar to that seen in 
ECM adherent neutrophils, following cytokine stimulation. 208 
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Neutrophil spreading on the ECM has subsequently been shown to be 
• • .c-. h dh . d d . t b t 282-284 a prerequisite 1or t e a es1on- epen ent respira ory urs . 
Both p2-integrin mediated adhesion and respiratory burst have been 
shown to be linked to protein tyrosine phosphorylation - tyrosine 
kinase inhibitors are capable of blocking both these responses,283·285 
whilst P2-integrin dependent adhesion to the ECM triggers tyrosine 
phosphorylation of a variety of neutrophil proteins. 285·286 As tyrosine 
phosphorylation is an important signalling mechanism in neutrophil 
activation,287-289 the increased levels of tyrosine phosphorylation 
triggered by P2-integrin mediated adherence is likely to influence a 
variety of important neutrophil responses. Indeed, in addition to its 
effect on the respiratory burst, Pi-integrin mediated adhesion 
upregulates several other neutrophil inflammatory responses. This 
includes the release of specific granules from the neutrophil,290 which 
as noted earlier, alters the membrane phenotype cell and therefore a 
variety of inflammatory functions. Beta-2-integrin mediated adhesion 
also appears to upregulate neutrophil cytokine production, as 
suggested by the enhanced production of IL-8 noted in adherent 
neutrophils stimulated with LPS.206 As IL-8 is a potent 
chemoattractant for neutrophils, this may have important 
consequences for neutrophil recruitment to sites of inflammation. 
Whilst the molecular events involved in signal transduction from the 
integrin receptor to the cytoskeleton will not be addressed here, a 
recent review suggests these processes are both highly complex and 
incompletely understood. 200 
Neutrophil interaction with fibrinogen 
Many of the studies investigating the effect of P2-integrin-dependent 
adhesion on neutrophil function (see above) have used fibrinogen as 
the ECM substrate.2°6·208·286·290 This suggests that surface adherent 
fibrinogen has the ability to modulate neutrophil function at 
inflammatory sites. 
On the neutrophil, the P2-integrins, CD11b/CD18 and CD11c/CD18, 
as well as the p3-integrin, LRI, serve as receptors for 
fibrinogen. 244·251 ·254 The nature of the stimulus determines which of 
the P2-integrin receptors will bind fibrinogen. 
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D Neutrophils stimulated with the phorbol ester PMA bind to 
surface adherent fibrinogen via the CD1 lb/CD18 (Mac-1) integrin 
receptor.244 This was initially reported to occur via the K-Q-A-G-
D-V sequence situated at the carboxyl terminus of the fibrinogen 
y-chain, as suggested by studies using peptide mimicry. 244 It was 
later shown that, in neutrophils stimulated with the chemotactic 
peptide FMLP, Mac- I recognises fibrinogen via a different region 
of the y-chain, as suggested by the inhibition of neutrophil binding 
to both soluble and surface adherent fibrinogen by peptides · 
corresponding to the y-chain sequence Gly190-Val202.
281 More 
recently, it has been suggested that this region together with they-
chain region y-377-395 forms a binding pocket for the I-domain 
on CD1 lb/CDI8.291 
D Neutrophils stimulated with TNFa., have been reported to bind to 
fibrinogen coated surfaces via CD1 lc/CD18, interacting with the 
G-P-R sequence at positions 17-19 of the amino terminus of the 
fibrinogen a.-chain.251 
Although soluble fibrinogen has been reported . to associate 
specifically with 132-integrin receptors on neutrophils under certain 
conditions,281·291 it has been suggested that the affinity of these 
receptors for soluble fibrinogen is very low.244·251 It has been 
suggested that clotted fibrinogen, or fibrinogen coated surfaces, in 
which the carboxyl terminus of the gamma chain is "multivalent", is 
the biologically relevant substrate for these receptors.244·251 
Neutrophils can also bind to soluble fibrinogen via a member of the 
A • • f: · 1 1 1 uk · · (LRI) 240 254 1-13-mtegrm am1 y, name y e ocyte response mtegrm . ' 
Like the platelet !33-integrin receptor, a.nbl33, LRI reported to bind to 
both the R-G-D sequence of the fibrinogen a-chain as well as the K-
Q-A-G-D-V sequence of the carboxyl terminus of the fibrinogen y-
chain. The interaction of neutrophils with soluble fibrinogen and 
fibrin( ogen) degradation products is discussed in greater detail in the 
following chapter (see pages 85-87). 
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F ibrinogen is best known for its role in haemostasis in which it 
serves as a precursor for fibrin clots and an essential ingredient of 
platelet aggregates. In addition to its role in haemostasis, fibrinogen 
has become increasingly recognised as a multifunctional protein 
which interacts with a variety of cells and proteins, and regulates a 
number of important biological processes. 
Structure 
Fibrinogen is a 340 kDa acid glycoprotein, comprising approximately 
3000 amino acids, and made up of two identical halves. 1'2 Each half 
molecule contains 3 distinct polypeptide chains, known as the Aa, 
B~ and y chains,• and these two halves are held together by a network 
of disulphide bonds3•5 (figure 1). 
Structural studies have revealed fibrinogen to be an elongated, 
trinodal molecule, with its six polypeptide chains arranged in three 
globular domains, one located centrally (known as the E-domain) and 
two peripherally (the D-domains).6"8 The central E domain is formed 
by the amino termini of all six chains as they come together at the 
dimer interface, whereas the two peripheral D domains are formed by 
the carboxyl termini of the beta and gamma chains (figure 1).9"11 The 
alpha chain carboxyl termini do not form part of the D-domain, but 
are thought to fold back and interact directly with the central globular 
domain. 12•14 The E domain is linked to the D domains by a ·triple 
helix rope-like connector, comprising a 111 amino acid residue 
stretch of the 3 polypeptide chains, twisted tightly round one another 
and interacting via hydrogen bonds, to form a three stranded helix 
frequently referred to as the "coiled coil."15 
• Also referred to as the a, J3 and y chains. 
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Fibrinogen 
Figure 1. A schematic representation of the fibrinogen molecule. Fibrinogen 
consists of two half molecules, each comprising three polypeptide chains (Aa, B{J 
and r). These half molecules are joined by disulphide bonds at the amino terminal 
regions of the 3 polypeptide chains. This arrangement gives fibrinogen a trinodal 
structure with the central E-domain comprising the amino termini of the six 
polypeptide chains, and the peripheral D-domains comprising the carboxyl termini 
of the BP and r chains. The alpha chain carboxyl termini fold back and interact 
directly with the central globular domain. The E- and D-domains are linked by a 
triple helix formed by the 3 polypeptide chains, frequently referred to as the "coiled 
coil." Also indicated are the factor XIII (fXIII) and ( a2PI) a2-antiplasmin binding 
sites. (Adapted from Reference 100) 
The fibrinogen molecule is stabilised by 29 disulphide bonds, 17 of 
which link the 6 chains to one another (interchain disulphide bonds), 
and 12 of which link different regions within individual polypeptide 
chains (intrachain disulphide bonds). 16-19 
The assembly of the two half molecules is dependent upon 3 
interchain disulphide bonds at the amino terminus as well as three 
pairs in the amino terminal region of the coiled coil. 20-22 In contrast, 
the interchain disulphide linkages on the carboxyl terminal side of 
the coiled coil region are not essential for chain assembly; however, 
if they are not present fibrinogen is assembled but not secreted, 
probably due to improper folding. 20 
Each half molecule has six intrachain disulphide bonds, which form 
loops in the carboxyl-terminal regions of each polypeptide chain; the 
Aa chain has one, the B~ chain three, and they chain has two such 
bonds.23 This combination of inter- and intrachain disulphide 
linkages together with the coiling of the three chains, imparts a 
·t t 
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specific structure to fibrinogen which is likely to influence its 
biological activities. 
Biosynthesis and regulation 
The fibrinogen gene 
Each polypeptide chain is encoded by a separate mRNA, transcribed 
from 3 distinct, single copy genes.24"26 The cDNAs for each chain of 
human fibrinogen have been cloned and their nucleotide sequences 
are known.26"31 The striking homology that exists between the 
cDNAs encoding the three chains suggests that they may have 
evolved from a common gene. Furthermore, the observation, in both 
the rat and the human, that the a. and y genes lie in an opposite 
transcriptional orientation to the p gene, and that all three lie in very 
close proximity to one another, suggests that both gene duplication 
and inversion may have been involved in the evolution of the three 
chains of fibrinogen from a single ancestral gene. 24,25 
Fibrinogen biosynthesis 
Fibrinogen is synthesised by the hepatocne32 at a rate of 1. 7-5 grams 
per day under steady state conditions. 3 ,34 Once in the circulation, 
fibrinogen has a half-life of approximately 3-5 days.35 
During the steady state, the synthesis of the BP chain afc&ears to be-
the important rate limiting step in fibrinogen synthesis, ,37 whereas 
during the acute phase response (see below), a proportional increase 
in the mRNA encoding all three chains is seen.3 Following synthesis 
on separate polysomes, the three translated chains are transported to 
an assembly site within the lumen of the endoplasmic reticulum 
where they are assembled by electrostatic, hydrophobic and 
disulphide interactions into a dimeric structure.39 This involves a 
pathway of sequential steps with the generation of a number of 
probable intermediates. Although there are conflicting reports as to 
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the nature of these intermediates, 36'4047 the final step of this pathway 
appears to involve the dimerisation of two Aa.B~y half molecules, 
with disulphide bonds in the amino terminal region of the Aa and y 
chains joining these two half molecules together (figure 2).4042 





Figure 2. A schematic representation of the final step in fibrinogen assembly 
which involves the dimerisation of the two AaB/Jy half molecules. Disulphide 
bonds in the amino terminal region of the Aa and r chains join the two half 
molecules together. 
Regulation of fibrinogen synthesis 
In addition to the opposing forces of synthesis and catabolism that 
regulate the levels of any plasma protein, fibrinogen levels in the 
plasma are influenced by two additional factors. Firstly, fibrinogen 
( either soluble or clotted) is also degraded by plasmin, the protease 
responsible for the dissolution of fibrin clots. Secondly, a variety of 
inflammatory conditions (including infection, physical, chemical or 
thermal trauma, and neoplasia) may provoke a systemic response 
associated with changes in the plasma levels of a group of proteins 
(known as acute phase reactants) of which · fibrinogen is one. 48 
During this response, known as the acute phase · response, the 
concentration of fibrinogen may increase 2-20-fold, and is associated 
with a similar elevation in mRNA levels.49-51 Thus, in determining 
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the factors which r~gulate fibrinogen synthesis, it is important to 
distinguish between non-specific stimuli, which induce fibrinogen 
synthesis through activation of the acute phase response, and specific 
signals for fibrinogen synthesis. 
Several non-specific stimuli of fibrinogen synthesis have been 
identified. Peripheral blood leukocytes, when incubated with plasmin 
derived fragments of fibrinogen or fibrin, have been reported to 
secrete a factor which upregulates the synthesis of fibrinogen ( and 
other acute phase proteins) by rat hepatocytes.52 Similarly, human 
peripheral blood monocytes have been shown to release a factor 
which is capable of inducing increased production of acute phase 
proteins by cultured hepatocytes. 53-55 This factor was subsequently 
identified as interleukin 6.56"58 On the other hand, several factors, 
including interleukin- I (IL-1 ), tumour necrosis factor (TNF)57 and 
transforming growth factor p (TGFP),59 have been shown exert an 
inhibitory effect on hepatocyte production of acute phase proteins. 
The possibility that fibrinogen levels may serve as a feedback 
mechanism for fibrinogen synthesis has been considered. Indeed, a 
massive defibrination in rats ( effected by the administration of 
Malayan pit viper venom) was shown to induce an increase in 
fibrinogen mRNA levels in excess of 10-fold.38 It was unclear, 
however, whether this was due to low fibrinogen levels or the 
fibrinogen breakdown products generated as a result of disseminated 
intravascular coagulation. A subsequent study, investigating the 
effect of purified plasmic fragments of fibrinogen on fibrinogen 
synthesis in the rat, suggested that the fibrinogen degradation 
products themselves induced increased fibrinogen synthesis. 60 It was 
shown that intravenous or intraperitoneal injection of purified 
fragment D (in concentrations equivalent to those seen with lysis of 
approximately 8% of intravascular fibrinogen) resulted in a four-fold 
increase in the synthesis of fibrinogen. Significantly, :fragment D did 
not affect the level of other acute phase reactant proteins, and 
therefore appears to be specific for fibrinogen. This suggests that 
plasmin fragments of fibrinogen may well provide a feedback 
mechanism which may regulate fibrinogen synthesis. 60 
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Fibrin formation 
The fibrin clot promotes haemostasis by providing a structural 
support and scaffholding for cellular and other blood components 
which constitute the thrombus in vivo. In the final step of the 
coagulation cascade, soluble fibrinogen is cleaved by thrombin, 
resulting in the spontaneous polymerisation of the altered fibrinogen 
molecules to form the long threadlike polymer, fibrin. The process of 
fibrin formation is broadly divided into three steps (see figure 3) each 
of which will be considered separately below. These include: 
( 1) Thom bin cleavage of fibrinogen 
(2) Non-covalent assembly of fibrin monomers 
(3) Covalent crosslinking of fibrin monomers catalysed by factor XIIIa 
FPA 
~
1 ~ Thrombin cleavage 
- -
~ - -
2 Spontaneous polymerisation 
Figure 3. A schematic representation of the three basic steps in the process of 
fibrin formation (1) Thombin cleaves fibrinogen releasing fibrinopeptides A and 8. 
(2) This exposes polymerisation sites on fibrin monomer resulting in the 
spontaneous, non-covalent polymerisation of fibrin monomers (3) The fibrin 
polymer is stabilised by covalent cross/inking of r chains catalysed by factor XII/a. 
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Thrombin cleavage of fibrinogen 
Whilst thrombin is best known for its role in the conversion of 
fibrinogen to fibrin, it is in fact a multifunctional protease whose 
varied actions, both on cells and soluble protein substrates, may 
influence several important (patho )physiological processes (figure 4). 
Thrombin is a potent activator of platelet aggregation,61 •62 it is 
chemotactic for monocytes, 63 mitogenic for lymphocytes and 
mesenchymal cells (including vascular smooth muscle cells),64"66 and 
has a number of important effects on the vascular endothelium; these 
include the stimulation of endothelial cell production of 
prostacyclin, 67 platelet activating factor (P AF), 6 plasminogen 
activator inhibitor (PAI), 69 and platelet derived growth factor 
(PDGF).70 Thrombin also induces increased endothelial cell 




• (I) Chemotaxis Aggregation 
Proliferation 
( Thrombin) 
Endothelial cell Haemostatic system 
~ Mesenchymal cell -t prostacyclin, PAF, ·~. PAI, PDGF production. Cleavage of fibrinogen, 
t neutrophil adhesion factors V, VIII and XIII, 
Proliferation protein C and platelet 
thrombin receptor. 
Figure 4. An illustration of the varied actions of thrombin on cells and protein 
substrates which influence a number of important biological processes. 
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It has numerous actions on proteins of the haemostatic system 
including the conversion of fibrinogen to fibrin monomers, as well as 
the proteolytic processing of factor V, 72 factor VIII, 73 factor XIII, 74 
protein C, 75 and the platelet thrombin receptor. 76 
Thrombin interacts with fibrin( ogen) via two types of complementary 
binding sites on the fibrin( ogen) molecule. The first, the fibrinogen 
substrate site (figure 5a), interacts with the thrombin active site 
facilitating the cleavage of fibrinogen to form fibrin monomers.77"81 
The second type of site on fibrin is not associated with proteolysis 





Figure 5. Thrombin interacts with fibrin(ogen) via two types of complementary 
binding sites on the fibrin(ogen) molecule: (a) The substrate site, which is located 
at amino terminal residues Aa 7-16, interacts with thrombin facilitating the cleavage 
fibrinopeptides A and B. (b) Non-substrate sites of high and low affinity are 
present on fibrin. The high affinity site (also present in fibrinogen) is situated in the 
0-domain of the r'-chain. The low affinity sites are situated in the fibrin E domain. 
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The thrombin active site has two separate domains: a catalytic site 
(which includes the Asp-His-Ser catalytic residues, the specificity 
pocket and an apolar pocket) and an extendedjibrinogen recognition 
site. 87•88 Thrombin binding to the fibrinogen substrate site ( amino 
terminal residues Aa. 7-16) is mediated through the anion binding 
jibrinogen recognition site which is situated in an extended patch of 
positively charged residues in the region of thrombin's loop segment 
centred around Lys 70-Glu 80.89•90 The side chain of Arg-16 is 
inserted into the specificity pocket of thrombin91 •92 and, following 
cleavage at an RG bond of the Aa. (Aa.16/17) and BJ3 chains 
(BJ314/l 5), fibrinopeptides A and B are released. 77"81 The release of 
FP A and B results in the formation of intermediate fibrin monomers 
which expose new binding sites. 93 Whilst the release of 
fibrinopeptide A occurs rapidly and is independent of fibrin 
polymerisation, cleavage of the BJ3 chain is much slower and is 
largely dependent on fibrin polymerisation.94"96 
Thrombin also associates with fibrin via non-substrate sites82-86 
(figure 5b) and this appears to play an important role in the regulation 
of fibrin assembly. Fibrin possesses two types of non-substrate 
thrombin binding sites, one of high affinity and the other of low 
affinity.83•97 The high affinity site, which is present in fibrinogen as 
well as fibrin, is located exclusively in the D-domains of the y' 
variant• of the gamma chain, whilst the low affinity sites are situated 
in the fibrin E domain, and may represent a residual aspect of the 
substrate recognition sites in fibrinogen.97 Thrombin binding to fibrin 
non-substrate sites appears to have several physiologically important 
consequences. It has been suggested that this binding, by limiting the 
diffusion of thrombin, plays an important role regulating · clot 
propagation, as patients whose fibrin lacks one or more of the non-
substrate binding sites have a tendency to develop recurrent 
thromboembolic disease.98"100 In addition, fibrin bound thrombin is 
resistant to inhibition by circulating heparin-antithrombin III 
complexes. 101•102 This might explain the limited effectiveness of 
heparin in preventing coronary reocclusion after successful treatment 
with the thrombolytic, tissue plasminogen activator (t-PA). 103•106 
• The y' variant is a structural variant of the fibrinogen y-chain and is present in 
about 10% of plasma fibrinogen molecules. 
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Thrombin binding to non-substrate sites on fibrin also appears to play 
an important role in accelerating fibrin assembly by a mechanism that 
is not dependent on thrombin's catalytic activity.82 Finally, the fibrin-
thrombin complex, formed as a result of thrombin binding at the 
fibrin non-substrate site, accelerates the activation of factor XIII, 
thereby upregulating the process of fibrin matrix assembly. 107 
Non-covalent polymerisation 
Following the cleavage of the fibrinopeptides A and B, the fibrin 
monomers polymerise spontaneously to form a fibrin clot. 108 The 
newly exposed sites (figure 6) in the E domain link up with the D-
domains on neighbouring molecules via non-covalent 
interactions.78•79•81 The polymerisation process comprises a number 
of different interactions: Two sites on the E domain (EA and Ee) are 
involved in interactions with two corresponding sites on the D-
domain (Da and Db respectively). In addition, two other important 
types of association occur between fibrin monomers. One involves 
the association of D-domains (D:D associations) whilst the other 
involves association of the carboxyl termini of the Aa chains (the aC 
domains) of neighbouring molecules. 
aC 
D-domain 
Figure 6. Thrombin cleavage of fibrinogen exposes several polymerisation sites on 
the fibrin monomer. Two sites on the E domain (EA and Ee) are involved in 
interactions with two corresponding sites on the 0-domain (Da and Db 
respectively). Other polymerisation sites exposed include sites on the D-domain 




Figure 7. A schematic representation of the interactions involved in fibrin 
polymerisation. (a) Cleavage of fibrinopeptide A exposes the primary 
polymerisation site, EA, which interacts with a complementary site, Da, sitmited at 
the carboxyl terminal segment of the y-chain in the D-domain. This interaction 
results in the formation of double stranded fibrils. (b) The cleavage of fibrinopeptide 
B exposes a second polymerisation site, Ea which interacts with a complementary 
site situated in a carboxyl terminal ~chain segment of the D-domain, known as the 
Db site. 
Fibrin assembly is initiated by the exposure of the polymerisation site 
EA following the cleavage of the amino terminal region of the Aa 
chain.78·79·81 This site is composed of at least two peptide sequences, 
one of which is located at the amino terminal end of the fibrin Aa 
chain, the Gly-Pro-Arg sequence (Aal 7-20), 109,IIO whilst the other is 
in the amino terminal region of the fibrinogen BP chain (BP 15-
42).111 The newly exposed EA site subsequently associates with a 
complementary binding site on the D-domain, Da, 112-115 which is 
situated in the carboxyl terminal y chain segment (y337-339)ll6,II7 
(figure 7a). These Da:EA associations result in the formation of 
double stranded fibrils, with fibrin molecules arranged in an 'end-to-
middle' domain staggered overlapping fashion (see figure 3).108·118·120 
The cleavage of fibrinopeptide B, which occurs more slowly than that 
of fibrinopeptide A and is dependent on fibrin polymerisation,78·79·81 
exposes a second polymerisation site, · E8 , 
121 beginning with the 
BPIS-18 sequence, GHRP. 109·110 This site interacts with a 
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complementary site situated in a carboxyl terminal P-chain segment 
of the D-domain, known as the Db site (figure 7b). 114•121 Although 
the E8 :Db interaction contributes to the formation of lateral 
associations between fibrin strands, it is not an absolute requirement 
for this process. 121-122 
Associations between the D domains on neighbouring molecules 
involve two distinct and recently defined self association sites on the 
fibrinogen D domain. One overlaps with, and is part of, the y chain 
crosslinking site in the middle portion of the D domain, and the other 
is situated at the outer end of each D domain (Figure 7c). 123-125 These 
sites associate with corresponding regions on adjacent fibrinogen 
molecules and these interactions appear to be essential for proper 
alignment of fibrin molecules in the assembling polymers as well as 
branching of fibres. 124 
yXL 
(c) The D-domains on neighbouring molecules associate with one another via two 
self association sites, namely (i) the r chain cross/inking site in the middle portion 
of the D domain and (ii) a site situated at the outer end of each D domain. 
In addition, associations between the carboxyl termini of the Aa 
chains (the aC domains) also play an important role fibrin 
assembly. 126•127 Prior to proteolytic attack by thrombin, the aC 
domains tend to be associated non-covalently with the fibrinogen E 
domain; however, following thrombin cleavage of PPB, the aC 
domains become untethered and available for interaction with other 
aC domains (figure 7d), thereby promoting lateral fibril associations 
and fibrin assembly. 128•129 
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(d) Interactions between the carboxyl-termini of the Aa chains (the aC domains) 
promote lateral fibril associations. 
In summary, fibrin strands initially align spontaneously through D:E 
interactions which are supported by end-to-end D:D interactions. 
Subsequently and concommitantly fibrin strands undergo lateral 
associations vhf a combination of D:E, D:D and aC:aC interactions 
resulting in the thickening and branching of fibres giving rise to the 
meshwork of fibres that constitutes the fibrin clot (see figure 9). 
Covalent crosslinking 
Fibrin clots held together by non-covalent interactions alone are 
easily disrupted when subjected to the forces of stress and strain 
associated with blood flow through the vasculature. 130 However, the 
incorporation of covalent bonds between the fibrin units in the 
assembled matrix, dramatically alters the mechanical properties of 
the clot, providing structural stability, integrity and elasticity to an 
otherwise easily deformable fibrin clot. 131 ' 132 Factor Xllla, catalyses 
the covalent stabilisation of fibrin, via formation of peptide linkages 
between the E-NH2 group of certain lysine residues and the y-CONH2 
of certain glutamines, with the consequent formation of E-(y-glu)lys 
isopeptide bonds. 133-134 Each y-chain contains both a glutamine 
(residue 398 or 399) and a lysine (residue 406) which undergo 
reciprocal crosslinking with another y-chain (figure 8), orientating 
--.:: Glu3ea,e-. · LyS4oe==---
Lys406 _,,_ Glu39819 
Figure 8. The factor XIII catalysed covalent stabilisation of fibrin via reciprocal 
peptide linkages between ychain glutamine (398 or 399) and lysine (406) residues. 
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the two polypeptides in a symmetrical anti-parallel manner to form a 
y-dimer. 135-137 Whilst y-chain crosslinking has long been thought to 
involve end-to-end crosslinking of adjacent D-domains, recent 
studies suggest that transverse crosslinking between y-chains on 
adjacent fibrils predominates. 138 Higher order forms of cross-linked y 
chains, including y trimers and y tetramers also occur providing 
stability to branched structures.139,140 
In addition to y chain crosslinking, crosslinking among a chains 
(which occurs more slowly) generates oligomers and larger a chain 
polymers which also play an important role in the stabilisation of 
fibrin clots. 141 Factor Xllla also catalyses the crosslinking of a chains 
toy chains. 139' 140 A variety of other proteins may become crosslinked 
to fibrin. The most important include fibronectin, which may alter the 
mechanical properties of the clot, 142 and the plasmin inhibitor, a 2-
antiplasmin ( a2PI), whose efficiency increases when it is crosslinked 
to fibrin. 143 Another property conferred by factor XIIIa crosslinking 
is a relative increase in the resistance of the fibrin gel to lysis by 
plasmin. 
The final result of the fibrin assembly process is the generation of a 
three dimensional, highly interconnected meshwork of fibrin fibres 
which function as a haemostatic plug (figure 9) .. 
r-chain crosslink Lateral fibril associations 
. Figure 9. A schematic representation of the branched structure of fibrin which 
results from D:D, D:E, aC:aC and r- and a-chain crosslinkfng reactions. 
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Plasmin mediated fibrin{ogen)olysis 
The fibrin clot is not a permanent structure and once it has fulfilled 
its role in achieving haemostasis it must be dismantled. Thus, 
immediately following fibrin formation, processes are set in motion 
which are directed at its dissolution. These processes are as important 
as the formation of the clot itself, as failure of this system can lead to 
life-threatening thromboembolic events including myocardial 
infarction, cerebrovascular occlusion and pulmonary embolism. 
Fibrin dissolution is effected by the plasminolytic system which, 
under the control of a variety of activators and inhibitors, gives rise 
to the fibrinolytic enzyme plasmin. 
Plasminogen activators 
Plasminogen activators convert the circulating pro-enzyme 
plasminogen into the active fibrinolytic protease, plasmin. Two 
major plasminogen activators have been identified in mammals: 
tissue plasminogen activator (t-PA) and urokinase plasminogen 
activator (u-PA). 144 Both t-PA (70 kDa) and uPA (55 kDa) are serine 
proteases, encoded by separate genes. The two plasminogen 
activators possess distinct targeting determinants in their non-
catalytic regions: the "growth factor domain" of u-PA facilitates the 
binding of u-PA to specific receptors on the plasma membrane of a 
variety of cell types, 145' 146 whilst specific structural domains int-PA 
enhance its binding to fibrin and other components of the 
extracellular matrix. 147 Cell surface expression of u-PA, through the 
localised generation of plasmin, is thought to play an important role 
in a number of physiological as well as pathological processes, 
including cell migration, tissue remodelling and metastasis. 148 On the 
other hand, t-P A appears to be the major plasminogen activator at 
sites of fibrin formation due to its high affinity for fibrin. 149 The 
adsorption of tP A together with plasminogen on the fibrin fibre 
surface allows the neccessary contact required to effect optimal 
activation rates for plasmin production; 150 fibrin binding confers 
upon tPA an approximate 1000-fold increase in its affinity for 
plasminogen. 151 Two sites in fibrin are involved in the binding and 
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upregulation oft-PA, namely Aa148-160 and y312-324. 152-155 These 
sites, which are inaccessible in fibrinogen, become exposed 
following the conversion of fibrinogen to fibrin. 156,157 
A group of inhibitors have evolved to keep the plasminogen 
activators in check. These include plasminogen activator inhibitors 1 
and 2 (PAI 1 and 2) and protease-nexin 1. 158 PAI-1 is the major 
plasminogen activator inhibitor in the plasma, having a high affinity 
for both tP A and uP A, whilst the latter two inhibitors are 
predominantly directed at uP A. 159 
Plasminogen and plasmin 
Plasmin is a relatively broad spectrum serine protease and, whilst its 
primary substrate is fibrin, it is also capable of degrading most 
extracellular matrix (ECM) proteins. 160 Thus, in addition to its role in 
fibrinolysis, plasmin may play an important additional role in ECM 
degradation. Its inactive precursor, plasminogen, is a glycoprotein of 
approximately 92-94 kDa161 and is present in the plasma and 
extracellular fluids at a concentration of 1-2 µM. 159 Plasminogen 
consists of a heavy amino terminal non-catalytic region made up of 
five homologous domains of triple looped, disulphide bridged 
structures commonly known as kringles, 162 and a lighter catalytic C-
terminal domain (Figurel 0). 161 The kringle regions contain the lysine 
binding sites which are involved in binding of plasminogen and 
plasmin to fibrin and a number of other macromolecules. 163,164 
Plasminogen, in its native form, has one high affinity lysine binding 
site (on the first kringle domain), its major binding site for fibrin, and 
approximately 5 sites of lower affinity. 165-167 Upon binding to lysine, 
plasminogen undergoes a conformational change from a closed, 
compact structure, in which the 5 kringle domains and 2 domains 
from the serine protease region are in close contact with each other, 
to an open extended structure with these domains no longer closely 
associated. 168 This conformational change renders plasminogen far 
more susceptible to proteolytic activation by plasminogen 
activators169 and, following their intimate contact on the fibrin 
surface, plasminogen is cleaved at an Arg-Val bond, to yield the 
active, disulphide linked two chain serine protease, plasmin. 170 
Alpha-2-antiplasmin serves as the primary inhibitor of plasmin in the 
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plasma. 171 However, when plasmin is generated on the clot surface it 
is relatively protected from inactivation by this inhibitor. 172 This 
helps to localise plasmin activity to the immediate vicinity of the 
fibrin clot, allowing t-P A to initiate clot lysis without inducing a 







Figure 10. A schematic representation of the plasminogen molecule illustrating 
the heavy NH2-tenninal non-catalytic domain comprising kringle loops and a 
lighter catalytic COOH-tenninal domain. 
Fibrin(ogen) degradation 
The architecture of the fibrin clot is as suited to its dissolution, as the 
structure of fibrinogen is suited to polymerisation. This is due to the 
a~cessibility and vulnerability of essential connections between the 
nodular bodies (D and E domains) to proteolysis. As intermolecular 
contacts between fibrin monomers are limited to the nodular bodies, 
channels to the interdomainal connectors are left open, facilitating 
the diffusion of proteolytic agents throughout the fibrin clot. 
Moreover, rather than having to cut all the way through a solid 
polymer, plasmin need only cleave the slender three strand 
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connectors. Consequently, the dissolution of a fibrin clot requires 
lysis of a relatively small number of bonds. Intermediate polymers 
are formed by the cleavage of any two connectors along the length of 
a fibril. Proteolytic digestion then continues until these intermediate 
polymers are reduced to core fragments. 173 
As plasmin degradation of fibrinogen yields products that are very 
similar to those that it generates from fibrin, 174' 175 it is helpful to 
consider plasmin degradation of fibrinogen prior to that of fibrin. The 
major differences between the products of fibrinogen and fibrin 
digests reflect the covalent crosslinking associated with factor XIlla 
stabilised fibrin. 176' 177 
Prolonged exposure of fibrinogen to plasmin can ultimately catalyse 
the cleavage of nearly 60 bonds, although only 5 to 6 of these bonds 
are cleaved rapidly. 178 Degradation of fibrinogen begins in the Aa 
chain (at several sites in the C-terminal region) and is shortly 
followed by degradation of the BP chain (where the BP 1-42 peptide 
is cleaved from the N-terminus). 179 They chain is the most resistant 
to degradation and the last to degrade. 180 
Degradation initially results in the release of the Aa peptides, 
fragments A, B and C (with molecular weights of approximately 
15kDa), leaving the residual intermediate fibrinogen product, 
fragment X (240-265 kDa), which may exist in a number of forms 
depending on the extent to which the Aa and BP chains are degraded 
(Figure 11). 180 As degradation continues, the size of fragment X 
becomes progressively smaller, giving rise to discreet fragments 
called D (83-100 kDa), E (41 kDa) and a transient fragment Y 
(approximately 150 kDa) which consists of a D-E core. Further 
degradation of Y yields the terminal fragments D and E. 180 
Fragment D contains extensively degraded Aa chains, partially 
degraded BP chains, and y chains at various stages of degradation. 
Depending on the degree of y chain degradation, fragments D are 
designated D1, D2 or D3 (with D1 having the least, and D3 the most, 
extensively degraded y chains). 175' 180' 181 However, as extracellular y 
chain- digestion by plasmin does not occur in the presence of calcium 
ions, it is likely that fragment D1 is the only physiologically important 
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D-species in vivo. 182 Fragment E contains extensively degraded Act, 
BP and y chains which are linked through disulphide bonds. 180 
The terminal degradation products generated by plasmic degradation 
of fibrin show slight differences to those described above, largely as 
a result of crosslinking of fibrin monomers by factor XIIIa. Covalent 
crosslinking of antiparallel y chains results in the formation of the 
dimeric degradation product, DD (known as D-dimer), rather than the 
Fragment D 
(83-100 kDa) 
Fibrinogen (340 kDa) 
Fragment X (240-265 kDa) 
Fragments A, B & C (15 kDa) 
Fragment Y (± 150 kDa) 
10 kDa m 
.&t@" m11t 
Fragment E (41 kDa) i-. 
M 10 kDa 
Fragment D 
(83-100 kDa) 
Figure 11. A schematic representation of plasmin mediated fibrinogenolysis. 
Degradation of fibrinogen initially releases the Aa peptides, fragments A, B and C. 
The residual intennediate fibrinogen product, fragment X may exist in a number of 
fonns depending on the extent of Aa- and B~chain degradation. With continued 
degradation, fragment X gives rise to fragments D (83-100 kDa), E (41 kDa) and a 
transient fragment Y (± 150kDa) which consists of a D-E core. Further degradation 
of Y yields the tenninal fragments D and E. 
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individual D fragments, 176 and the non-covalent interaction of the 
central E domain with two distal D domains is sufficiently strong for 
the generation of the heterotrimer D2E (figure 12).
183 In addition, 
monomeric fragment E has been identified as a major soluble 
derivative of crosslinked fibrin, although this does differ slightly 
from fragment E derived from fibrinogen. 184,185 
ll\ 
e-e! -. ~ V 
Figure 12. The terminal degradation products generated by plasmic degradation of 
fibrin. As a result of covalent cross/inking of y-chains as well as non-covalent 
interactions between E and D domains, plasmic digestion of fibrin yields terminal 
degradation products which differ from those generated from fibrinogen. These 
products include D-dimer (DD), the heterotrimer D2E and soluble monomeric 
fragment E. 
Although these fragments appear to be the major soluble products 
arising from the digestion of crosslinked fibrin, in vitro, larger 
soluble intermediate degradation products are more likely to circulate 
during fibrinolysis in vivo. 186 Fibrinolysis in vivo appears ·to be a 
stepwise process involving the following sequence of events. 
Initially, polypeptide chain cleavages occur which do not disrupt the 
solid clot matrix. Further degradation generates high molecular 
weight derivatives which remain associated with the clot. Continued 
degradation then results in the release of several of these non-
covalently bound derivatives into solution. Further degradation of 
these products in solution eventually yields the terminal products 
DD, D2E and E.
186 This appears to occur in progressive cycles of 
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proteolysis of accessible superficial regions of the clot, allowing for 
layer by layer dissolution of thrombi without the release of partially 
lysed, but insoluble material into the circulation. 186-188 This ensures 
that partially lysed, but insoluble material does not enter the 
circulation, thereby reducing the risk of thromboembolic events 
following fibrinolysis. 
Non plasmin mediated fibrin{ogen)olysis 
Although plasmin mediated fibrinolysis constitutes the primary 
pathway for fibrin dissolution, several alternative pathways have 
been identified. These are largely cell mediated and, in particular, 
involve neutrophils189-197 and monocyte/macrophages. 198-199 
The ability of leukocytes to degrade fibrin clots was first noted at the 
tum of the century by Rulot and Opie who found that fibrin 
dissolution was greatly enhanced in the presence of leukocytes.200-201 
Since then the intimate association of leukocytes with fibrin deposits 
has frequently been noted both intra- and extravascularly. Within the 
vascular compartment, leukocytes frequently accumulate within 
complex thrombi consisting of fibrin and platelets.202-204 At 
extravascular sites, the migration of neutrophils to sites of injury 
where fibrin has accumulated is a central feature of the inflammatory 
response.204-206 Fibrinopeptide B, released during fibrin formation, 
has been shown to enhance neutrophil chemotaxis and facilitates 
neutrophil migration towards the fibrin clot.207 Once localised within 
fibrin deposits, the direct interaction of neutrophils with fibrin 
molecules may induce the release of granule proteases which can 
then digest fibrin. 190 
The neutrophil proteases responsible for fibrin( ogen) degradation 
were distinguished from plasmin on the basis of several observations. 
Firstly, neutrophils were shown to contain only very low levels of 
plasminogen, insufficient to effect fibrinolysis. 95'208,209 Secondly, 
fibrinogen degradation products generated by leukocyte extracts were 
shown to be structurally and immunochemically distinct from those 
produced by plasmin. 191 ' 195'210 Finally, plasmin(ogen) inhibitors and 
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activators did not influence the fibrinolytic activity of leukocyte 
extracts. 195,211 It was subsequently revealed that the two major 
proteases in leukocyte extracts, responsible for fibrin(ogen) 
degradation, were human neutrophil elastase (HNE) and cathepsin 
G.212-214 As these proteases reside primarily in the neutrophil 
granules, potential mechanisms for the activation of the neutrophil 
fibrinolytic pathway include neutrophil degranulation, phagocytosis, 
cell lysis as well as fibrin formation itself. Recent studies have shown 
that these granule proteases can further process the terminal products 
of plasmic fibrin degradation.215'216 HNE degradation of fibrinogen 
generates high molecular weight degradation products that are non-
clottable, and several of these have been shown to be capable of 
competitively inhibiting thrombin cleavage of fibrinogen. 197 A 
characteristic feature of fibrinogen proteolysis by HNE is the release 
of the Aal-21 peptide from the N-terminal region of the Aa chain of 
fibrinogen, and plasma levels of this peptide have been used as a 
k fHNE • · . · 217 mar er o activity m vivo. 
More recently, the physiological relevance of HNE mediated 
fibrin( ogen)olysis has been questioned, as relatively high 
concentrations of HNE are required for significant fibrinolysis in 
vivo. 193 Moreover, the presence of high affinity inhibitors of HNE in 
the extracellular space,218 has cast further doubt over the direct role 
of HNE in neutrophil mediated fibrinolysis. This has turned attention 
to the indirect roles of HNE in fibrinolysis, in particular its 
modulatory effects on the plasminogen activator/plasmin system, a 
number of which require significantly lower concentrations of 
HNE. 193,219 For instance, HNE used at relatively low concentrations 
has been reported to cleave, and thereby inactivate, two major 
inhibitors of the plasminolytic system, namely the plasmin inhibitor, 
alpha-2-antiplasmin,219 and the plasminogen activator inhibitor, PAi-
l. 193 In addition, HNE has been shown to cleave plasminogen to 
miniplasminogen, which is more susceptible to cleavage by 
plasminogen activators,220 and less susceptible to inhibition by alpha-
2-antiplasmin.221 Cathepsin G may also play an indirect role in the 
regulation of the fibrinolytic pathway through the cleavage and 
activation ofu-PA.222 
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Despite controversy over the direct roles of HNE and cathepsin G in 
neutrophil mediated fibrinolysis, considerable evidence has now 
accumulated to suggest that these proteases may, in fact, be able to 
escape inhibition by naturally occurring protease inhibitors and focus 
their activity in the immediate pericellular environment and at sites 
of fibrin formation. Firstly, HNE, once bound to a fibrin clot has 
been found to escape inhibition by naturally occurring proteinase 
inhibitors.223 Secondly, neutrophil adhesion to fibrin, via integrin 
receptors, has been found to create zones of close contact between 
the neutrophil and fibrin (so-called "protected compartments") which 
prevent access of plasma anti-proteinases to HNE released at the cell-
substrate interface.217'224 Finally, it has been shown that, following 
degranulation, HNE and cathepsin G bind to the neutrophil 
membrane where they remain catalytically active but resistant to 
naturally occurring proteinase inhibitors.225•229 In this way the 
neutrophil is able to focus and preserve HNE activity on the cell 
surface allowing HNE to play a direct role in fibrinolysis. -
In addition to its pro-fibrinolytic activity, HNE has recently been 
reported to inhibit plasmin-mediated fibrinolysis. This is due to its 
proteolytic action on fibrin which results in a diminution of the 
stimulatory effect of fibrin on t-PA mediated plasminogen 
activation. 194'230 It has been suggested that this effect may, in fact, 
dominate the pro-fibrinolytic effects of HNE. Precisely which is the 
dominant role for HNE in fibrinolysis in vivo remains unclear, as data 
obtained in vitro has tended to vary with experimental design. For 
instance, whereas many of the earlier experiments investigated the 
effect of HNE on fibrinogen or fibrin clots used in isolation, the latter 
study tested the effect of HNE on plasmin-mediated lysis of whole 
blood clots. 
In addition to their role in fibrin( ogen)olysis HNE and cathepsin G 
can also influence the coagulation pathway by the proteolytic 
modification of a variety of other clotting factors including factors V, 
VII, IX, X and protein S.231 -234 
Recently, a 600 kDa neutrophil membrane associated protease was 
reported to degrade fibrinogen. 235 This protease was shown to render 
fibrinogen non-clottable, a process considered to be important in 
limiting fibrin deposition at sites of inflammation. It was later shown 
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to degrade fibrin clots, 236 leading to the suggestion that neutrophil 
mediated fibrinolysis is not necessarily dependent on neutrophil 
degranulation.236 As with HNE, this protease was reported to cleave 
the Aa 1-21 peptide from the N-terminus of the Aa chain of 
fibrinogen.235 Both fibrinogen and fibrin degradation products 
generated by this protease appear to have biological activity. Low 
molecular weightfibrinogen peptides generated by this protease have 
been reported to associate with neutrophil Pi-integrin receptors 
modulating neutrophil adhesion to immobilised fibrinogen.237 Fibrin 
degradation products generated by this protease also possess 
biological activity. Low molecular weight peptides inhibit thrombin 
induced platelet aggregation whilst higher molecular weight products 
partially overcome platelet induced resistance of fibrin to plasmic 
lysis. 238 
In addition to the contribution made by granule and membrane 
associated proteases, neutrophils may also enhance fibrinolysis by 
expression of plasminogen activators on their surface, in particular u-
P A.239 
The monocyte/macrophage is also thought to play an important role 
in fibrinolysis. It is· capable of assembling the components of the 
plasminogen activator system which ultimately results in the 
generation of plasmin.240'241 In addition, macrophage degradation of 
fibrin may also occur via a plasmin independent pathway. This 
alternative pathway involves the binding of fibrinogen to the cell 
surface integrin CD 11 b/CD 18 (Mac 1 ), followed by internalisation 
and trafficking to the lysosome where the aspartyl protease, cathepsin 
D, degrades the protein. 198 Another potential mechanism of non-
plasmin mediated fibrinolysis is the uptake of fibrin monomer into 
macrophage lysosomes through a process involving the interaction of 
the amino-terminus of the alpha chain of fibrin with a specific cell 
surface receptor.242 
Thus there appears to exist a number of leukocyte mediated 
mechanisms which may provide alternatives to the plasmin-mediated 
fibrinolytic system. The notion of physiologically relevant non-
plasmin mediated fibrinolytic pathway(s) has gained support from 
two recent sets of studies performed on animal and man. The first 
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reported that patients with a total congenital deficiency of 
plasminogen survived without any major thromboembolism but 
suffered from numerous inflammatory disorders.241 The second 
showed that endogenous lysis of pulmonary emboli does still occur 
(albeit relatively slowly) in animals devoid oft-PA and u-PA.243,244 
Fibrinogen interactions 
Fibrinogen is a multifunctional protein which, in addition to its role 
in haemostasis, can influence a variety of other physiological 
processes. Fibrin( ogen) has been shown to interact with a variety of 
cells including platelets, neutrophils, monocyte/macrophages, 
endothelial cells, smooth muscle cells and fibroblasts, often 
modulating important cellular events (figure 13). Fibrinogen also 
interacts with a number of extracellular matrix proteins including 
fibronectin whose incorporation into fibrin changes the 
physicochemical properties of the fibrin clot. In addition, fibrinogen 
binds to a variety of micro-organisms, including several pathogens, 
and may contribute to the ability of these organisms to invade host-
tissues and evade host defences. Finally, through its ability to interact 
with various components of the coagulation and fibrinolytic systems 
(including thrombin, plasminogen, t-P A, and factor XIII), 
fibrin( ogen) is central to many. of the important feedback 
mechanisms that regulate haemostasis. 
Interaction with neutrophils 
Neutrophil interaction with fibrin( ogen) has been the subject of 
intense interest over the last decade as events following this 
interaction have the potential to modulate both the inflammatory and 
coagulation responses. Fibrinogen binds specifically to integrin 
receptors on the neutrophil surface, predominantly via the P2-
integrins, CD1 lb/CD18 (Mac1)245"247 and CD1 lc/CD18 
(plS0/95),248 and to a lesser extent via the p3-integrin, leukocyte 
response integrin.249'250 Specific sequences on the fibrinogen 
molecule are recognised by these receptors, and the nature of the 
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stimulus appears to determine which integrin receptor is involved. 
For instance phorbol ester stimulated neutrophils adhere to surface 
adherent fibrinogen via CD1 lb/CD18 which recognises the K-Q-A-
G-D-V sequence situated at the carboxyl terminus of the fibrinogen 
y-chain.245 In neutrophils stimulated with the chemotactic peptide 
fMLP, CD11b/CD18 recognises the y-chain sequence Gly190-
Vah02.246 In neutrophils stimulated with TNFa, CD11c/CD18 
mediates binding to fibrinogen coated surfaces and recognises the G-
P-R sequence at positions 17-19 of the NH2 terminus of the a-
chain.248 The binding of neutrophils to surface adherent fibrinogen 
via P2-integrin receptors induces tyrosine phosphorylation of certain 
neutrophil proteins251 which, in turn, signal for the initiation of 
various important cellular events such as cell spreading,252,253 the 
respiratory burst,254 and degranulation.255 
Neutrophils stimulated with FMLP have been reported to recognise 
the y-chain sequence y190-202 on both immobilised and soluble 
fibrinogen.246 Recent studies suggest that this region, together with 
the y-chain sequence y377-395, form a binding pocket for the I-
domain of CD11b/CD18.256 The p3-integrin receptor, leukocyte 
response integrin (LRI), recognises soluble fibrinogen both via the R-
G-D sequence of the fibrinogen a-chain as well as the K-Q-A-G-D-V 
sequence of the· carboxyl terminus of the fibrinogen y-chain.249,250 
Soluble fibrinogen has been reported to inhibit neutrophil 
chemotactic activity and oxygen consumption in response to certain 
stimuii.257 Several fibrin(ogen) degradation products (FDP) have also 
been found to modulate neutrophil function. Fibrinopeptide B has 
been shown to enhance neutrophil chemotaxis, 207 whilst plasmin 
generated fibrinogen degradation products have been reported to 
inhibit neutrophil chemotaxis, · respiratory burst, bactericidal 
activity,258 and adhesion to EC and protein coated surfaces.259 
Fibrin degradation products are also capable of modulating 
neutrophil function. Plasmin derived D-dimer and D-monomer have 
recently been shown to be potent neutrophil chemoattractants.260 
HNE degradation of fibrin also generates products which are 
chemotactic for neutrophils.261 Moreover, secondary digestion by 
HNE of plasmin derived FDP produces molecules that are more 
potent chemoattractants than native plasmin derived FDP.261 The 
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fibrin matrix itself has been shown to inhibit neutrophil chemotaxis 
in neutrophils stimulated with FMLP or TNFa,262 and this appears to 
be due to strong interactions between fibrin and the neutrophil 131-
integrin receptors, a 5[3 1.
263 
Interaction of fibrinogen and fibrin with the neutrophil results in the 
release of the recently reported 600 kDa membrane associated 
protease into the surrounding medium.235-238 It has been suggested 
that this interaction occurs near the CD11c/CD18 receptor as 
monoclonal antibodies directed against this receptor cause marked 
inhibition of fibrin( ogen)olysis.237'238 The fibrin( ogen) degradation 
products generated by the membrane associated protease have been 
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Figure 13. A schematic representation of the various ways in which fibrin(ogen) and 
its products may influence cellular processes. 
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Interaction with monocyte/macrophages 
The contribution of macrophages to the clearance of microparticulate 
fibrin from the bloodstream has long been recognised. Disseminated 
intravascular coagulation, induced in various animal experimental 
models, has been shown to be associated with the rapid accumulation 
of particulate fibrin within the macrophages of the liver (Kuppfer 
cells), spleen and lung.264'265 In vivo studies using guinea pig 
macrophages have demonstrated binding of fibrinogen and fibrin to 
these cells.266 Later studies showed macrophages to bind fibrin with a 
much higher affinity than fibrinogen via a process that appeared to be 
receptor mediated. 267 Further studies have demonstrated absorptive 
endocytosis of fibrin monomer (but not fibrinogen) by rabbit 
peritoneal macrophages via a cell surface receptor which interacts 
specifically with the Aa N-terminal sequence G-P-R, exposed 
following the cleavage of fibrinopeptide A.241 
More recently, fibrinogen has been reported to associate specifically, 
and calcium dependently, with activated monocytes.268 This process 
is mediated by the integrin receptor CD 11 b/CD 18 and internalisation 
of receptor bound fibrinogen leads to its degradation. 198 
The fibrin degradation product D-dimer has been reported to bind to 
CD 11 b/CD 18 on the surface of monocytes, inducing the release of a 
factor which suppresses lymphocyte proliferation.269 Following 
internalisation and degradation of DD, monocyte synthesis of 
biologically active IL-1 p, IL-6, and P Als is enhanced.270 
Interaction with platelets 
Platelet aggregation, with the subsequent formation of a platelet plug, 
is central to the process of haemostasis. The role of fibrinogen as a 
vital co-factor in platelet aggregation has long been known. 
Aggregation is mediated by the bridging of two integrin receptor 
molecules, aubPJ (GPIIb/IIIa), by dimeric fibrinogen. 271 The regions 
of fibrinogen which bind to the aubPJ receptor include the RGD 
sequence of the a-chain272 as well as the dodecapeptide sequence 
400-411 on the extreme carboxyterminus of the y-chain.273 
The platelet a-granule provides an important source of fibrinogen to 
be used during platelet aggregation, comprising 3-10% of total 
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platelet protein.274 Recent data indicate that platelet fibrinogen is not 
synthesised by megakaryocytes (the nucleated precursors of platelets) 
as was previously thought, but is aquired exclusively from the 
plasma. This is suggested by the absence of a-granule fibrinogen in 
patients who lack the a11hP3 receptor,275 and the ability of specific 
a11bP3 antagonists to inhibit fibrinogen uptake into alpha-
granules. 276,277 Recent studies have reported that internalisation of 
surface bound fibrinogen by activated platelets may result in 
downregulation of platelet aggregation, suggesting an additional 
modulatory role for fibrinogen in haemostasis.278 Finally, it has also 
been suggested that fibrinogen may modulate platelet function by 
inducing tyrosine phosphorylation of platelet proteins which is 
independent of platelet aggregation. 279 
Interaction with endothelial cells 
Fibrinogen, fibrin and their respective degradation products have all 
been shown to interact with endothelial cells (EC), and are capable of 
modulating their activity. As fibrin deposition on vascular EC is a 
consistent feature of a variety of pathological processes (including 
trauma, infection, inflammation and neoplasia),280 fibrin related 
products may influence EC behaviour in a number of clinical 
settings. Fibrinogen has been reported to bind via the RGD sequence 
of the a-chain to an EC protein immunologically related to the anhP3 
receptor on platelets, with the subsequent upregulation of EC 
migratory activity.281 More recently, fibrinogen has been shown to 
bind to the EC adhesion molecule, ICAMl, which then serves as a 
bridging molecule enhancing leukocyte adhesion to the 
endothelium.282 This raises the possibility that fibrinogen may play 
an important role in leukocyte-EC interactions in vivo. ·Fibrinogen 
also appears to have vasoactive effects and has been reported to 
cause ICAMl dependent relaxation of saphenous vein rings at 
concentrations up to 2µM, with this relaxation being reversed at 
higher concentrations.283 
Fibrinogen degradation product fragment D has been reported to 
induce the detachment of EC from the substratum, as well as 
inducing the release oft-PA and u-PA.284 It was shown that the 
secretion of these plasminogen activators, via the generation of 
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plasmin, contributed to the proteolysis of the extracellular matrix and 
thus the EC detachment. 284 
Fibrin is also capable of binding specifically to vascular endothelium 
and has been reported to exert numerous effects. For instance, it has 
been reported to induce cytoskeletal reorganisation which is 
associated with a reversible disruption of EC monolayers,285 as well 
as increased EC adhesion and spreading.286 Fibrin also induces the 
release of several biologically active factors including von 
Willebrand factor,287 prostacyclin, t-PA288 and IL- 8.289 Fibrin 
deposition can also induce new capillary formation in vitro290 and an 
angiogenic response in vivo.291 The exposure of the BP 15-42 
sequence following thrombin cleavage of fibrinopeptide B, has been 
reported to enhance the spreading and proliferation of EC growing on 
fibrin matrices.292 Recently, it has been shown that fibrin induces the 
upregulation of ICAMl expression on EC, raising the possibility that 
the adhesiveness of ECs for leukocytes may be modulated at sites of 
fibrin deposition.280 
Interaction with other cells 
Fibrin(ogen) may contribute to the process of wound healing via its 
potent mitogenic effect on fibroblasts. This appears to be mediated 
by the binding of the BP-chain of fibrinogen to calcireticulin on the 
fibroblast surface.293 Fibrin has also been shown to stimulate the 
proliferation of smooth muscle cells, whereas FDP, produced by the 
fibrinolytic action of these cells, appears to cause inhibition of 
proliferation.294 As the proliferation of smooth muscle cells is central 
to pathogenesis of atherosclerosis, 295 fibrin may thus promote the 
generation of atherosclerotic lesions. Indeed, the presence of 
fibrin( ogen) in atherosclerotic plaques has been documented by 
several morphologic and immunohistochemical studies.296-300 
Interaction with micro-organisms 
Fibrinogen binding capacity is not unique to mammalian cells. 
Fibrinogen is also bound by a wide variety of micro-organisms and 
such binding may influence their pathogenicity.301 -314 Coating of the 
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cell surface with fibrinogen confers anti-phagocytic protective 
properties to certain micro-organisms. For instance, the binding of 
fibrinogen to the M protein of group A streptococci enhances its 
resistance to phagocytosis by neutrophils.301 ,302 This effect has also 
been observed in animal hosts, where fibrinogen binding protects 
streptococcus equinus subspecies equi. from phagocytosis by equine 
neutrophils.303 However, fibrinogen binding may also achieve the 
opposite effect, as observed in the case of actinomyces pyogenes, 
where fibrinogen coating enhances its uptake by bovine 
neutrophils. 304 
Binding to fibrin( ogen) in the extracellular matrix may facilitate the 
invasion of host tissues by certain micro-organisms. The interaction 
of aspergillus fumigatus with fibrinogen is thought to mediate 
attachment of the fungus to host tissues, thereby facilitating 
invasion.305 A similar mechanism is proposed for bacteroides 
gingivalis,306 and may also be used by staphylococcus aureus307 and 
candida albicans. 308 Interestingly, the fibrinogen binding capacity of 
various strains of E. coli has been found to correlate with the 
pathogenicity of the organism.309 It was suggested that this may be 
due to the facilitation of binding to ulcerated tissue or by preventing 
complement induced lysis of bacteria. Fibrinogen interactions with 
bacteria may also affect platelet function. Recently it has been shown 
that staphylococcus aureus induces platelet aggregation via a 
fibrinogen dependent mechanism which is independent of the anbl33 
fibrinogen binding domains.311 It was suggested that this may play an 
important role in the pathogenesis of infective endocarditis, through 
the generation of infected thrombi on heart valves. 
Interaction with calcium 
The importance of calcium in fibrinogen polymerisation has long 
been known. Calcium accelerates fibrin clot formation and enhances 
the rigidity of these fibrin clots.315'316 The fibrinogen molecule 
possesses 3 high affinity and 12 low affinity calcium binding sites.317 
One high affinity site is located on each of the two D-domains318 
whilst the other appears to be located in the central domain.319 In 
circulatin~ fibrinogen these three calcium binding sites are all 
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occupied.319 Calcium ions also appear to play an important role in 
maintaining the structure and stability of fibrinogen, by protecting 
against plasmin digestion of fibrinogen and fibrin, as well as against 
heat and alkali denaturation.320,321 
Interaction with proteins 
The ability of fibrin( ogen) to interact with a variety of other proteins 
allows it to play an important regulatory role in haemostasis and 
fibrinolysis. 
1. Thrombin 
The interaction of fibrin( ogen) with thrombin via non-substrate 
binding sites (see figure 5b, page 68) is important in regulating 
thrombin activity.82-86 Fibrin binding to thrombin localises thrombin 
activity to the immediate vicinity of the fibrin clot98-100 and, 
importantly, fibrin bound thrombin is resistant to inhibition by 
circulating heparin-antithrombin m. 101 ,102 This allows thrombin 
activity to be focussed at the of site clot formation, preventing 
uncontrolled propagation of the thrombus. 
2. Plasminogen 
The interaction of plasminogen with fibrin plays an important role in 
regulating plasmin mediated fibrinolysis. Fibrin binding of 
plasminogen allows it to be more readily cleaved by t-PA. 168,169 In 
addition, the susceptibility of fibrin bound plasmin to inhibition by 
alpha-2-antiplasmin is markedly reduced compared to circulating 
plasminogen. 172 Thus, fibrin binding serves to localise plasminogen 
activation, as well as its catalytic activity, in the immediate vicinity 
of the fibrin clot. 
3. Tissue plasminogen activator 
Fibrin binding of t-PA substantially enhances its affinity for 
plasminogen thereby upregulating plasmin generation at the site of 
fibrin formation. 151 
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4. Transglutaminase (factor Xllla) 
The zymogen form of factor XIII circulates as a complex bound to 
the D-domain of plasma fibrinogen.322'323 Several observations 
suggest that specific interactions of factor XIII with fibrinogen and 
fibrin may regulate its activation in vivo. Fibrinogen has been shown 
to lower the calcium requirement for efficient activation of factor 
XIII,324 and increases the rate of exposure of the active site at a given 
calcium concentration.325 This "promoting" activity has been 
localised to the midportion of the fibrinogen Aa chain.326 Fibrin 
serves as a co-factor for the thrombin mediated conversion of factor 
XIII. to its active form factor XIIIa. This is achieved through the 
formation of a fibrin-factor XIII complex which has a much greater 
susceptibility to thrombin catalysed activation than does factor XIII 
alone.327 -
5. Fibronectin 
Fibronectin comprises about 3-4% of a normal plasma clot.328 This 
large dimeric plasma glycoprotein has an affinity for fibrinogen and, 
in particular, fibrin. Several types of interactions between fibronectin 
and fibrin( ogen) can occur, as fibronectin has both specific fibrin 
binding domains and a covalent cross-linking site. It can be cross-
linked to fibrin by transglutaminase; this involves the a-chain of 
fibrin329 and the N-terminal region of fibronectin.330 At 
physiologically relevant concentrations, fibronectin incorporation 
into the fibrin clot enhances its elasticity.331 Fibrin-fibronectin 
interactions also have important consequences at the site of wound 
healing. Fibrin-bound fibronectin, particularly when crosslinked, 
provides an excellent substratum for the migration and adhesion of 
fibroblasts. 332 
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Chapter Four 
Attempts to purify a 600 kDa protease 
Incubation of C-reactive protein (CRP), fibrinogen and fibrin with 
PMA-stimulated neutrophils leads to degradation of these substrates 
by a membrane associated protease. 1-3 Modulation of inflammatory 
reactions, either by the generated products or by the proteolytically 
modified substrates appears to be an important consequence of the 
membrane associated proteolytic activity on these substrates. In the 
case of CRP, the generated peptides inhibit neutrophil function,4 
whilst fibrinogenolysis generates· non-clottable fibrinogen which is 
proposed to limit the deposition of fibrin at sites of inflammation.2 
The synergistic activity of this membrane associated proteolytic 
activity with plasmin has been shown to aid fibrin dissolution.3 
The products generated · from CRP, fibrinogen and fibrin by the 
neutrophil membrane associated protease have been reported to have 
distinctly different apparent molecular mass values from those 
produced by neutrophil granule proteases, pure human neutrophil 
elastase (HNE) or plasmin. 1-3 This protease has been shown to be 
completely inhibited by the serine protease inhibitor PMSF 
(phenylmethylsulphonyl fluoride), but resistant to several inhibitors 
of azurophil granule serine proteases.2·3 Partial release of this 
protease into the extracellular medium could be achieved with a dose 
of PMA that does not cause azurophil granule release. 1-3 Association 
of this protease with neutrophil cytoskeleton fractions led to the 
suggestion that it is a submembrane protease localised at sites of 
interaction of the cytoskeleton with the membrane. 1•2 
This protease was shown by size exclusion chromatography to be 600 
kDa in size1 and to resolve into subunits of 200 kDa, 316 kDa, 398 
kDa and 501 kDa in size when subjected to SDS-PAGE.1-3 Whilst 
the 600 kDa protease appeared to be distinct from other known 
neutrophil proteases on the basis of its molecular weight, inhibitor 
profiles and proteolytic products, it was yet to be purified from crude 
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extracts. As a result, its structural and catalytic properties remained to 
be elucidated. 
The purpose of this study was to purify and further characterise this 
novel membrane associated protease. Attempts by others to purify 
this protease, involved a variety of column chromatographic 
techniques, but had proved unsuccessful (personal communication 
Sharon Kelly). The present study explored new avenues whereby the 
membrane associated protease could be purified. Three different 
approaches to the purification and characterisation of this protease 
are described in this chapter. Whilst unsuccessful and, in many 
instances incomplete, the collective conclusions drawn from these 
purification attempts clearly suggested a need to identify, more 
carefully, the nature of the membrane associated protease responsible 
for the degradation of CRP, fibrinogen and fibrin. 
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Methods 
Chemicals and reagents 
See Appendix 1, pages 225-226 
Preparation and iodination of fibrinogen 
Fibrinogen, isolated by ammonium sulphate precipitation of plasma 
obtained from heparinised blood donated by healthy laboratory 
workers, 5 migrated as a single band corresponding to an apparent 
molecular mass of 340 kDa when analysed by SDS-P AGE (non-
reduced). The preparation contained a trace amount of factor XIII. 
The clottability of fibrinogen prepared in this way was 97%. 
Fibrinogen was iodinated using iodogen as an oxidising agent and 0.5 
µCi [1251]-Na/µg fibrinogen.6 Iodinated fibrinogen had a specific 
activity of 0.5µCi/µg fibrinogen and showed no evidence of 
degradation when subjected to 5-20% SDS-PAGE and 
autoradiography ( 400 000 cpm/track). 
Preparation of CRP 
CRP was prepared from a pool of acute phase sera obtained from 
patients 48 hours post surgery. Informed consent and ethics 
committee approval was obtained. CRP was isolated from serum via 
calcium-dependent phosphorylethanolamine affinity chromatography 
and Sephacryl S-200 gel filtration. 7 Purified CRP migrated as a 
single band with an apparent molecular mass of 24 kDa when 
subjected to 12% SDS-PAGE (reduced). 
Isolation of neutrophils 
Neutrophils were isolated from heparinised blood (donated by 
healthy laboratory workers) by Ficoll-Hypaque centrifugation 
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followed by dextran sedimentation and hypotonic lysis of 
erythrocytes. 8 This procedure yields neutrophil preparations with a 
purity and viability of greater than 95% as determined by Wright-
Giemsa staining and trypan blue exclusion respectively. Purified 
neutrophils were resuspended in either phosphate-buffered saline 
(PBS) or Hanks balanced salt solution (HBSS). Neutrophils were 
used immediately following purification. 
Preparation of neutrophil conditioned medium 
For the preparation of neutrophil conditioned medium, neutrophils 
were resuspended in HBSS at 10 x 106 cells/ml and warmed to 37°C 
for 15 minutes. Cells were then stimulated with phorbol 12-myristate 
13-acetate (PMA) at a final concentration of 5 or lOng/ml at 37°C for 
20 minutes. Cells were gently resuspended every 5 minutes to 
prevent aggregation. Following centrifugation (2000rpm, 3 minutes, 
4 °C) the cell free supernatant was collected and used immediately as 
the neutrophil conditioned medium. When necessary, conditioned 
media were also prepared from non-stimulated neutrophils as well as 
neutrophils stimulated with high dose PMA (150 ng/ml). 
Preparation of neutrophil cytoskeleton 
Neutrophil cytoskeletons were isolated by lysing neutrophils (20 x 
106/ml) for 10 minutes on ice in lysis buffer (50mM Tris-HCI, pH 
7.5, containing 160mM KCl, lOmM EDTA and 1% (v/v) Triton X-
100).9 The triton insoluble cytoskeletons were pelleted by 
centrifuging at 12000g for 10 minutes at 4 °C, and then washed in the 
lysis buffer without Triton X-100. Following 3 washing steps the 
proteins of the neutrophil cytoskeletal pellet were solubilised in 10 
mM Tris-HCl (pH 7.4) containing IM NaCl, for 1 hour on ice. 
Insoluble protein was removed by microfuging at 12000g for 5 
minutes at 4°C. The supernatant (1-2ml) was then dialysed against 
PBS at 4°C for 20 hours (3 x 500ml), and stored at 4°C until use. 
When necessary, concentrated preparations were made by dialysing 
the supernatant against dH20 for 1 hour (3 x 500ml) instead of PBS, 
after which it was lyophilised and stored at -70°C until further use. 
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Preparations of crude solubilised membranes 
Crude preparations containing solubilised neutrophil membranes 
were used as a source of the membrane protease during purification 
attempts. 10 Isolated neutrophils were resuspended in HBSS at 30 x 
106 PMN/ml and warmed to 37°C for 10 minutes prior to stimulation 
with PMA (5ng/ml). Following incubation at 37°C for a further 5 
minutes, cells were centrifuged at 2000rpm for 3 minutes at 4°C. The 
supernatant was removed and the neutrophils were then resuspended 
in an equal volume of HBSS containing 25µM p-nitrophenyl-p-
guanidinobenzoate (NPGB), and divided into 500µ1 aliquots in 
eppendorf tubes. Cells were microfuged for 10 seconds after which 
the supernatant was removed, and cells resuspended in 500µ1 cell 
lysis buffer (Tris 50mM, KCl 160mM, CaCh lmM, MgCh lmM, 
NPGB 25µM, pepstatin 2µM, leupeptin 2µM, octylglucoside 20 mM, 
pH=7.4). The cells were maintained in lysis buffer at 4°C for 1 hour 
after which they were microfuged for 5 minutes. The supernatant was 
then removed and used as a crude source of the membrane protease 
for subsequent purification attempts. 
Affinity chromatography 
Preparation of matrices 
Cyanogen bromide activated Sepharose 48 
10mg fibrinogen in PBS was coupled to 3.5ml of cyanogen bromide 
(CNBr) activated sepharose 48 beads according to manufacturers 
instructions. The coupling efficiency, as determined by measuring the 
OD2so of the supernatant after coupling, was found to be 95%. 
Excess active groups were blocked with 1 M ethanolamine for 2 
hours at room temperature. Uncoupled ligand was then removed by 5 
alternating washes with low pH (O.IM sodium acetate, IM NaCl, 
pH=4.0) and high pH (Tris 0.025M, IM NaCl, pH=8.5) buffers. The 
fibrinogen-sepharose beads were then washed thoroughly with PBS 
and stored at 4°C in PBS containing 0.02% NaN3• A similar 
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procedure was followed for the coupling of CRP (17.Smg/ml) to 
CNBr sepharose 4B (2.5ml) and a coupling efficiency of 
approximately 90% was obtained. 
Tosyl-activated Dynabeads® 
Dynabeads® M-280 Tosylactivated are superparamagnetic 
polystyrene beads activated with p-sulphonyl chloride treatment for 
chemical binding to proteins. Fibrinogen (0.5mg/ml) was coupled to 
20mg Dynabeads® according to manufacturers instructions. The 
coupling efficiency, as determined by measuring the OD2so in the 
supernatant after coupling, was 86%. Protein coupled beads were 
washed with PBS (2 x IOml) and then acetate buffer (O.IM sodium 
acetate, IM NaCl, pH=4) to remove non-specifically bound ligand. 
Monitoring of the supernatant (OD2so) revealed that minimal protein 
was removed during this step. Beads were then washed with 
PBS/0. I% BSA (3 x IO minutes at room temperature, I x 30 minute 
at room temperature, and overnight at 4°C) prior to use. CRP 
(Img/ml) was coupled to 25mg Dynabeads, as described above, with 
a coupling efficiency of 50%. 
Affigel 10 
Affigel 10 is an N-hydroxysuccinamide ester of a derivatised 
crosslinked agarose bead support which contains a 10 atom spacer 
arm. One millilitre of Affigel IO was coupled to 0.2mg/mi of the 
serine protease inhibitor, AEBSF ([2-aminoethyl]-benzenesulphonyl 
fluoride) according to manufacturers instructions. As AEBSF absorbs 
at 280nm, the coupling efficiency could be determined as described 
above. Interference by released N-hydroxysuccinamide ester was 
eliminated the addition of IN HCl to a pH of 2.5 prior to measuring 
OD2so. The coupling efficiency was found to be 64%. Excess active 
groups were then blocked with IM ethanolamine buffer, pH=8. The 
gel was then equilibrated in PBS prior to use. 
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Affigel 10 AEBSF Affigel 10 - AEBSF NHS 
The coupling of AEBSF to Affigel 10. The amino group of AEBSF displaces the 
N-hydroxysuccinamide (NHS) group of the NHS ester forming a stable amide bond. 
Affinity chromatography 
These affinity matrices were used to isolate the CRP and fibrinogen 
degrading activity from neutrophil conditioned medium, soluble 
cytoskeleton proteins, and crude preparations of soluble membrane 
proteins. Protease preparations were exposed to the affinity matrices 
either by circulation through a column packed with matrix, or 
through mixing the protease source with an aliquot of matrix in an 
eppendorf tube. Experiments were performed at 4 °C to limit 
proteolytic activity during protease-substrate interactions and 
incubation times with the matrix were varied in order to optimise 
binding of protease. Binding of the proteolytic activity to the affinity 
matrix was detected by a loss of [125I]-labelled fibrinogen degrading 
activity in crude extracts following incubation with the matrix.* For 
this, [125I]-labelled fibrinogen was incubated (1-3 hours, 37°C) with 
the relevant protease sources before and after incubation with the 
affinity matrix. [125I]-labelled fibrinogen degradation was measured 
by precipitating duplicate 50µ1 aliquots of the reaction mixture with 
TCA (10% final concentration) and quantifying the TCA soluble 
peptide formation. The concentration of [125I]-labelled fibrinogen 
used in each degradation assay was chosen such that the crude 
enzyme preparations, before exposure to affinity matrices, generated 
approximately 30% TCA soluble [125I]-labelled fibrinogen peptides 
at 2 hours. When a decrease in the [125I]-labelled fibrinogen 
• The quantity of substrate linked to matrices was always in excess of protease 
levels in the crude preparations, allowing for adsorption to the column to be 
monitored by loss of proteolytic activity. 
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degrading activity of the crude extract was detected, bound material 
was eluted from the matrix using 4M NaCl and assayed for [1251]-
labelled fibrinogen degrading activity. 
Molecular biology 
Oligonucleotide probes 
A short synthetic oligodeoxynucleotide probe, coding for a highly 
conserved region near the active site in a variety of different serine 
proteases, was used to screen a human bone marrow cDNA library. 
This strategy was based on previous studies in which this probe had 
been used to isolate a variety of serine proteases including factor IX, 
prothrombin, complement Clr and hepsin, from hepatocyte cDNA 
libraries.11'12 A mixture of tetradecadeoxynucleotides was 
synthesised by Genosys according to the following sequence: 
G 
I 
5' C-C-A-G-C-G-C-A-G-A-A-C-A-T 3' 
I I I 
T A A 
I 
C 
Bone marrow cDNA library 
As neutrophil serine proteases are synthesised in neutrophil 
precursors, but not in mature neutrophils, a human bone marrow 
rather than a neutrophil cDNA library was screened for serine 
protease cDNA. This cDNA library, contained within the t..DR2 
expression vector, was obtained from Clontech. 
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[y-32P]ATP labelling of oligonucleotide probe 
Oligonucleotide probes were 5' end labelled with [y-32P]ATP using 
T4 polynucleotide kinase. Forty pmole of oligonucleotide and 80 
pmoles [y-32P]ATP (in 50mM Tris-HCl pH=7.6, lOmM MgCli, 
lOmM 2-mercaptoethanol) were incubated with T4 polynucleotide 
kinase (IOU) for 30 minutes at 37°C. Radiolabelled oligonucleotide 
was separated from unbound [y-32P]ATP by sephadex PD-50 column 
chromatography. Fractions were collected, radioactivity measured 
using a J3-counter, and peak fractions pooled and stored at -20°C until 
used during hybridisation procedures. 
Preparation of bacterial cultures 
Bacterial cultures · were prepared under a laminar flow hood. A wire 
loop was flamed until red hot and following cooling was used to loop 
up a single colony of E. coli, strain K802. The loop was placed in an 
eppendorf tube containing 500µ1 of Luria broth (tryptone 1 %, yeast 
0.5%, NaCl 1 %, pH=7 .0) and agitated gently, prior to transfer of the 
contents of the tube into a flask containing Luria Broth ( + 1 OmM 
MgS04). The flask was incubated overnight in a 37°C shaking 
incubator set at 200 rpm. Following centrifugation of the overnight 
culture at 2500 rpm for 10 minutes at 4 °C, the pellet was 
resuspended and diluted with SM buffer (50mM Tris-HCl, O.lM 
NaCl, IOmM MgS04, 0.01% gelatin, pH=7.5) until the OD6oo 
measured ±0.5. 
Preparation of plates and top agar 
Luria agar (tryptone 1 %, yeast 0.5%, NaCl 1 % and agar 1.5%) was 
autoclaved and allowed to cool before adding MgS04 (1 OmM final 
concentration). The agar was then poured into 150mm diameter 
plates which were stored at 4 °C until use. 
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Plating of phages 
Top agar was melted and then maintained in a liquid state in a 55°C 
water bath until required. Five microlitres of the working 
bacteriophage stock solution* was added to an eppendorf tube 
containing 400µ1 of E. coli (OD600 = 0.5) and incubated at 37°C for 
15 minutes, with gentle agitation every 5 minutes. Top agar (7ml) 
was removed from the 55°C water bath, and MgS04 was added to 
achieve a final concentration of 1 OmM. After cooling the top agar to 
approximately 3 7°C, the contents of an eppendorf were added to it, 
mixing briefly but thoroughly. The top agar was then poured onto an 
agar plate (which had been equilibrated to 37°C) with tilting and 
swirling to ensure an even spread. After solidification (15 minutes), 
the plates were incubated at 37°C. Phage colonies appeared as small 
translucent plaques due to their lysis · of transfected E. coli after 
approximately 6-8 hours. 
Plaque lifts 
Once plaques were clearly visible they were ready to be lifted onto 
Hybond-N™ nylon membranes (Amersham) for subsequent 
hybridisation. Plates were kept at 4 °C for at least 1 hour prior to 
plaque lifts to ensure that top agar was solidified. Membranes were 
placed on top of the agar for 60 seconds during which time the plates 
and membranes were marked in 3 assymetric points to provide a 
record of the position of the filter relative to the plate. Membranes 
were then removed and placed plaque side up in denaturing solution 
(1.5M NaCl, 2% w/v NaOH) for 30 seconds. Membranes were then 
submerged in this solution for a further 60 seconds before immersing 
* 
The concentration of the working stock was determined by titering the original 
bacteriophage stock solution. Serial dilutions of the phage stock were made (from 10-1 to 
10.(;). E. coli were transfected as described above, and each dilution was plated). After 8 
hours the number of plaques were counted, and the titre of the phage stock was 
calculated using the following equation: Colony forming units (cfu) /ml= (# plaques 
x dilution factor x 103µ1/ml) / µl used. From this titre it was calculated that 5µ1 of the 
10·3 dilution produced approximately 5000 plaques/plate. The 10·3 diluted phage 
solution was thus used as the working stock in all subsequent experiments. 
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in neutralising solution (1.5M NaCl, 0.5M Tris-HCl, EDTA lmM, 
pH=7.2) for 5 minutes. Thereafter membranes were rinsed with 3 x 
SSC (20 x SSC stock: 3M NaCl, 0.3M sodium citrate, pH=7.0) and 
placed on filter paper where they were air dried. Once this process 
was completed, a second membrane was placed on the same plate, 
marked at the same location and subjected to the same process as 
described above. Membranes were placed in a UV crosslinker for 12 
seconds to fix the phage DNA to the membrane. In general 5 plates at 
a time ( and thus 10 membranes) were prepared. 
Hybridisation using oligonucleotide probes 
Membranes were incubated in 40ml prehybridisation solution (6 x 
SSC, 1 x Denhardt's solution, lOOµg/ml salmon sperm DNA, 0.5% 
SDS and 50% formamide) at 42°C for 90 minutes. The 
oligonucleotide probe was heated to 100°C for 2 minutes (to release 
any secondary structure that may have formed) and then chilled 
quickly on ice. The oligonucleotide probe was then added at a 
minimum of 1 x 106 cpm/ml and hybridisation was allowed to 
continue for 24 hours at 30°C. Membranes were then subjected to a 
series of 10 minute washing steps of increasing stringency as follows: 
(1) 6 x SSC - room T0 (2) 3 x SSC- room T0 (3) 1 x SSC- room T0 
(4) Repeat 1 x SSC- room T0 (5) 1 x SSC+ 0.1 % SDS- room T0 (6) 
0.1% SSC+ 0.1% SDS- room T0 (7) 0.1% SSC+ 0.1% SDS at 
37°C. After each washing step the radioactivity of the membranes 
was monitored with a Geiger counter and washes were continued 
until the backround radioactivity appeared to be sufficiently low. A 
number of the hybridisation conditions were varied over the course of 
several experiments in an attempt . to optimise hybridisation of the 
probe. These included the temperature and duration of hybridisation, 
as well as the stringency of washes. Following washing steps, 
membranes were dried, taped onto a piece of filter paper placed 
within an X-ray cassette and marked so that developed films could 
later be accurately superimposed on membranes. Membranes were 
then subjected to autoradiography, the time of exposure varying from 
1-4 days depending on the intensity of the signal. Once developed, X-
ray films could be positioned such that duplicate membranes could 
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be compared. Any strong signal occurring in the same position on 
both of the duplicate filters suggested the presence of a hybridising 
clone. 
Electrophoretic transblottting 
Neutrophil cytoskeleton and conditioned medium preparations were 
prepared as described above. Following lyophilisation, preparations 
were reconstituted in dH20 at 1/10 of the original volume, dialysed 
for 1 hour at 4°C against 3 changes of dH20 after which Vi volume of 
3 x concentrated SDS sample buffer (0.012 M Tris-HCl [pH 6.8] 
with 4% (w/v) SDS, and 24% (v/v) glycerol) was added and the 
mixture boiled. Samples were then analysed by 3-13% SDS-P AGE 
(non-reduced) according to the method of Laemmli. 13 Following 
electrophoresis, the gels were subjected to silver staining using a 
silver staining kit (Amersham) according to manufacturers 
instructions. Molecular weight markers ranging in molecular weight 
from 14 to 200 kDa (Amersham) were used to identify the apparent 
molecular weights of proteins of interest. When required the 
separated proteins were electrophoretically blotted onto 
polyvinylidene difluoride (PVDF) protein sequencing membrane as 
described previously. 14 As the subunits of the 600 kDa membrane 
associated protease are not detected by coomassie blue staining, and 
proteins on PVDF membranes cannot be silver stained, protein 
transfer was monitored by the disappearance of silver stained bands 
from polyacrylamide gels following transblotting. 
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Results 
Affinity chromatography 
Attempts to purify the 600 kDa protease using affinity 
chromatography utilised three sources of protease, · including the 
conditioned medium of PMA (lOng/ml) stimulated neutrophils, 
soluble cytoskeleton proteins and soluble membrane proteins. 
Substrate chromatography 
Two substrates for this protease, namely fibrinogen and CRP, were 
used as affinity ligands in attempts to purify the 600 kDa protease. 
The substrates were coupled to either agarose (CNBr activated 
sepharose 4B) or tosyl-activated superparamagnetic polystyrene 
beads (Dynabeads®). The extent to which these matrices could 
extract the protease from crude preparations was determined by 
measuring [1251]-labelled fibrinogen degrading activity before and 
after exposure to these matrices. 
Neither CRP-sepharose nor fibrinogen-sepharose were able to extract 
proteolytic activity from crude preparations of either neutrophil 
membrane, cytoskeleton or conditioned medium. The mode of 
exposure of protease to the matrix (i.e. circulating through a column 
versus mixing in a test tube) and the duration of exposure (2-20 hours 
at 4°C) did not influence protease binding. In one experiment there 
was a 50% decrease in the fibrinogen degrading activity of a 
cytoskeleton preparation following exposure to CRP-sepharose for 
20 hours at 4°C. However, subsequent attempts to elute proteolytic 
activity from the matrix using NaCl concentrations as high as 4M 
were unsuccessful. 
Similarly, fibrinogen and CRP linked to Dynabeads, failed to extract 
proteolytic activity from these enzyme sources. 
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Inhibitor chromatography 
In contrast to substrate linked matrices, AEBSF-linked affigel 10 was 
found to cause profound depletion of the fibrinogenolytic activity 
from cytoskeleton preparations containing the 600 kDa protease. (No 
attempt was made to isolate the proteolytic activity from membrane 
preparations and conditioned medium using this matrix). The [125I]-
labelled fibrinogen degrading activity of the neutrophil cytoskeleton 
was reduced by 94% following exposure to AEBSF-affigel 10. An 
attempt was not made to elute this protease from the beads as the 
interaction between serine proteases and AEBSF is irreversible.* To 
analyse the protein associated with the AEBSF-affigel 10 matrix, the 
beads were boiled in SDS sample buffer, and solubilised protein 
subjected to SOS-PAGE and silver staining. 
No staining was observed in the areas of the gel previously reported 
to contain the proteolytically active subunits of the 600 kDa protease, 
(namely 200 kDa, 316 kDa, 398 kDa and 501 kDa),1-3 (see figure 1, 
track 1). Instead there appeared to be two major areas of staining, one 
at approximately 30 kDa (which appeared to comprise 3 thin bands) 
and one between the 69 and 97 kDa molecular weight markers. 
Analysis of the composition of the cytoskeleton preparation before 
and after exposure to AEBSF-affigel 10 suggested a relative decrease 
in the intensity of bands at ±30 kDa and ±14-21 kDa (figure 1, tracks 
2 and 3). The high molecular weight subunits of the 600 kDa 
protease were not visible on silver stained gels either before or after 
exposure to the matrix. In the context of earlier reports attributing 
95% of the proteolytic activity of the cytoskeleton preparation to a 
600 kDa protease, 1 the binding of low molecular weight proteins to 
the inhibitor linked matrix was thought, at the time, to represent non-
specific binding and was not pursued further. 
• Whilst it would not be possible to elute inhibitor boi.Jnd protease, this technique 
was still considered to have potential applications provided sufficient quantities of 
purified 600 kDa protease could be extracted. A protease inhibitor complex could, 
for example, be used for the generation of antibodies. 
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Figure 1. A cytoskeleton preparation 
(from 25 x 106 neutrophils) was 
mixed with 200µ1 of packed AEBSF-
affigel 10 beads in a final volume of 
500µ1, and rolled overnight at 4 'C. 
The beads were then allowed to 
settle and an aliquot of the 
supernatant collected. Beads were 
then washed and solubilised in an 
equal volume of 3 x SOS sample 
buffer and boiled, after which the 
beads were microfuged and the 
supernatant analysed by SOS-PAGE 
and silver staining (Track 1). The 
cytoskeleton preparations before and 
after exposure to AEBSF-affigel 10 
are shown in tracks 2 and 3 
respectively. 
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An alternative approach, using molecular biology, was also initiated 
in an attempt to purify and characterise the 600 kDa protease. A 
strategy was chosen that involved the screening of a human bone 
marrow cDNA library with a short synthetic oligodeoxynucleotide 
probe encoding a highly conserved region near the catalytic site of a 
variety of serine proteases. 11 ,12 
Early attempts at screening this library failed to detect clones which 
hybridised with this oligonucleotide probe, leading to a series of 
experiments aimed at optim1smg hybridisation conditions. 
Concurrently with this a number of important observations were 
made which led to a re-evaluation of whether the protease was in fact 
composed of subunits with apparent molecular mass values of larger 
than 200 kDa. The outcome of these experiments indicated that an 
attempt to identify the protease using molecular biology was no 
longer necessary (see below). 
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Electrophoretic transblotting 
Attempts to electrophoretically transblot the membrane associated 
protease were undertaken with two purposes in mind: (1) to obtain an 
N-terminal amino acid sequence and (2) to generate antibodies to 
transblotted protein. 
This protease has been reported to separate into four distinct subunits 
when membrane, cytoskeleton and conditioned medium fractions 
from [125I]-labelled neutrophils are subjected to SDS-PAGE and 
autoradiography. 1 These subunits were shown to contain the 
proteolytic activity of the membrane associated protease. 1-3 Whilst 
these subunits cannot be detected using coomassie blue staining, 1 
silver staining had been successful in detecting several proteins with 
apparent molecular mass values greater than 200 kDa, in particular a 
strongly stained band thought to represent the 316 kDa subunit of this 
protease (personal communication). 
For the present study, preparations of soluble cytoskeleton proteins, 
and later conditioned medium proteins, were used as sources of 
protease. Concentrating steps were required to ensure that sufficient 
protein could be detected in SDS-polyacrylamide gels. This was 
achieved by lyophilisation and reconstitution in 1/10 of the original 
volume (see Methods) prior to electrophoresis. Solubility pro bl ems 
were frequently 
encountered, even 
after the addition of 
SDS sample buffer. 
Following electrophor-
esis, transfer of a high 
molecular weight band 
in the 300 kDa region 
of the gel was 
successful (figure 2). 
However repeats of 
this experiment with 











etic transfer of ± 300 
kDa band. Two aliquots 
of cytoskeleton proteins 
from 100 x 106 
neutrophi/s were sub-
jected to SOS-PAGE 
(3-13%). Track 1 was 
silver stained while 
track 2 was transblotted 
onto PVDF membranes 
prior to silver staining. 
The successful trans-
fer is suggested by the 
absence of staining in 
the gel following 
transblotting. 
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indicated poor reproducibility in the position to which proteins with 
apparent molecular mass values of greater than 200 kDa migrated. 
Similar irreproducibility in proteins migrating with apparent 
molecular mass values of greater than 200 kDa was encountered 
when the conditioned medium was used as the source of protease 






-69 -69 -69 -69 
-46 -46 -46 -46 




1 2 3 4 
Figure 3. Variable appearance of conditioned medium preparations on SDS-
PAGE. Four different preparations of conditioned medium (1-4) had different 
appearances when subjected to 3-13% SOS-PAGE and silver staining. In all gels 
the top of the gel was darkly stained. The variable appearance of bands above 
200k0a can be seen. 
When present, the intensity of bands with apparent molecular mass 
values of greater than 200 kDa were too low to suggest that they 
could be used for either protein sequencing or antibody generation. In 
an attempt to increase the concentration of the protease relative to the 
other constituents of the conditioned medium, neutrophils were 
stimulated with an increased dose of PMA (150ng/ml). Although this 
dose of PMA is known to induce azurophil granule release, 15' 16 the 
protease of interest would subsequently be separated from the lower 
molecular weight granule proteases by electrophoresis, thereby 
preventing unwanted contamination with granule proteases. For 
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comparative purposes, two conditioned media were generated, one 
using low dose (IOng/ml) PMA (reported not to release azurophil 
granule proteases), 1' 17 and one using PMA at 150ng/ml, and these were 
subjected to SDS-PAGE and silver staining (Figure 4). Unexpectedly, 
the electrophoretic profile of the conditioned medium generated by 
high dose PMA appeared extremely similar ( albeit more 
concentrated) to that generated by low dose PMA. As high dose PMA 
is known to induce 
neutrophil release of 
azurophil granules, this 
finding suggested that 
conditioned medium 
generated by neutrophils 
stimulated with low dose 
PMA might contain 
azurophil granule proteas-
es. All further attempts to 
purify and characterise the 
membrane associated 
protease were suspended 










Figure 4. Conditioned 
media were prepared from 
neutrophils (20 x 1iflml) 
stimulated with either low 
(10nglml) or high 
(150nglml) dose PMA. 
Following lyophilisation 
conditioned media were 
reconstituted in equal 
volumes and subjected to 
3-13% SOS-PAGE. Track 
1 shows conditioned 
medium generated by 
low dose PMA, whilst track 
2 shows conditioned 
medium generated by high 
dosePMA. 
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Discussion 
Attempts to purify and further characterise the 600 kDa membrane 
associated protease utilised three different approaches - affinity 
chromatography, molecular biology and electrophoretic transblotting. 
Affinity chromatography, using fibrinogen- and CRP-linked 
matrices, proved unsuccessful in extracting proteolytic activity from 
crude preparations containing the membrane associated protease. 
This may have been due to proteolytic cleavage of substrates 
releasing protease from the matrix, although this possibility was not 
investigated. 
A matrix linked to the serine protease inhibitor AEBSF was able to 
extract proteolytic activity from preparations of soluble cytoskeleton 
proteins. However, SDS-PAGE analysis of the matrix bound material· 
suggested that the 600 kDa protease had not been extracted. Instead, 
a broad band was observed in 30 kDa region of the gel as well as a 
narrow band in the 69-97 kDa region. These bands were thought at 
the time to represent non-specific binding to the agarose matrix, and 
the significance of this observation was not realised until later (see 
discussion, Chapter 5). 
The purification of this protease was also attempted via the molecular 
biological route. This was stimulated by an earlier study which had 
used a similar approach to identify the cDNA encoding a novel serine 
protease in hepatocyte cDNA libraries. 11 ' 12 The aim was to identify 
clones hybridising to this probe and, through DNA sequencing, to 
identify those clones encoding novel serine proteases. It was hoped 
that these could be expressed in a mammalian expression vector 
system, and that clones expressing the novel 600 kDa protease could 
be identified either immunologically (attempts were underway at the 
time to generate an antibody to this protease) or functionally (using 
indices such as substrate preference, nature of degradation products 
and inhibitor profiles). Finally, with the aid of molecular biological 
manipulations (such as the introduction of an affinity tag), it was 
hoped that this protease could be purified and further characterised. · 
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Early attempts were unsuccessful in detecting clones hybridising to 
the oligonucleotide probe, resulting in a series of experiments aimed 
at optimising hybridisation conditions. At this time it became 
apparent from concurrent biochemical studies that the nature to the 
membrane associated protease needed to be re-evaluated. These 
studies involved attempts at electrophoretically transblotting the 316 
kDa subunit of this protease. The purpose was to obtain an N-
terminal amino acid sequence of this subunit and to use it for the 
generation of antibodies against the membrane associated protease. 
Although proteins with apparent molecular mass values of greater 
than 200 kDa could be successfully transblotted from cytoskeleton 
preparations, the presence of such proteins was irreproducible and the 
concentration too low for raising antibodies. Concentrating steps, 
which were required for the detection of these bands, resulted in 
solubility problems, and there was a tendency for large aggregates of 
insoluble material to form following reconstitution of lyophilised 
material. These processes may have accounted for the inconsistent 
staining of areas of the gel previously reported to contain the subunits 
of the 600 kDa protease. This raised the possibility that the 
previously documented subunits of the 600 kDa protease might, in 
fact, be aggregates of other proteases. 
Several recent studies suggested that HNE might be a candidate 
protease. Neutrophils stimulated with FMLP, IL-8 or high dose PMA 
were reported to release HNE which could bind to the neutrophil 
membrane and remain proteolytically active. 15' 16' 18 Moreover a recent 
study reported the time dependent expression of HNE on the 
membrane of neutrophils stimulated with 0.8 nM (0.4 ng/ml) PMA. 19 
The existence of both secreted and membrane bound forms of HNE 
suggested that HNE could be present in both the conditioned medium 
and membrane preparations used as a source of the 600 kDa protease. 
It appeared, however, that this possibility had been excluded as 
several lines of evidence suggested that the proteolytic activity of the 
600 kDa protease was distinct from that of HNE. 1-3 
1. The 600 kDa protease was reported to generate fibrinogen and 
fibrin degradation products with distinctly different apparent 
molecular mass values from those produced by purified HNE.2'3 





chloromethyl ketone inhibitors of HNE whilst demonstrating only 
partial sensitivity to a third.2•3 
3. High performance liquid chromatography revealed that HNE 
digestion of fibrinogen produced many peptides with retention 
times different from those produced by the conditioned medium 
from PMA stimulated neutrophils. In addition, several peptides 
generated by the neutrophil conditioned medium were reported to 
still possess HNE sensitive sites.2 
4. Amino acid sequencing of fibrinogen peptides produced by 
limited proteolysis by the conditioned medium suggested that 
fibrinolysis occurs in the N-terminal region of the Aa chain and 
the C-terminal regions of the Bl3 and y chains.2 This was reported 
to be contrary to fibrinogenolysis by neutrophil lysates and 
purified HNE which cleave all three chains of fibrinogen from the 
N-terminus.2 
5. The dose of PMA which was used to induce release of the 600 
kDa protease into the conditioned medium was reported not to 
induce the release of azurophil granules. 1•17 
However, the observation, made during the present study, that the 
conditioned media generated by neutrophils stimulated with low 
(lOng/ml) and high (150ng/ml) dose PMA had similar 
electrophoretic profiles, suggested that low dose PMA might in fact 
induce release of azurophil granules and thus HNE. An additional 
observation made during an unrelated study ( data presented in 
appendix 3, page 230), added to concerns that HNE might contribute 
to the proteolytic activity of the conditioned medium. In this study 
the conditioned medium was noted to degrade plasminogen, 
generating products which appeared remarkably similar to those 
generated by purified HNE. Thus, despite strong evidence to the 
contrary, several findings suggested the need to exclude HNE as a 
source of the proteolytic activity previously ascribed to a 600 kDa 
membrane associated protease. 
As the molecular biology study represented a considerable 
undertaking in terms of time and expense, a more careful 
characterisation of the membrane associated proteolytic was essential 
before continuing along this line. This provided the stimulus for the 
study presented in the following chapter. 
Chapter 4 126 
References 
1. Shephard EG, Kelly SL, Anderson R, Fridkin M. (1992) Clin. Exp. lmmunol. 81, 
509. -
2. Kelly SL, Adams SA, Robson SC, Kirsch RE, Shephard EG. (1994) Biochem. J. 
298,689. 
3. Adams SA, Kelly SL, Kirsch RE, Robson SC, Shephard EG. ( 1995) Blood Coag. 
Fibrinol. 6, 693. 
4. Shephard EG, Anderson RA, , Rosen 0, Myer MS, Fridkin M, Strachan AF, De 
Beer FC. (1990) J. lmmunol. 145, 1469. 
5. Kalvaria I, Rabinowitz S, Frith LOC, Kirsch RE. (1986) Thrombosis Res. 43,287. 
6. Fraker PJ, Speck Jr. JC. (1978) Biochem. Biophys. Res. Commun. 80, 849. 
7. De Beer FC, Pepys MB. (1982) J. lmmunol. Methods. 50, 17. 
8. Boyum A. (1968) Scand. J. Lab. Invest. 21 (Suppl. 97), 77. 
9. Yassim R, Shefayk J, White JR, Tao W, Volpi M, Molsk TFP, Nacacche PH, 
Feinstein MB, Sharafi RI. (1985) J. Cell Biol. 101, 182. 
IO. Brown EJ, Goodwin JL (1988) J. Exp. Med. 167, 777. 
11. Leytus SP, Kurachi K, Sakariassen KS, Davie EW. (1986) Biochemistry. 25, 4855. 
12. Leytus SP, Loeb KR, Hagen FS, Kurachi K, Davie EW. (1988) Biochemistry. 27, 
1067. 
13. Laemmli UK. (1970) Nature. 227, 680. 
14. Towbin H, Staehelin T, Gordon T. (1979) Proc. Natl. Acad. Sci. USA. 76, 4350. 
15. Bangalore N, Travis J. (1994) Biol. Chem. Hoppe Seyler. 375, 659. 
16. Owen CA, Campbell MA, Sannes PL, Boukedes SS, Campbell EJ. (1995) J. Cell 
Biol. 131, 775. 
17. Pontremoli S, Melloni E, Michetti M, Sacco 0, Sparatore B, Salamino F, Damiani 
G, Horecker BL. (1986) Proc. Natl. Acad. Sci. USA. 83, 1685. 
18. Owen CA, Campbell MA, Boukedes SS, Campbell EJ. (1997) Amer. J. Physiol. 
272, L385. 
19. Gaudin P, Berthier S, Barro C, Zaoui P, Morel F. (1997) Eur. J. Cell. Biol. 72, 345. 
Characterisation of membrane associated fibrinogenolytic activity 127 
Chapter Five 
Characterisation of the fibrinogen 
degrading activity of the neutrophil 
membrane 
The findings presented in the previous chapter suggested the need to 
identify more carefully the nature of the membrane associated 
protease responsible for the degradation of fibrinogen, fibrin and 
CRP.1-3 Recent reports of a membrane bound form of HNE4-7 
suggested that HNE might have been a constituent of neutrophil 
membrane preparations used in previous studies. This study sought 
to test the hypothesis that the proteolytic activity previously ascribed 
to a 600 kDa membrane associated protease was, at least in part, due 
toHNE. 
Study design 
o The conditioned medium of PMA (5-1 Ong/ml) stimulated 
neutrophils ( due to the relative ease with which it is prepared) 
was used as the source of membrane associated protease for this 
study. Since the proteolytic activity of the conditioned medium 
has been reported to be identical to that of both neutrophil 
membrane and cytoskeleton fractions, 1-3 it was considered to be a 
representative source of the reported membrane associated 
protease. 
o In this study the proteolytic activity of the conditioned medium 
was characterised with respect to its inhibitor profile, the nature 
of its proteolytic products as well as its molecular weight. 
Chapter 5 128 
Methods 
Chemicals and Reagents 
The sources of chemicals and reagents used in this study are listed in 
Appendix 1, page 225. 
Preparation & iodination of fibrinogen, neutrophil isolation, 
preparation of conditioned medium & solubilised cytoskeleton 
proteins 
These procedures were performed as described previously (see 
chapter 4, Methods, page 107-108) 
Preparation of granule enzymes 
For the preparation of granule (lysosomal) enzymes, neutrophils 
were resuspended at 40 x 106 cells/ml and warmed to 3 7°C for 15 
minutes. Cells were preincubated for 5 minutes with cytochalasin B 
(5µg/ml) and then stimulated with the chemotactic peptide N-formyl-
L methionyl-leucyl-L-phenylalanine (FMLP) at a concentration of 
1 µM for a further 3 minutes. This is a very strong stimulus for the 
· release of azurophil granules.8 Following centrifugation at 2000 rpm 
for 3 minutes at 4°C, the cell free supernatant was collected and used 
immediately. 
Degradation of [1251]-labelled fibrinogen 
[
1251]-labelled fibrinogen, in HBSS, was incubated with the various 
enzyme sources ( conditioned medium of PMA stimulated 
neutrophils, granule enzyme preparations, purified HNE and purified 
cathepsin G) for various durations of time (5 minutes - 20 hours, 
3 7°C), in a final reaction volume of 100µ1. The concentrations of 
fibrinogen and the enzyme sources used in these experiments varied 
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and are clearly indicated in the results section. These concentrations 
were distinctly different from those used in previous studies2·9 which 
investigated the degradation of fibrinogen at a physiological 
concentration of 2mg/ml by conditioned medium from 10 x 106 
PMN. Changes to these concentrations allowed a detailed 
characterisation of the proteolytic activity of the conditioned 
medium. Degradation reactions were also performed in the presence 
of the specific HNE inhibitor, Me0-Suc-(Ala)2-Pro-Val- CH2Cl 
(lmM), and the cathepsin G inhibitors Z-Gly-Leu-Phe-CH2Cl 
(O.lmM) and chymostatin (O.lmM). These inhibitors were 
preincubated with the enzyme source for 15 minutes at 37°C prior to 
the addition of fibrinogen. At selected time points, degradation was 
measured quantitatively as 10% TCA soluble peptide formation by 
the addition of 50% TCA (w/v) at 4°C to an aliquot of the reaction 
mixture to give a final concentration of 10% (w/v). For qualitative 
analysis, an aliquot of the reaction mixture was mixed with an equal 
volume of SDS-sample buffer (0.012 M Tris-HCI [pH 6.8] with 4% 
(w/v) SDS, and 24% (v/v) glycerol with or without 10% (v/v) 2-
mercaptoethanol) and analysed by 5-20% SDS-PAGE (non-reduced) 
and 10% SDS-PAGE (reduced). Following electrophoresis, the gels 
were dried and the products visualised by autoradiography. Pre-
stained molecular weight markers ranging in molecular weight from 
14 to 200 kDa were used to identify apparent molecular mass values 
of fibrinogen degradation products. 
Production of fibrinogen peptides and separation by h.p.l.c. 
Unlabelled fibrinogen (2mg) was digested with HNE (2µg, 0.04 
units), or neutrophil granule enzymes (from 106 PMN) at 37°C in a 
final volume of 2ml HBSS. The reaction was stopped at the specified 
times (see results) by the addition of 50% (w/v) TCA to a final 
volume of 10% (w/v). Following an overnight incubation at 4°C, the 
sample was centrifuged (2000 rpm, 10 minutes, 4 °C) to remove 
precipitated protein. The supernatant was collected and the TCA was 
extracted four times with 8ml of diethyl ether. The remaining peptide 
mixture was then lyophilised and resuspended in deionised H20 at 
10% the original volume. The peptides were separated using a Merck 
Hibar Column (250 x 4mm) prepacked with LiChrosorb RP-18 
(5µM). H.p.l.c. was performed using a Waters Associates liquid 
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chromatograph with a 600E controller, solvent delivery system 
(model 6000), automatic injector (model 710B), variable wavelength 
detector (model 484 set at 220nm), and a Jlat bed recorder. The 
column was loaded with peptide aliquots (volumes ranging up to 
120µ1) and eluted using a binary gradient formed from 0.1 % 
trifluoroacetic acid (solution A) and 0.1 % trifluoroacetic acid in 
acetonitrile/water (75:25, solution B). The initial condition of 95% 
solution A and 5% solution B was run isocratically for 7 minutes and 
then followed by a linear gradient for a further 53 minutes to 30% of 
solution A and 70% of solution Bat a flow rate of lml/min. 
Zymography 
The method used for polyacrylamide gel electrophoresis in SDS 
containing gels was essentially that described by Laemmli 10 except 
that the protein substrates ( casein, fibrinogen and CRP) were 
copolymerised within the polyacrylamide gels. 11 The various 
substrates were incorporated into SDS polyacrylamide gels (3-13%) 
at final concentrations ranging from 50µg to lmg/ml. Samples were 
mixed with an equal volume of SDS-sample buffer (see above) and 
allowed to stand at room temperature for 30 minutes before being 
applied to the gels. Electrophoresis was performed at a constant 
voltage (150V) at 4°C, after which the gels were washed to remove 
SDS. This involved successive washes with 50ml portions of 2.5% 
(w/v) Triton X-100 in distilled water (two washes, 10 minutes each) 
and 2.5% (w/v) Triton X-100 in Tris-HCI (50mM), pH 7.4 (two 
washes, 10 minutes each). The excess triton was removed by 2 
washes (10 minutes each) in PBS (100ml). Following washing steps, 
the gels were placed in a dish with 100ml of PBS and incubated at 
3 7°C for 24 hours. Gels were then stained with coomasie blue 
(methanol 40% [v/v], acetic acid 16 % [v/v], coomassie brilliant blue 
0.12% [w/v]) and destained to reveal zones of substrate lysis. 
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Results 
1. The effect of the specific HNE inhibitor, MeO-Suc-(Ala)rPro-
Val-CH2CI. 
Neutrophil conditioned medium 
The specific HNE inhibitor, MeO-Suc-(Ala)2-Pro-Val- CH2Cl, was 
found to cause marked inhibition of the fibrinogen degrading activity 
of the conditioned medium, as measured by TCA-soluble peptide 
formation and the integrity of fibrinogen on SDS-PAGE (figures 1 
and 2). This inhibitory effect was particularly evident at earlier time 
points but gradually diminished with the progression of time. (figures 
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Figure 1a: The effect of MeO-Suc-(Ala)2-Pro-Val-CH2CI on the [125f!s·labelled-
fibrinogen degrading activity of the conditioned medium. [1 /}-labelled 
fibrinogen (10µg) was incubated (37°C, 0-60 minutes) with the conditioned medium 
from 106 PMA (5ng!ml) stimulated neutrophils in a final volume of 100µ/. Reactions 
were performed in the absence (-0-) and presence(-() -) of MeO-Suc-(Ala)2-Pro-Val-
CH2CI (1mM). Degradation was measured as 10% (wlv) TCA soluble peptide 
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Figure 1b: The inhibitory effect of Me0-Suc-(Ala)2-Pro-Val-CH2CI (1mM) at 
later time points. The ( 251]-labelled fibrinogen degrading activity of the conditioned 
medium of PMA stimulated neutrophils, in the absence (-0-) and presence (-¢-) of 
MeO-Suc-(Ala)2-Pro-Val-CH2CI, was tested at later time points (1-24 hours) under 
the same conditions as described in figure1a. Each data point represents a single 
measurement. An additional experiment gave similar results (see page Appendix 3, 
page 231) 
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Rgure 2: Degradation of f'J:il]-fibrinogen by 
the neutrophil conditioned medium in the 
presence and absence of a specific inhibitDr 
of HNE (MeO-Suc-(Ala):rPrc>VaJ.CHzCQ. ( 251} 
labelled fibrinogen (101{}) was incubated 
(37CC, 4-20 hours) with the conditioned 
medium (CM) from 1cf PMA (5ng,'mlj 
stimulated neutrophils in a final volume of 
100µ. Reactions were also performed in the 
presence of MeO-Suc-(Ala)r PrrrVa/-CH-iCJ 
(1mM). At selected time points, the nature of 
the degradation produds was assessed by 
SOS.PAGE (5-20";;,, non-reduced). The left 
hand panel shows the fibrinogen degradation 
products generated by the conditioned 
medium at 4, 8, and 20 hours, whilst the right 
hand panel shows the fibrinogen degradation 
products generated by the conditioned 
medium in the presence of MeO-Suc-(Ala)r 
PrrrVal-CH-iC/ at the corresponding time 
points. On the far right is non degraded 
fibrinogen. 
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Intact neutrophils 
MeO-Suc-(Ala)2-Pro-Val-CH2Cl was also found to inhibit the 
fibrinogenolytic activity of intact neutrophils. The specific HNE 
inhibitor was found to inhibit neutrophil mediated generation of TCA 
soluble [125I]-labelled fibrinogen peptides by 83%, 58%, 57% and 
50% at 10 minutes, 30 minutes, 1 hour and 5 hours respectively. 
SDS-PAGE analysis of these samples confirmed the inhibitory effect 
of Me0-Suc-(Ala)2-Pro-Val-CH2Cl on fibrinogenolysis (Figure 3). 
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Figure 3: The effect of MeO-Suc-(Ala)r 
Pro-Val-CH2CI on the degradation of 
{1251]-fibrinogen by PMA stimulated 
neutrophils. { 251]-labelled fibrinogen 
(25µg) was incubated (37'C, 30 minutes -
5 hours) with 2.5 x 1d PMA (5ng/ml) 
stimulated neutrophils in a final volume of 
50µ. Prior to the addition of [1251]./abelled 
fibrinogen, neutrophils were incubated 
(37'C, 15 minutes) in the presence or 
absence of MeO-Suc-(Ala)r?ro-Val-CH,P 
(1mM). At selected time points, samples 
were subjected to SOS-PAGE (non-reduced, 
~20"!6 polyacrylamide) and autoradio-
graphy. The left lane shows non-degraded 
fibrinogen. The left hand panel shows 
fibrinogen degradation products generated 
at 0.5, 1, 2.5 and 5 hr by PMA stimulated 
neutrophils. The right hand panel shows 
fibrinogen degradation products generated 
by PMA stimulated neutrophils in the 
presence of MeO-Suc-(Ala)rPro-Val-CH20 
at the corresponding time points. 
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2. Comparison of the fibrinogen degradation products 
generated by the conditioned medium to those generated 
by HNE 
SDS-PAGE and autoradiography 
The [1251]-labelled fibrinogen degradation products generated by the 
conditioned medium were compared to those generated by HNE. 
HNE, 5 µg/ml, generated fibrinogen degradation products at 20 hours 
with apparent molecular weight values distinctly different from those 
generated by the conditioned medium. However, when the 
concentration was reduced to 0.2µg/ml , HNE generated fibrinogen 
degradation products with very similar apparent molecular mass 
values to those produced by the neutrophil conditioned medium 







































Figure 4: Degradation of [1 25/J-labelled fibrinogen by the conditioned medium 
of PMA stimulated neutrophils compared to that by human neutrophil 
e/astase. [1251]-labelled fibrinogen (20µg) was incubated (37°C, 1-20 hours) with 
the conditioned medium from 106 PMA stimulated neutrophils in a final volume of 
100µ/. At selected time points the nature of the products generated was assessed 
by SOS-PAGE under both reducing and non-reducing conditions. (a) Non-reducing, 
5-20% polyacrylamide gel: The left hand lane contains non-degraded fibrinogen. 
The next panel shows the fibrinogen degradation products generated by the 
conditioned medium at 1,3,5,8 and 20 hours respectively. The next two panels 
show the fibrinogen degradation products generated by low dose (0. 2µglml) and 
high dose (5µglml) HNE at the corresponding time points. (b) Reducing, 10% 
polyacrylamide gel: The fibrinogen degradation products generated by the 
conditioned medium and HNE (as described above) were also analysed under 
reducing conditions. 
High performance liquid chromatography 
High performance liquid chromatography (h.p.l.c.) was used to 
compare the pattern of fibrinogen peptides generated by low dose 
HNE to that previously reported for the conditioned medium. As a 
baseline against which to compare HNE generated peptides, an 
aliquot of TCA soluble fibrinogen peptides generated by the 
neutrophil conditioned medium was obtained (with permission) from 
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Conditioned medium 
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Neutrophil elastase 
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Figure 5: H.p.l.c. separation of (10%) trichloroacetic acid soluble fibrnogen 
peptides. Unlabelled fibrinogen (2mglml) was incubated (37 'C, 9 hr) with 
conditioned medium from PMA stimulated neutrophils (10 x 106) or purified HNE 
(2µg!ml) in a final volume of 2ml. TCA soluble peptides obtained were separated 
using a C18 reverse phase column (flow rate 1ml/min) as described in the Methods 
section). This figure shows the h.p.l.c. profiles of fibrinogen peptides generated by 
the neutrophil conditioned medium (top) and by purified HNE (bottom) at 9 hours. 
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a stored batch used in a previous study.* (The ratio of HNE to 
fibrinogen (2µg:2mg) was the same as that which generated 
fibrinogen degradation products shown in the central panels of 
figures 4a and b). The peptide profile generated by HNE appeared 
markedly different to that which had been published previously,2 and 
bore a much closer resemblance to the peptide profile generated by 
the neutrophil conditioned medium, with the majority of the peptides 
having a retention time of between 25-40 minutes (see brackets, 
figure 5). The HNE in the previous study was from Sigma (specific 
activity 60 units/ml) unlike the HNE used this study which was from 
Calbiochem (specific activity 20 units/ml). Thus depending on the 
activity of the HNE, vastly differing peptide profiles could be 
obtained. 
3. The contribution of cathepsin G to the proteolytic activity 
of the conditioned medium. 
The persistence of fibrinogen degradation in the presence of the 
specific HNE inhibitor, MeO-Suc-(Ala)2-Pro-Val-CH2Cl (Figure 1), 
suggested the presence of a second protease in the conditioned 
medium. To determine whether this residual activity was due to 
another azurophil granule protease, cathepsin G, further inhibitor 
studies were performed. Two inhibitors of cathepsin G, namely the 
choromethyl ketone inhibitor, Z-Gly-Leu-Phe-CMK (O.lmM) and 
the reversible chymotrypsin inhibitor, chymostatin (O. lmM), were 
tested for their ability to inhibit the fibrinogen degrading activity of 
the conditioned medium. These inhibitors were used alone or in 
combination with the specific HNE inhibitor MeO-Suc-(Ala)2-Pro-
Val-CH2Cl (lmM). 
The two inhibitors of cathepsin G were found to have a marked 
inhibitory effect on the residual (MeO-Suc-(Ala)2-Pro-Val-CH2Cl 
resistant) fibrinogenolytic activity of the neutrophil conditioned 
medium. When used in combination, MeO-Suc-(Ala)2-Pro-Val-
CH2Cl and Z-Gly-Leu-Phe-CMK were found to inhibit the 
• This was obtained from stores of Sharon Kelly (Liver Research Centre, UCT, 
SA). These TCA soluble peptides had been generated during in an earlier study2 by 
digesting fibrinogen (1 Omg/ml) with the conditioned medium from 10 x 106 
neutrophils at 37°C for 9 hours . Aliquots of peptides were stored at -70°C. 
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fibrinogenolytic activity of the neutrophil conditioned medium by 
100 % at 2 hours, 95% at 4 hours, 93% at 7 hours and 86% at 20 
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Figure 6a: The effect the specific cathepsin G inhibitor (Z-Gly-Leu-Phe-CMK) 
on the [1251]-labelled fibrinogen degrading activity of the conditioned medium. 
[1251]-labelled fibrinogen (10µg) was incubated (37'C, 1-20 hours) with conditioned 
medium (from 106 PMA stimulated neutrophils) in a final volume of 100µ/. Reactions 
were performed in the presence and absence of Z-Gly-Leu-Phe-CMK (0.1mM), 
used alone or in combination with MeO-Suc-(Ala)rPro-Val-CH2CI (1mM). At 
selected time points, 10% (wlv) TCA soluble {/125]-labelled fibrinogen peptide 
formation was measured in each group as described earlier. The four groups are 
represented as follows: No inhibitor (-0-); Z-Gly-Leu-Phe-CMK alone (-D-); MeO-
Suc-(Ala)r Pro-Val-CH2CI alone (-0-); Z-Gly-Leu-Phe-CMK plus MeO-Suc-(Ala)r 
Pro-Val-CH2CI (-6.-) . Each data point represents a single measurement. 
Similarly, when chymostatin was used in combination with the 
specific HNE inhibitor, the fibrinogenolytic activity of the 
conditioned medium was reduced by 93%, 94% and 93% at 1 hour, 2 
hours and 3 hours respectively. At 5 hours there was 87% inhibition 
and by 20 hours it decreased to 83% (figure 6b). 
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Figure 6b. The effect of chymostatin on the [1 251]-labelled fibrinogen degrading 
activity of the conditioned medium. [1251]-fibrinogen (10µg) was incubated (37"C, 
0.5-5 hours) with conditioned medium (from 106 PMA stimulated neutrophils) in a 
final volume of 100µ/. Reactions were performed in the presence and absence of 
chymostatin (0.1mM), used alone or in combination with MeO-Suc-(Ala)rPro-Val-
CH2CI (1mM). At selected time points, 10% (wlv) TCA soluble {/125]-labelled 
fibrinogen peptide formation was measured in each group. The four groups are 
represented as follows: No inhibitor (-0-) ,chymostatin alone (-0-); MeO-Suc-(Ala)r 
Pro-Val-CH2CI alone (-() -);chymostatin plus MeO-Suc-(Ala)2-Pro-Val-CH2CI (-6-). 
Each data point represents a single measurement. 
Fibrinogen degradation products generated by the conditioned 
medium in the presence of Me0-Suc-(Ala)2-Pro-Val-CH2Cl were 
compared to those generated by cathepsin G. The pattern of 
fibrinogen degradation by the two proteases appeared almost 
identical (Figure 7a and 7b), with complete degradation of the Aa 
chain occurring before significant digestion of BJ3 or y-chains (Figure 
7b, next page). 
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Figure 7. Proteolysis of [1 251}-labelled fibrinogen by MeO-Suc-(Ala)z-Pro-Val-
CH2Cl-inhibited conditioned medium compared to that by cathepsin G. 
Conditioned medium (CM) from 106 PMA stimulated neutrophils, was incubated in 
the presence of MeO-Suc-(Ala):rPro-Val-CH2CI (1mM), with [
1251]-labelled fibrinogen 
(1 µg) for various durations of time. In parallel experiments, purified cathepsin G 
(0.025µg) was incubated [1 251]-labelled fibrinogen (1µg) . Samples were then 
subjected to SOS-PAGE and autoradiography. (a) Non-reducing gel, 5-20% 
polyacrylamide. The left lane shows non-degraded fibrinogen. In the left hand panel 
lanes 1-3 represent fibrinogen degradation products generated by the MeO-Suc-
(Ala)2-Pro-Val-CH2Cl-inhibited conditioned medium at 2.5, 5 and 24 hours 
respectively. In the right hand panel, lanes 1-3 represent the fibrinogen degradation 
products generated by cathepsin G at 1, 2.5 and 5 hours respectively. (b) The same 
products were also analysed under reducing conditions in a 10% polyacrylamide gel. 
4. Comparison of the fibrinogen degradation products 
generated by the conditioned medium to those generated 
by granule proteases. 
Data acquired thus far suggested that the proteolytic activity of the 
conditioned medium was due to a combination of the azurophil 
granule proteases HNE and cathepsin G. To further substantiate this 
suggestion, the [1251]-labelled fibrinogen degradation products 
generated by the conditioned medium were compared to those 
generated by preparations rich in azurophil granule proteases (see 
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Methods). When used at low concentrations, granule protease 
preparations generated fibrinogen degradation products with 
apparent molecular mass values which closely resembled those of 
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Figure 8: Degradation of K25/J-label/ed fibrinogen: Conditioned medium 
versus granule enzymes. r1 51]-label/ed fibrinogen (2.5µg) was incubated (37°C, 
10 minutes -20 hours) with either conditioned medium (from 106 neutrophils) or with 
granule enzymes (released from 105 neutrophils) in a final volume of 100µ/. At 
selected time points samples were subjected to SOS-PAGE (5-20%, non-reducing) 
and autoradiography. The fibrinogen degradation products generated by the 
conditioned medium (left hand panel) and by granule enzymes (right hand panel) 
are indicated above. The fibrinogen standard is in the extreme left hand lane. 
The h.p.l.c. profiles of fibrinogen peptides generated by diluted 
granule preparations appeared similar to those generated by the 
neutrophil conditioned medium, most peptides having retention times 
of between 25-40 minutes (Figure 9).This profile was very different 
to that published previously for fibrinogen peptides generated by 
granule enzymes. 
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Figure 9: H.p.l.c. separation of (10%) trichloroacetic acid soluble fibrinogen 
peptides. Unlabelled fibrinogen (2mglml) was incubated (37 'C, 9 hr) with 
conditioned medium (from 10 x 105 PMA stimulated neutrophils) * or granule 
enzymes (from 105neutrophils) in a final volume of 2ml. TCA soluble peptides 
obtained were separated using a C18 reverse phase column (flow rate 1ml/min) as 
described in the Methods section. This figure shows the h.p.l.c. profiles offibrinogen 
peptides generated by neutrophil conditioned medium (top) and granule enzymes 
(bottom) at 9 hours. (* see footnote page 137) 
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5. Identification of the apparent molecular mass of the 
membrane associated proteolytic activity 
To determine the molecular mass of the proteolytic activity 
associated with the conditioned medium, a highl(i sensitive protease 
detection technique, known as zymography, 1 was used (see 
Methods). Due to availability at the time, the proteolytic activity of 
neutrophil cytoskeleton preparations was analysed initially. 
Cytoskeleton HNE 














(a) Casein (1mg!ml) was copolymerised within a 3-13% polyacrylamide gel. The 
neutrophil cytoskeleton fraction (from 2.5-, 5- and 10 x 106 neutrophils) was loaded 
in wells 1-3 respectively. Purified HNE (0.5µg) was loaded in well 4. (Samples wero 
boiled in SOS sample buffer prior to electrophorosis). Following removal of SOS, 
gels were incubated at 37 'C overnight prior to staining with coomassie blue. 
(b) Fibrinogen (1mg!ml) was copolymerised as above. Neutrophil cytoskeleton 
prepared from 20 x 106 cells was subjected to zymography as described above. 
Casein, widely regarded as a universal substrate which is degraded 
by almost all proteases, 12 was used as the substrate in initial 
experiments (Figure 1 Oa). The caseinolytic activity of soluble 
cytoskeleton proteins was located in 30 kDa region of the gel and 
appeared to be comprised of three separate bands. Significantly no 
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proteolytic activity was detected in regions of the gel previously 
reported to contain the proteolytic activity of the 600 kDa protease. 
Purified HNE appeared to migrate to the same position as the 
proteolytic activity of the cytoskeleton preparation (Figure 10a, track 4). 
When cytoskeleton preparations were subjected to zymography in 
fibrinogen containing gels (Figure 1 Ob), the fibrinogen degrading 
activity migrated to a discrete band in the 50 kDa region of the gel 
(Figure 1 Ob). This most likely reflects altered mobility of proteolytic 
activity in fibrinogen- compared to casein-containing zymograms 
(see discussion). 
In these experiments, samples were boiled prior to electrophoresis, a 
step which is generally omitted due to the risk of irreversible 
denaturation and loss of catalytic activity. I I As it was possible that 
heat-sensitive proteolytic activity might have been lost as a result of 
the boiling step, experiments were repeated using unboiled samples. 
A band in the 69-97 kDa region of the gel appeared when unboiled 
cytoskeleton preparations were subjected to casein zymography 
(figure 11 , left hand panel, track 1). Interestingly, a band of identical 
electrophoretic mobility was observed in zymograms of unboiled 
HNE (figure 11, left panel, right track). The similar zymographic 
characteristics of cytoskeleton preparations and HNE suggested that 
HNE was the dominant protease in cytoskeleton preparations. The 
additional band which appeared in zymograms of non-boiled samples 
was most likely due to aggregate formation (rather than a distinct 
protease) as it was also present in preparations of purified HNE. 
The caseinolytic activity of both cytoskeleton preparations and HNE 
was completely abolished if samples were pre-incubated with MeO-
Suc-(Ala)2-Pro-Val- CH2Cl (lmM) prior to electrophoresis (figure 
11, right hand panel), further suggesting that the proteolytic activity 
of cytoskeleton preparations was due to HNE. 
The proteolytic activity associated with the neutrophil conditioned 
medium was subsequently tested in both fibrinogen- and CRP-
zymograms. Fibrinogen zymography revealed a zone of clearing 
corresponding to an apparent molecular mass of 30-60 kDa, and no 
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Figure 11: The effect of Me0-Suc-(Ala)2-Pro-Val-CH2C/ on the caseinolytic 
activity of the neutrophil cytoskeleton and HNE. The left hand panel shows 
casein gels (as in figure 10a) loaded with neutrophil cytoskeleton (Cyto) from 5 x 
106 neutrophils (non-boiled or boiled - lanes 1 and 2 respectively) or purified HNE 
(non-boiled). The right hand panel shows identical samples which had been pre-
incubated with MeO-Suc-(Ala)rPro-Val-CH2CI (37"C, 15 minutes) prior to 
electrophoresis. 
zones of clearing in the high molecular weight regions of the gel 
(Figure 12a). The same pattern was observed in 3 consecutive 
zymograms. In one ultraconcentrated preparation (in which a large 
amount of insoluble material was present) proteolysis extended 
beyond 69 kDa and a discrete zone of proteolysis was observed at the 
very top of the gel (Figure 12b). At lower concentrations this 
proteolytic zone was never observed, suggesting that it was most 
likely the result of aggregate formation which accompanies 
concentrating steps. CRP zymograms consistently revealed a zone of 
clearing confined to the 30 kDa region of the gel (Figure 12c). 
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Figure 12: Zymography of the conditioned medium. 
(a) Fibrinogen (O.OBmglml) was co-polymerised within a (3-13%) polyacrylamide 
gel. Neutrophil conditioned medium from 1.2 x 106, 6 x 1a5 and 3 x 105 PMA 
stimulated neutrophils was loaded in tracks 1, 2, and 3 respectively. Following the 
removal of SOS, gels were incubated for 36 hours at 37'C prior to staining with 
coomasie blue. 
(b) Fibrinogen (0.1 mg/ml) zymography (as above) of conditioned medium from 20 x 
106 PMA stimulated neutrophils, lyophilised and reconstituted in dH20 at 1/50 
original volume. 
(c) C-reactive protein (CRP) (0.1mglml) zymography of conditioned medium from 
1.2 x 106 PMA stimulated neutrophils. 
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Discussion 
This study sought to identify more carefully the nature of the 
proteolytic activity previously ascribed to a 600 kDa membrane 
associated protease. On the basis of its inhibitor profile, its 
fibrinogen degradation products, and its apparent molecular mass, 
this study suggests that the proteolytic activity of the neutrophil 
membrane is due to proteases of the azurophil granule. In the 
discussion which follows, data obtained during this study is reviewed 
in the context of earlier studies. Thereafter, the mechanisms by 
which these proteases become associated with the three neutrophil 
fractions are considered. 
The effect of the specific HNE inhibitor, MeO-Suc-(Ala)rPro-
Val- CH2CI 
Several observations made during attempts to purify the 600 kDa 
protease suggested that HNE might contaminate neutrophil fractions 
reported to contain this protease. The presence of HNE was initially 






14 The conditioned medium of 
PMA stimulated neutrophils was used as the source of this protease 
in this study for two reasons. Firstly, it is prepared more easily than 
the other two neutrophil fractions, and secondly, earlier studies in 
which the 600 kDa protease was characterised, used the conditioned 
medium as the principal source of this protease. 
The fibrinogen degrading activity of the conditioned medium as well 
as that of intact neutrophils was found to be very sensitive to Me0-
Suc-(Ala)z-Pro-Val-CH2Cl, particularly at earlier time points. There 
was a gradual decrease in its inhibitory effect on the fibrinogenolytic 
activity of the conditioned medium (and intact cells) over time. At 20 
hours, inhibition by MeO-Suc-(Ala)z-Pro-Val-CH2Cl of the 
fibrinogenolytic activity of the conditioned medium was close to the 
previously reported 50%.2 
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The conditioned medium has also been reported to be resistant to 
other two specific HNE inhibitors, Suc-(Ala)3-CH2Cl and Suc-
(Ala)i-Val-CH2Cl.2 However, subsequent investigation has revealed 
that the nitroanilide (NA) derivatives of the abovementioned peptides 
(i.e. Suc-(Ala)3-NA and Suc-(Ala)i-Val-NA) rather than the 
chloromethyl ketone derivatives were used. While peptide 
chloromethyl ketones are often used as irreversible inhibitors, 
peptide nitroanilides function as chromogenic substrates. The 
chloromethyl ketone group alkylates the active site histidine forming 
a tetrahedral adduct with the active site serine. This causes 
inactivation of the protease15 (Figure 13). 
Ser 
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IV I ~H---His 
I 
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~ I ; 
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Figure 13. Serine protease inactivation by peptide chloromethyl ketone 
inhibitors. The peptide chloromethyl ketone inhibitor (grey) binds to the serine 
protease substrate binding site (S1) via a targeting peptide sequence (P). This is 
followed by the alkylation of the active site histidine to form a tetrahedral adduct 
with the active site serine. This results in irreversible inactivation of the protease. 
(Adapted from Reference 15) 
The chloromethyl ketone group therefore plays a central role in the 
inhibitory activity of these peptide inhibitors. Nitroanilide 
derivatives, on the other hand, do not alter the active site, and at 
most, may competitively inhibit protease activity. However, as their 
efficacy as HNE inhibitors had not established prior to their use on 
the conditioned medium, their reported lack of inhibitory activity 
with respect to the conditioned medium is impossible to interpret. 
Whilst a review of recent studies indicates that Me0-Suc-(Ala)2-Pro-
Val-CH2Cl is the most widely used inhibitor of HNE,6•7•13-15 no 
reports regarding the use of the two abovementioned NA-peptide 
substrates as inhibitors of HNE have been found. 
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It was thus clear that inhibitor profiles could no longer reliably 
exclude the presence of HNE in the conditioned medium. 
Comparison of the fibrinogen degradation products generated 
by conditioned medium and HNE 
Although it had been reported that the neutrophil conditioned 
medium generated fibrinogen degradation products with distinctly 
different apparent molecular mass values from those produced by 
HNE,2 data obtained during inhibitor studies suggested that this 
should be re-investigated. A comparison of the proteolytic activity of 
HNE and conditioned medium was therefore made over a wide range 
of HNE concentrations. Consistent with earlier reports,2 it was found 
that when used at relatively high concentrations, the fibrinogen 
degradation products generated by HNE appeared distinctly different 
to those generated by the conditioned medium. However, if used at 
sufficiently low concentrations, HNE generated fibrinogen 
degradation products which appeared very similar to those produced 
by the conditioned medium of PMA stimulated neutrophils. 
When HNE was used at 0.04 units/2mg fibrinogen (as opposed to 
0.12 units/2mg fibrinogen used in previous studies),2 peptide profiles 
bore a much closer resemblance to those generated by the 
conditioned medium, and were vastly different to those previously 
reported for HNE. 2 This previous study had shown that the peptides 
generated by the conditioned medium of PMA stimulated neutrophils 
still possessed HNE sensitive sites. 2 Thus the process and extent of 
fibrinogenolysis by HNE appears to be dependent on protease 
concentration. 
These findings suggest that the previously reported differences in the 
pattern of fibrin( ogen) degradation between the conditioned medium 
and HNE, most likely represented concentration effects rather than 
differences in proteolytic activity. Taken together with the inhibition 
data, this strongly suggests the presence of HNE in the conditioned 
medium of PMA stimulated neutrophils. 
The fibrinogen peptide profiles generated by HNE and conditioned 
medium were not identical, however, and differences were more than 
likely due to the presence of one or more additional proteases in the 
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conditioned medium. Two other factors suggested that the 
conditioned medium contained additional proteases besides HNE. 
Firstly, as the release of HNE is not selective, but accompanied by 
the release of other azurophil granule proteases, its presence in the 
conditioned medium would imply the presence of other azurophil 
granule proteases as well. Secondly, consistent with previous 
reports,2 the present study found the conditioned medium to possess 
residual fibrinogen degrading activity which persisted in the presence 
of the specific HNE inhibitor, MeO-Suc-(Ala)2-Pro-Val-CH2Cl. 
The contribution of cathepsin G to the proteolytic activity of 
the conditioned medium. 
It was postulated that the "MeO-Suc-(Ala)2-Pro-Val-CH2Cl 
resistant" proteolytic activity of the conditioned medium was largely 
attributable to a second major azurophil granule serine protease, 
cathepsin G. Inhibitor studies revealed that this residual activity was 
sensitive to two inhibitors of cathepsin G, namely the specific 
chloromethyl ketone cathepsin G inhibitor, Z-Gly-Leu-Phe-CMK, as 
well as the chymotrypsin inhibitor, chymostatin. When Z-Gly-Leu-
Phe-CMK was used in combination with MeO-Suc-(Ala)2-Pro-Val-
CH2Cl, the fibrinogenolytic activity of the neutrophil conditioned 
medium was inhibited by nearly 100% up to 3 hours. Chymostatin, in 
combination with MeO-Suc-(Ala)2-Pro-Val-CH2Cl, inhibited the 
fibrinogen degrading activity by over 90% over the corresponding 
time period. At later time points there was a gradual decrease in the 
levels of inhibition until, at 20 hours, inhibition levels were 86% and 
83% for Z-Gly-Leu-Phe-CMK and chymostatin (used in combination 
with MeO-Suc-(Ala)2-Pro-Val-CH2Cl) respectively. Analysis of the 
fibrinogen degradation products generated by the conditioned 
medium in the presence of MeO-Suc-(Ala)2-Pro-Val-CH2Cl, 
revealed them to be very similar to those produced by purified 
cathepsin G. Together this data suggested that cathepsin G was 
responsible for the bulk of the "non-HNE" proteolytic activity of the 
conditioned medium. 
Whilst previous studies had reported the fibrinogen degrading 
activity of the conditioned medium to be resistant to a specific 
chloromethyl ketone inhibitor of cathepsin G,2 further investigation 
··, e• 
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revealed that, once again, a nitroanilide rather than chloromethyl 
ketone derivative of this peptide substrate had been used. 
A small amount of fibrinogen degrading activity (mainly evident at 
later time points) was noted to persist in the presence of HNE and 
cathepsin G inhibitors. It is likely that this residual fibrinogen 
degrading activity was due the third serine protease of the azurophil 
granule, proteinase 3 (PR3). Like HNE and cathepsin G, this protease 
has also been shown to be associated with the neutrophil 
membrane. 16 Whilst the involvement of PR3 was not investigated in 
this study, previous reports that the proteolytic activity of the 
conditioned medium is completely abolished by the serine protease 
inhibitor PMSF, suggests that this residual activity is due to a serine 
protease.2 Furthermore, the presence of HNE and cathepsin G in the 
conditioned medium implies the presence of other azurophil granule 
constituents which would include PR3. 
It is interesting to note that a 21 amino acid peptide, cleaved from the 
N-terminus of the Aa chain of fibrinogen, has previously been 
identified in the peptide mixture generated by the conditioned 
medium of PMA stimulated neutrophils in the presence of Me0-Suc-
(Ala)2-Pro-Val-CH2Cl. 2 This peptide was once considered to be 
produced exclusively by HNE and its presence in plasma had been 
used as an indicator of a1-antitrypsin· deficiency. 17·18 From this study 
it appears that cathepsin G (and/or perhaps PR3) may also generate 
this peptide and account for the of MeO-Suc-(Ala)2-Pro-Val-CH2Cl-
insensitive pathway for producing this peptide noted previously.2 
Comparison of the fibrinogen degradation products generated by 
conditioned medium and granule proteases. 
Data accumulated thus far suggested that the proteolytic activity of 
the neutrophil conditioned medium was due to azurophil granule 
proteases. Although it had been reported that neutrophil granule 
proteases•• generated fibrinogen-, fibrin- and CRP-degradation 
products with distinctly different apparent molecular mass values to 
• a 1-antitrypsin (a1-antiproteinase) is a naturally occurring inhibitor ofHNE . 
.. Referred to as lysosomal enzymes in previous studies. 1•3 
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those generated by the neutrophil conditioned medium, 1-3 it appeared 
that this might have been due to discrepancies in protease 
concentrations. Granule enzyme preparations had been obtained by 
stimulating neutrophils with the chemotactic peptide FMLP in the 
presence of cytochalasin B, a process known to induce very high 
levels of de granulation by neutrophils. 8 In contrast, neutrophils 
stimulated with low dose PMA have been reported to release 
insignificant amounts of granule enzyme into the conditioned 
medium. 1,19,20 Thus, in order to. compare the proteolytic activity of 
these two preparations, it is essential that serial dilutions of granule 
enzyme preparations are used. Indeed, the present study found that 
when sufficiently diluted, granule enzymes generated fibrinogen 
degradation products with apparent molecular mass values identical 
to those generated by the conditioned medium. 
Investigation of the apparent molecular mass of the membrane 
associated proteolytic activity 
Although it appeared that the proteolytic activity of the conditioned 
medium was due to proteases of the azurophil granule (Mr ±25-30 
kDa), previous studies had identified this membrane associated 
proteolytic activity in regions of the gel corresponding to molecular 
mass values of 501, 396, 316 and 200 kDa. 1- In these studies the 
molecular size of this proteolytic activity was determined by eluting 
the enzyme activity from gel slices after separating concentrated 
enzyme preparations by SDS-PAGE.1-3 In contrast, the present study 
employed zymography to determine the molecular weight of the 
membrane associated proteolytic activity. Due to the sensitivity of 
this technique, concentrating steps were not required prior to 
electrophoresis as in earlier studies. 
Using casein as a substrate, zymography provided strong evidence 
that HNE was associated with the neutrophil cytoskeleton fraction. 
Not only did the proteolytic activity of the cytoskeleton preparation 
migrate to identical positions to that of purified HNE, but these 
bands were abolished following pre-incubation with Me0-Suc-
(Ala)2-Pro-Val-CH2Cl. When samples were not boiled prior to 
electrophoresis, the proteolytic activities of both purified HNE and 
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cytoskeleton preparations were detected as a broad band in the 30 
kDa area of the gel and a narrow band in the 69-97 kDa region. The 
latter probably represents a trimeric aggregate of HNE. It is 
interesting to note that AEBSF affinity chromatography (see chapter 
4) isolated proteolytic activity from cytoskelefon preparations with 
electrophoretic mobility which appeared identical to that seen on 
zymograms of these unboiled preparations - compare figure 11 (page 
145) to figure , lane 1, ( chapter 4, page 119). It thus appears that 
AEBSF-affinity chromatography may well have been successful in 
isolating granule proteases from cytoskeleton preparations. 
With respect to the proteolytic activity of the conditioned medium, 
fibrinogen zymography revealed proteolysis to be confined to the 30-
60 kDa region of the gel. As the concentration of the sample was 
increased, activity extended higher up the gel, but never beyond 90 
kDa. With the exception of one ultraconcentrated preparation (see 
later) there were no areas of activity in the regions of the gel 
previously reported to contain the subunits of the 600 kDa protease. 
In CRP zymograms, proteolytic activity was confined to the 30 kDa 
region of the gel. The zone of proteolysis between 30-60 kDa seen in 
fibrinogen zymograms is not incompatible with azurophil granule 
proteases. The reduced electrophoretic mobility of these proteases 
may have been attributed to two factors. 
Firstly, in order to preserve proteolytic activity, samples are not 
boiled prior to zymography. Whilst enabling proteases to retain their 
catalytic activity, this does however, result in a tendency for proteins 
to aggregate. I I Indeed, it has been noted that in most commercial 
enzyme preparations, proteolytic activity is associated with more 
than one band, and it has been suggested that this is most likely due 
to presence of catalytically active aggregates of enzymes, the 
catalytically active autodigestion products of these enzymes, or to the 
presence of other contaminating proteases.2I,22 
The tendency to form aggregates was, in fact, observed when the 
neutrophil cytoskeleton fraction, as well as commercially obtained 
HNE, were analysed in casein zymograms. In samples which had 
been boiled, the proteolytic activity was noted to be confined to the 
25-30 kDa region of the gel. However, when the same samples did 
not undergo a boiling step prior to electrophoresis, a portion of the 
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proteolytic activity was present in the 69-97 kDa region, suggesting 
the formation of trimeric aggregates. This tendency to form 
aggregates, in the absence of boiling, may explain the extension of 
proteolytic activity observed beyond the 30 kDa area in fibrinogen 
containing zymograms. However, this would not explain the 
confinement of proteolytic activity to the 30 kDa area in CRP 
zymograms. 
A second possible explanation is that the inclusion of protein 
substrates within gels affects the migration of proteases within the 
polyacrylamide gel. This would, however, be expected to affect the 
migration of protein standards as well. 11 It is possible, however, that 
affinity reactions between the protease. and the co-polymerised 
substrate may decrease the electrophoretic mobility of certain 
proteases. Indeed it was noted that whilst the proteolytic activity of 
the cytoskeleton fraction migrated to the 25-30 kDa region of the gel 
in casein zymograms, the proteolytic activity of the same preparation 
migrated as a band corresponding to approximately 50 kDa in 
fibrinogen zymograms. Two factors suggest that the 50 kDa band in 
fibrinogen zymograms represented the same proteolytic activity as 
that associated with the 25-30 kDa band in casein zymograms. 
Firstly, casein is widely acknowledged as a universal substrate, 12 and 
is readily degraded by almost all proteases. Therefore, if the band in 
the 50 kDa area of the fibrinogen zymogram had represented a 
distinct protease, it would have been observed in a similar region in 
,casein zymograms. Secondly, there was strong evidence to suggest 
that the band in the 25-30 kDa region of casein zymograms of 
cytoskeleton preparations was HNE (see above). As HNE is known 
to degrade fibrinogen, it should be detected in fibrinogen zymograms 
as well. Therefore the absence of such a band in the 25-30 kDa area 
in fibrinogen zymograms, in the face of a solitary band in the 50 kDa 
region, suggested that the latter most likely represented HNE. 
Therefore, reduced migration of azurophil granule proteases in 
fibrinogen containing gels may offer the more likely explanation for 
the extension of the proteolytic activity beyond the 30 kDa area. 
These findings confirm that the proteolytic activity of the 
conditioned medium and cytoskeleton preparations is associated with 
proteases of low molecular weight. The previously reported 
f ~· ). • 
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association of proteolytic activity with high molecular weight regions 
of the gel, 1-3 is most likely attributable to aggregates of granule 
proteases, which have a tendency to form during preparative 
procedures, in particular following· lyophilisation. It was indeed 
noted during the present study, that in an ultraconcentrated 
preparation containing a large amount of insoluble material, 
proteolytic activity extended into the high molecular weight regions 
of the gel, and a discrete area of proteolysis was noted at the very top 
of the gel. In samples that did not undergo these concentrating steps, 
however, this proteolytic zone was never observed. 
In summary, on the basis of inhibitor profiles, substrate degradation 
patterns and molecular weight, this series of experiments provided 
strong evidence to suggest that the proteolytic activity previously 
ascribed to a novel 600 kDa protease was in fact due to proteases of 
the azurophil granule, predominantly HNE and cathepsin G. 
The origin of granule proteases in the three neutrophil fractions 
Recent studies suggest several mechanisms whereby neutrophil 
membrane, cytoskeleton and conditioned medium fractions may 
come to be inhabited by azurophil granule proteases. The origins of 
these proteases in each neutrophil fraction are considered in tum 
below. 
1. Conditioned medium 
As azurophil granules represent the least mobilisable subset of the 
neutrophil granules, their constituents have traditionally been 
considered to play less of a role extracellularly than those of other 
granule subsets.23'24 More recently, however, neutrophils have been 
shown to express · azurophil granule proteases on their external 
membranes in response to a variety of stimuli (including PMA used 
at a concentration as low as 0.4ng/ml 13).4-7' 13 This implies the release 
of azurophil granules. It appears that neutrophils can release 
azurophil granule proteases even in the absence of exogenous 
stimuli. This is suggested by the recent observation that neutrophils, 
maintained at 37°C in fibronectin coated wells, periodically release 
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individual azurophil granules with accompanying bursts of 
proteolytic activity.25 It is well known that neutrophil isolation 
procedures can cause a degree of neutrophil activation,26,27 and this 
may contribute to azurophil granule release during subsequent 
incubation at 3 7°C. As the azurophil granule proteases are stored at 
high concentrations,25'26 a relatively minor release of these granules 
can be associated with a significant increase in proteolytic activity.25 
Recent studies therefore suggest that the conditioned medium of 
PMA (5-lOng/ml) stimulated neutrophils would be expected to 
contain azurophil granule proteases. 
2. Neutrophil membrane 
As mentioned above, several studies have demonstrated the 
expression of both HNE and cathepsin G on the neutrophil 
membrane. 
Whilst earlier studies appeared to exclude the presence of azurophil 
granule proteases in isolated neutrophil membrane fractions by 
testing for the presence of azurophil granule markers such as 
myeloperoxidase and p-glucuronidase, 19'20 recent evidence suggests 
that this may not be a reliable approach. Both HNE and cathepsin G 
are highly cationic proteins which bind readily to the neutrophil 
membrane by a charge related mechanism.4'6'28 This propensity for 
charge related interactions is not necessarily shared by the commonly 
employed azurophil granule markers. For instance, it has been shown 
that the neutrophil plasma membrane has a very high capacity. to bind 
HNE and cathepsin G in comparison to the azurophil granule marker 
myeloperoxidase. 4 It is possible that during membrane isolation 
procedures (which involve neutrophil lysis as an initial step), 
liberated HNE and cathepsin G may bind to solubilised neutrophil 
membranes, whilst the frequently used azurophil granule markers 
exhibit minimal binding. In this way neutrophil membrane 
preparations reported to be free of granule markers, may in fact 
contain azurophil granule proteases. 
Recent reports indicate that following subcellular fractionation, 
neutrophil membranes contain a significant proportion of total 
cellular content of HNE. 13 Membranes isolated from unstimulated 
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neutrophils have been reported to contain 14% of the total neutrophil 
HNE activity, and 20% in neutrophils incubated for 5 minutes at 
37°C prior to subcellular fractionation. 13 
3. Neutrophil cytoskeleton 
As with neutrophil membranes, the cytoskeleton fraction is prepared 
from neutrophil lysates.29 Following solubilisation of neutrophils 
with triton-X-100, it is possible that azurophil granule proteases may 
become associated with the triton-insoluble cytoskeleton via ionic 
interactions. It is worth noting that the solution which is subsequently 
used to elute proteins from the insoluble cytoskeleton is of the same 
ionic strength (IM KCl) as that which has previously been reported 
to elute HNE from neutrophil membranes.6 This may explain the 
presence of azurophil granule proteases in preparations of solubilised 
cytoskeleton proteins. 
Azurophil granule protease aggregation 
The cationic serine proteases of the azurophil granule have a 
tendency to form heteroaggregates with anionic serine/glycine 
proteoglycans.28 It has been suggested that such aggregation may 
play an important role in the packaging of neutrophil granules. 
Alterations in protein concentration, ionic strength and pH may all 
trigger aggregation of these proteases. 28 Whilst complexes of 
aggregated proteins usually dissociate following granule release,25 
serine proteases, still complexed to proteoglycans, have been 
reported to be exocytosed from rat mast cells. 30 
The tendency for azurophil granule proteases to form 
heteroaggregates with proteoglycans might explain their detection as 
high molecular weight proteolytic activity in earlier studies.1•3 
Finally, the formation of heteroaggregates with proteoglycans would 
explain the failure of this proteolytic activity to stain with coomassie 
blue, as proteoglycans are resistant to such staining. 
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Summary and conclusions 
' 
This study provides strong evidence to suggest that the proteolytic 
activity previously ascribed to a novel 600 kDa membrane associated 
protease is, in fact, due to the concerted effort azurophil granule 
proteases, predominantly HNE and cathepsin G. Thus the important 
observations in previous studies that the neutrophil membrane can 
degrade fibrinogen, fibrin and CRP with numerous consequences 
both for inflammation and coagulation can now be linked to these 
proteases. This is particularly interesting in view of the recent studies 
indicating that membrane bound azurophil granule proteases, through 
their abilility to evade naturally occurring protease inhibitors, may 
represent the biologically relevant forms of these proteases.4"7 
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Chapter Six 
The localisation of neutrophil 
associated fibrinogen products 
A reported con~equence of neutrophil mediated fibrinogenolysis is 
the association of low molecular weight fibrinogen degradation 
products (FDP) with the neutrophil (figure 1).2 These neutrophil 
associated products, which are all less than 30 kDa in size, have been 
shown to inhibit neutrophil adherence to immobilised fibrinogen.2 
The partial inhibition of [1 25I]-labelled PDP binding to neutrophils by 
antibodies directed against various P2-integrin receptors, led to the 
suggestion that these products, could inhibit P2-integrin dependent 
functions, and may thus modulate neutrophil responses at sites of 
inflammation.2 (For a review of Pi-integrin receptors see chapter 2, 
pages 38-41). 
Fibrinogen Degradation products 
G-+-0 e :.=.~ 






Figure 1. Fibrinogen 
proteolysis by a neutrophi/ 
membrane protease was 
reporled to generate low 
molecular weight FOP 
which associate specifically 
with neutrophit f]z-integrin 
receptors, thereby blocking 
neutrophil adhesion to 
immobilised fibrinogen. It 
was suggested that these 
products might modulate 
other hintegrin dependent 
functions as well. 2 
The present study aimed to confirm the relationship between FDP 
and Pi-integrin receptors, using immunoelectron microscopy to co-
localise these molecules on the neutrophil surface. 
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Methods 
Chemicals and Reagents 
The sources of chemicals and reagents used in this study are listed in 
Appendix 1, page 225-226. 
Neutrophil isolation and preparation and iodination of 
fibrinogen. 
These procedures were performed as described previously (see 
chapter 4, Methods, page 107-108). Purified ,neutrophils were 
resuspended in either phosphate buffered saline (PBS) or Hanks 
balanced salt solution (HBSS), and kept on ice until the beginning of 
experimental procedures. 
Biotinylation of fibrinogen and BSA 
Fibrinogen (6mg/ml). in 0.lM sodium bicarbonate buffer (O.lM 
NaHC03, O. lM NaCl, pH=8.2) was added to biotinamidocaproic 
acid-3-sulpho-N-hydroxysuccinaminde (NHS) ester* (1.92mg) in a 
volume of 3ml. This represents a molar ratio of biotin to fibrinogen 
of approximately 65: 1. The mixture was allowed to rotate end-on-end 
at room temperature for 60 minutes after which it was dialysed at 
4 °C against PBS (3 x 1 litre) over 16 hours. The biotinylated 
fibrinogen was divided into aliquots and stored at -70°C until use. 
Biotinylated BSA was prepared in a similar manner. Biotinylation of 
these proteins was confirmed by dot blotting using the biotin · 
streptavadin detection system. 
* 
Biotinamidocaproic acid-3-sulpho-N-hydroxysuccinaminde (NHS) ester is a water 
soluble NHS ester of biotin which has a 7 carbon atom spacer arm. 
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Neutrophil experiments for immunoelectron microscopy 
Neutrophil ~2-integrin expression 
Neutrophils (2 x 106/ml} in PBS were warmed to 37°C for 10 
minutes, after which they were stimulated with fMLP (lµM) for a 
further 15 minutes. Neutrophils were then centrifuged (2000rpm, 5 
minutes, 4°C) and following a washing step at 4°C in PBS containing 
0.5% BSA (PBS/A), cells were immunostained with monoclonal 
antibodies directed against CDllb, diluted 1:5 in PBS/A for 1 hour 
on ice. Control samples were stained with non-immune mouse IgG 
used at the same concentration. Neutrophils were then washed 3 
times with PBS/A and fixed with a combination of 3.5% 
paraformaldehyde and 0.2% glutaraldehyde in O.lM phosphate buffer 
(pH=7.4) for 1 hour at 4°C in preparation for ultracryotomy (see 
below). 
Neutrophil association with FDP 
Neutrophils (2 x 106/ml) in PBS (or HBSS) were warmed to 37°C for 
10 minutes, and then stimulated with PMA (5ng/ml). Immediately 
following the addition of PMA, biotinylated or unlabelled fibrinogen 
(1-2.5 mg/ml) was added to the neutrophils and the incubation was 
continued for various time intervals (5-60 minutes, 37°C). (During 
this incubation fibrinogen is degraded by the neutrophil generating a 
variety of high and low molecular weight FDP).2 At selected time 
points neutrophils were centrifuged (2000rpm, 5 minutes, 4 °C), 
washed 3 times with ice cold PBS/A, and fixed (as above) in 
preparation for ultracryotomy. . 
In some experiments neutrophils were immunostained prior to fixing: 
Following incubation with fibrinogen neutrophils were washed (as 
above) and then incubated with rabbit anti-human fibrinogen 
antibody (0.5 mg/ml) in PBS/A for 1 hour on ice. Cells were then 
washed 3 times and fixed as above. Controls were included which 
had been exposed to the same concentration of non-immune rabbit 
IgG. Staining with the secondary antibody was performed following 
ultracryotomy. 
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Neutrophil association with FOP and biotinylated BSA 
Neutrophils (2 x 106/ml) were stimulated with PMA as described 
above prior to the addition of biotinylated BSA (lmg/ml) and 
fibrinogen (lmg/ml). Neutrophils were then incubated at 37°C for 
various time intervals (5-60 minutes), after which they were 
centrifuged, washed and fixed as above in preparation for 
ultracryotomy. 
Ultracryotomy and immunostaining 
Following fixation, cells were washed once with PBS, embedded in 
2% low melting point agarose, infiltrated with 2.3 M sucrose and 
cryosectioned at -100 to -110°C.3 Ultrathin sections were retrieved 
with a droplet of 2.3 M sucrose suspended on a wire loop, and 
transferred to formvar coated nickel grids. Each grid was floated on 
PBS for at least ten minutes to allow for the diffusion of sucrose. 
Grids were then transferred to a droplet of 2% (w/v) gelatin for 10 
minutes, after which they were placed on droplets of 0.02M glycine 
(3 x 1 minute incubations). Each grid was transferred to a droplet of 
1 % BSA in PBS for 1 minute, prior to immunostaining at room 
* temperature. 
Detection of ~2-integrins 
As neutrophils had been immunostained with primary antibody 
( against CD 11 b and CD 18) prior to sectioning, post sectioning 
staining involved only the use of a secondary antibody. Sections were 
stained with 30nm-gold conjugated goat-antimouse IgG, diluted 1 :20 
in PBS containing 1% BSA (1% PBS/A), overnight in a humidified 
chamber.t 
• All procedures described below represent those which provided the optimal 
results for each particular approach. A number of conditions were varied during 
optimisation procedures, including fixation, antibody concentrations, duration of 
immunostaining and the composition of the incubation buffer. 
t Whilst this procedure was established for the detection of CD1 lb/CD18, the 
intention was to apply this procedure to the detection of CD 11 a/CD 18 and 
CDl lc/CD18 as well. However, for reasons discussed later (see results), this was 
not ultimately required. 
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Detection of biotinylated FOP 
For the detection of biotinylated FDP, three detection systems were 
tried. These are listed below: (All incubations were performed· at 
room temperature) 
• Streptavadin gold. Sections were stained with · 1 Onm-gold 
conjugated streptavadin (diluted 1:20 in PBS/A) overnight in a 
humidified chamber. 
• Streptavadin biotin bridge gold technique. Grids were 
floated on blocking buffer (1 % BSA, 0.01 % Tween 20, 0.5M 
NaCl in PBS) for 30 minutes prior to staining with streptavadin 
for 30 minutes. Following washing (10 x 2 minute washes on 
blocking buffer), sections were incubated with biotinylated BSA 
conjugated to 10nm colloidal gold (bBSA-gold) diluted 1 :50 for 
30 minutes. 
• Antibiotin antibody. Sections were stained with 15nm-gold 
conjugated goat antibiotin antibody (diluted 1:20 in 1% PBS/A) 
overnight in a humidified chamber. 
Detection of unlabelled FOP 
Sections were stained with rabbit anti-human fibrinogen antibody or 
non-immune rabbit IgG (2µg/ml) in 1 % PBS/A overnight and then 
washed (10 x 2 minute washes on 1 % PBS/ A), before staining with 
5nm-gold conjugated goat antirabbit IgG for 1 hour in the same 
buffer. 
Detection of biotinylated BSA 
Sections were stained with goat antibiotin antibody conjugated to 
15nm gold diluted 1 :20 in 1 % PBS/ A overnight in a humidified· 
chamber. 
Following immunostaining, sections were washed with 5 drops 1 % 
PBS/BSA over a period of 10 minutes, after which they were washed 
with 5 drops of PBS over the same period. Sections were then post-
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fixed on a drop of 1 % glutaraldehyde in PBS for 5 minutes, after 
which they were washed with PBS (2 drops, 5 minutes each), 
followed by distilled water (5 drops, 2 minutes each). Sections were 
then stained for 10 minutes with neutral uranyl acetate (2%) and 
washed briefly with distilled water (2 drops, 20 seconds each), prior 
to staining with acidic uranyl acetate (2%) in methylcellulose (1.8%) 
(2 drops, 5 minutes each). Grids were retrieved with a wire loop and 
air dried prior to viewing under the electron microscope. 
Association of ( 251]-labelled fibrinogen and BSA with neutrophils 
Neutrophils (5 x 106/ml) were warmed to 37°C for 10 minutes prior 
to stimulation with PMA (5ng/ml). Immediately following 
stimulation, [125I]-labelled fibrinogen or [125I]-labelled BSA were 
added at various concentrations and for various durations of time as 
indicated in the results section. At selected time points, cells were 
placed on ice and washed three times with 0.5% PBS/A at 4°C. 
Neutrophils were then transferred to clean tubes and the associated 
radioactivity was measured in a gamma counter. These experiments 
were performed using PBS, HBSS and HEPES buffered HBSS as 
incubation buffers. When necessary, adaptations were made to the 
basic experimental procedure and these are listed below. 
Release of internalised [1251]-labelled fibrinogen 
To determine whether [125I]-labelled fibrinogen internalised by the 
neutrophil was subsequently released, PMA (Sng/ml) stimulated 
neutrophils were incubated with [125I]-labelled fibrinogen for 10 
minutes at 37°C, and following washing steps (as above), cells were 
resuspended in HBSS containing PMA (5ng/ml), and incubated at 
3 7°C for various periods of time. The radioactivity released into the 
supernatant was measured and expressed as a percentage of total 
neutrophil associated fibrinogen (measured following washing steps). 
Viability, as determined by trypan blue exclusion, was greater than 
90% at the end of the experiment. The supernatants were lyophilised, 
reconstituted in SDS sample buffer, and subjected to SDS-
polyacrylamide gel electrophoresis and autoradiography. 
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• I 
Association of [1251]-labelled ligand at 4°C. 
Neutrophils were stimulated with PMA at 37°C for 30 minutes· (as 
above), placed on ice for a further 30 minutes, after which they were 
incubated in the presence of [125I]-labelled fibrinogen or BSA, on ice, 
for various periods of time (see results). Identical experiments were 
also performed using [125I]-labelled fibrinogen degradation products 
(see below). For these experiments, BSA in the washing buffer was 
replaced with an equal concentration of casein.•• 
Effect of BSA on [1 251]-labelled fibrinogen association 
In experiments where the effect of BSA on [125I]-labelled fibrinogen 
association with the neutrophil was investigated, neutrophils were 
pre-incubated in the presence of BSA (2mg/ml) for 10 minutes prior 
to the addition of [125I]-labelled fibrinogen. Control samples received 
an equal volume of assay buffer. Experiments were allowed to 
proceed as described above. 
Generation of [1251]-labelled fibrinogen degradation products 
PMA stimulated neutrophil conditioned medium was prepared as 
described earlier (Chapter 3, Methods, page 108). [125I]-labelled 
fibrinogen (2mg) was incubated with conditioned medium (from 15 x 
106 neutrophils) in a final volume of 2ml for 24 hours at 37°C. The 
percentage TCA solubility of [125I]-labelled fibrinogen degradation 
products prepared in this way exceeded 50%. 
·Neutrophils were stimulated at 37°C to allow the membrane phenotype of the 
neutrophil to change in response to PMA. Neutrophils were subsequently cooled in 
order to inhibit the endocytic apparatus of the neutrophil prior to exposure to 
radiolabelled ligand . 
•• As these studies were testing for surface binding of fibrinogen and BSA, the 
washing buffer could not contain BSA as it would compete with [1251]-Jabelled BSA 
during washing steps, potentially removing surface associated [1251]-labelled BSA. 
As a result BSA in the washing buffer was replaced with casein used at the same 
concentration. 
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Results 
lmmunoelectron microscopy 
Expression of lh-integrins 
In order to detect lh-integrin receptors, two adaptations to standard 
resin embedding procedures were made. It is well known that certain 
antigens, particularly those associated with the cell membrane, are 
inaccessible to antibodies when embedded in resin,4 and this proved 
to be the· case for P2-integrins (Figure 2a). Thus, the ultracryotomy 
approach of Tokayasu, which involves the cutting of thin sections 
from samples hardened by freezing rather than resin embedding, was 
implemented.3 Despite the use of this technique, P2-integrin receptors 
were still not detectable on the neutrophil surface. As the sensitivity 
of certain antigens to aldehyde fixation is well documented,• 
immunostaining with the primary antibody prior to aldehyde fixation 
and cryosectioning was attempted (see Methods). 5 
Using this procedure, membranes of activated neutrophils stained 
positively for the CDllb component of the P2-integrin receptor, 
CD11b/CD18 (figure 2b). The specificity of this procedure was 
confirmed by the absence of labelling when primary antibodies were 
substituted with non-immune control antibodies (figure 2c). In 
contrast to stimulated cells, unstimulated cells showed sparse 
labelling of their plasma membranes. A similar pattern of staining 
was obtained using antibodies directed against the CD 18 subunit of 
this receptor (not shown). 
Cell associated fibrinogen degradation product (FDP) 
Irrespective of the detection system used, FDP were not detected on 
the surface of either resting or PMA stimulated neutrophils incubated 
• This is particularly apparent when monoclonal antibodies are used. 
2a 
lµm 
(a) A resin section of an FMLP stimulated* 
neutrophil. Resin embedding is generally 
associated with superior ultrastructural 
preservation of cells compared to cryo-
sectioning. This micrograph shows the 
basic structure of the neutrophil with its 
multilobed nucleus (Nu) and its cytoplasm 
densely packed with granules (G) . lmmuno-
staining forCD11b!CD18 was unsucessful 
in resin embedded neutrophils. 
(b) A cryosection of an FMLP stimulated* 
neutrophil immunostained for CD11b!CD18. 
Neutrophils underwent pre-fixation staining 
with anti-CD 11 b monoclonal antibody. This 
antibody was detected on cryosections 
using 30nm-gold conjugated goat anti-
mouse lgG (see Methods). Numerous gold 
particles can be seen lining the surface 
of this neutrophil indicating the presence 
of C011b/C018 receptors. 
(c) To confirm the specificity of the immuno-
labelling procedure (above) for CD11b, a 
control was included in which anti-CD11b 
antibody was substituted with non-immune 
. mouse lgG (see Methods). No gold particles 




Figure 3. The immunoloca/isation offibrinogen products within intracellular vesicles 
of PMA stimulated neutrophi/s. (a) A cryosection of a PMA (5ng!ml) stimulated neutrophil 
(30 minutes, 37 degrees C) showing multiple vesicles (Ve) in the cytoplasm. (b) An intra-
cellular vesicle of a PMA stimulated neutrophil incubated with fibrinogen (2.5 mg/ml, 30 
minutes, 37 degrees C). Fibrinogen was detected using rabbit antihuman fibrinogen 
antibody followed by 5nm-gold conjugated goat antirabbit /gG (see Methods). (c) Intra-
cellular vesicles of a PMA stimulated neutrophil incubated with biotinylated fibrinogen 
(1.5 mg/ml, 30 minutes, 37 degrees C). Biotinylated fibrinogen was detected µsing the 
streptavadin-biotin bridge-gold (SBBG) technique (see Methods), (Pm=plasma membrane). 
(d) An intracellular vesicle of a PMA stimulated neutrophil incubated with biotinylated 
fibrinogen (1 . 75 mg/ml, 30 minutes, 37 degrees C). Biotinylated fibrinogen was detected 
using 15nm-go/d conjugated goat antibiotin antibody (see Methods). 
Figure 4: The co-localisation of fibrin-
ogen and biotinylated BSA within an 
intracellular vesicle. PMA (5 nq/ml) stim-
ulated neutrophils were incubated with 
fibrinogen (1mg!ml) and biotiny/ated BSA 
(1mg!ml) for 30 minutes at 37 degrees C. 
Cryosections were immunostained for 
fibrinogen using rabbit antihuman fibrin-
ogen antibody followed by 5nm-go/d 
conjugated goat antirabbit lgG. Biotin-
y/ated BSA was detected using 15nm-gold 
conj ugated antibiotin antibody (see 
Methods). Cytoplasmic granules can be 
seen within this vesicle (G, arrows). 
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with fibrinogen (1-2.5 mg/ml) at 37°C over a time course of 5-60 
minutes. PDP, were however, detected intracellularly within electron 
lucent vesicles (Ve) which were abundant in PMA stimulated 
neutrophils (Figures 3a-d). Indirect immunogold labelling (figure 3b) 
consistently provided the highest levels of intracellular labelling. 
Labelling was specific for fibrinogen as no labelling was observed 
when rabbit anti-human fibrinogen antibody was substituted with 
non-immune rabbit IgG. When ultrathin sections of neutrophils 
(which had been incubated with biotinylated fibrinogen) were stained 
with streptavadin conjugated to 10nm gold, no specific labelling was 
observed, despite a variety of adjustments to conditions of fixation as 
well as immunostaining (not shown). Two alternative approaches for 
the detection of biotinylated FDP were also pursued, namely the 
streptavadin-biotin bridge-gold (SBBG) technique, as well as the use 
of gold conjugated antibiotin antibody.* Whilst the SBBG technique 
was unable to detect biotinylated PDP at the neutrophil surface, a low 
level of labelling was noted intracellularly within electron lucent 
vesicles (figure 3c), but this was relatively weak and poorly 
reproducible. However, when (15nm) gold conjugated antibiotin 
antibody was used (figure 3d), labelling within electron lucent 
vesicles was consistent and reproducible. No surface labelling was 
detected using either of these techniques, despite various adjustments 
to the conditions of fixation and labelling (including pre and post-
fixation labelling as well as adjustments to concentration and 
duration of exposure to gold conjugates). Increasing the 
concentration of fibrinogen as high as 2.5 mg/ml did not change the 
level of surface labelling. 
The indirect immunogold labelling approach was used to investigate 
the uptake of PDP over a time course of 5-60 minutes. The 
intracellular accumulation of fibrinogen was time dependent and 
. . 
A review of related studies revealed that the use of gold conjugated streptavadin 
is often associated with poor labelling due to steric hinderence. 6"9 Two alternative 
approaches were suggested to be more sensitive and specific for the detection of 
biotinylated ligands. The first, known as the streptavadin-biotin-bridge-gold 
(SBBG) technique,6 is a two step staining procedure in which sections are first 
stained with streptavadin and thereafter with biotinylated BSA conjugated to 
colloidal gold. The second approach involves the use of a gold conjugated antibody 
directed against the hapten form ofbiotin.7 
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appeared to peak at about 30 minutes. In PMA stimulated 
neutrophils, gold labelled vesicles were plentiful and relatively 
densely labelled, whilst in unstimulated neutrophils these vesicles 
were much less frequently observed and were sparsely labelled. 
These findings were the same in neutrophils incubated in PBS and 
HBSS. These observations were consistent over a large number of 
cells in a particular section, over many sections and over many 
experimental samples. Thus the FDP that are associated with 
neutrophils2 appear from these results to be intracellular rather than 
surface bound. 
The next stage of this study aimed to determine the process by which 
FDP accumulated intracellularly. Since it may be possible that the 
previously documented neutrophil associated FDP2 represent, at least 
in part, the intracellular degradation products of fibrinogen taken up 
in intact form, the text that follows will refer to uptake of fibrinogen, 
used as a general term to describe both intact and degraded forms of 
fibrinogen. * 
Colocalisation of fibrinogen and biotinylated BSA 
Because fibrinogen products appeared to accumulate intracellularly 
with no evidence of accumulation on the neutrophil surface, it was 
thought, initially, that fibrinogen uptake might occur via fluid phase 
pinocytosis. ** To investigate this possibility, the pattern of fibrinogen 
uptake was compared to that of a frequently used marker of fluid 
phase pinocytosis, BSA.10-16 It was reasoned that if fibrinogen uptake 
resembled that of BSA, then fibrinogen was most likely being 
internalised via a non-specific pinocytic pathway. 
* 
Under the experimental conditions employed, neutrophils degrade fibrinogen to 
yield both high and low molecular weight products. 1 In addition, intact fibrinogen, 
(not yet been degraded), is also present in the surrounding medium. Therefore 
under the experimental conditions employed, neutrophils will encounter intact 
fibrinogen as well as high and low molecular weight degradation products . 
•• Pinocytosis is the internalisation of liquid droplets by a cell through 
invaginations in the plasma membrane which close to form fluid filled vesicles. 
During this process molecules in the surrounding medium may be internalised 
without any significant adsorption to the plasma membrane. 
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Initial experiments investigated, using immunoelectron microscopy, 
the intracellular localisation of fibrinogen and biotinylated BSA (both 
at lmg/ml) following incubation with PMA stimulated neutrophils. 
Neither fibrinogen nor bBSA accumulated on the neutrophil plasma 
membrane over a time course of 5-60 minutes. Both proteins 
consistently gained access to the same intracellular compartments as 
illustrated in figure 4. 
Uptake of [1251]-labelled fibrinogen and BSA 
The co-localisation of fibrinogen and BSA within intracellular 
vesicles initially suggested that these proteins may be taken up via a 
similar pathway. However, a quantitative comparison of total 
associated protein (fibrinogen versus BSA) was required before this 
possibility could be entertained. Quantification was important in 
order to exclude the possibility that BSA was being taken up as an 
"innocent bystander" in the fluid at sites of specific receptor 
mediated uptake of fibrinogen. If this were the case, one would 
expect that the quantity of fibrinogen internalised by the neutrophil 
would greatly exceed that of BSA, as receptor mediated endocytosis 
involves selective concentration of the ligand on the neutrophil 
surface prior to internalisation. 11-19 
In order to compare the process of fibrinogen and BSA uptake, the 
[1 25I]-labelled forms of these ligands were incubated with PMA 
stimulated neutrophils at 37°C. 
The dose response curve for the uptake of [125I]-labelled fibrinogen 
was found to be similar to that for [125I]-labelled BSA (figure 5) 
using both PBS and HBSS as assay buffers. In view of the similar 
patterns of uptake displayed by fibrinogen and BSA, it was thought 
initially that the uptake of fibrinogen was occurring entirely via fluid 
phase pinocytosis. However, a prerequisite for fluid phase 
pinocytosis is that uptake varies linearly with the concentration of 
solute in the medium showing no evidence of saturation over a large 
(mg/ml) range. 17 The non-linearity of the curves below a 
concentration of 0.12 mg/ml suggested that the uptake of both 
fibrinogen and BSA might also involve an element of specific 
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binding to the neutrophil surface. This was unexpected in view of the 
frequent use of BSA as a marker of fluid phase pinocytosis. 
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Figure 5: Association of [1251]-label/ed fibrinogen and BSA with PMA stimulated 
neutrophils (PMN), as a function of concentration. (a) [1251]-labelled fibrinogen 
(FBGN) or [1251]-labelled BSA (0-600µglml) were incubated f:37"C, 30 minutes) 
with PMA stimulated PMN (5 x 1061ml) in PBS. Association of [ 251]-labelled protein 
was measured and expressed as ng [1 251]-labelled protein per 106 PMN. Each data 
point represents a mean of duplicates. An additional experiment gave a similar 
result (appendix 3, page 232). (b) The same experiment was performed using 
HBSS as the assay buffer. 
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[
1251]-labelled fibrinogen and BSA also displayed similar patterns of 
uptake with respect to time (performed in PBS) as illustrated in 
Figure 6. 
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Figure 6: Association of [1 251}-labelled fibrinogen and BSA with PMA 
stimulated PMN as a function of time. / 251]-labelled fibrinogen or BSA (500JJ']lml) were 
incubated with PMA stimulated PMN (5 x 1061ml) in PBS for varying durations of 
time (37'C, 15-60 minutes). Association of ( 251]-labelled protein was measured and 
expressed as ng ( 25/J-labelled protein per 106 PMN. Each data point represents a 
mean of duplicates. 
Release of internalised fibrinogen 
The observed similarities (both qualitative and quantitative) in the 
pattern of uptake of fibrinogen and BSA suggested that fibrinogen 
was being internalised predominantly by non-specific pinocytosis. As 
pinocytosis involves the bi-directional cycling of the plasma 
membrane, 17•20 the early release of internalised proteins back into the 
extracellular space would be expected. This has been well 
documented in neutrophils,14 and various other cell types,21 •23 where 
a significant proportion of pinocytosed protein is rapidly released 
back into the surrounding medium, often in the form of catabolic 
products. 17 
To determine whether fibrinogen internalised by the neutrophil Was 
subsequently released, PMA stimulated neutrophils were incubated 
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with [125I]-labelled fibrinogen for 10 minutes and, following washing 
steps, were re-incubated at 37°C in the presence of PMA for various 
durations of time. The radioactivity released into the supernatant was 
measured and expressed as a percentage of the total radioactivity 
associated with the neutrophil at 10 minutes. 
As illustrated in figure 7, neutrophils released a substantial 
proportion of internalised fibrinogen. This occurred relatively early 
on, with 35% of internalised fibrinogen being released within the first 
10 minutes, 50% after 30 minutes, and thereafter minimal further 
release. A second experiment investigating release at earlier time 
points revealed that 30% and 31 % of internalised fibrinogen were 
released at 5 and 10 minutes respectively. Viability at each time point 
was greater than 90% .indicating that release of fibrinogen was not 
the result of cell death. 
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Figure 7: Release of neutrophil associated [1251]-labelled fibrinogen. PMA 
stimulated PMN were incubated with [1251]-labelled fibrinogen (37'C, 10 minutes) as 
described. PMN were then washed throe times at 4 'C and re-incubated at 37 'C in the 
presence of PMA for 1 O to 60 minutes (see methods). The radioactivity released into the 
supernatant was counted and expressed as a percentage of total radioactivity 
associated with PMN at 1 O minutes. Each data point represents a single measurement. 
FiJ!ure 8: SDS-PAGE analysis of the [1251]-labelled fibrinogen products. The 
£1 /]-labelled fibrinogen products released by the neutrophil after 15 minutes were 
subjected to SOS-PAGE and autoradiography. 
Localisation of neutrophil associated jibrinogen 177 
The [1251]-labelled fibrinogen products released by the neutrophil at 
15 minutes were analysed by SDS-PAGE and autoradiography 
(figure 8). These products were found to be of low molecular weight 
(mostly < 30kDa), resembling the [1251]-labelled FDP previously 
reported to associate with PMA stimulated neutrophils.2 No intact 
fibrinogen was present. 
Divalent cations and uptake of t'251]-labelled fibrinogen and BSA 
As previous studies had investigated the association of [1251]-labelled 
FDP with the neutrophil in both HBSS and PBS,2 these buffers were 
used in the present study. Consistent with earlier reports,2 uptake of 
[
1251]-labelled fibrinogen appeared similar in experiments performed 
in PBS (calcium free) and HBSS (which contains lmM CaCh and 
MgCh). During the present study, however, it was noted that HBSS 
was not able to maintain its pH at 7.4 for the duration of the assay, 
with the pH often rising to 7.8. Experiments were therefore repeated 
using (lg/1) HEPES (N-[2-Hydroxyethyl]piperazine-N'-[2-
ethanesulphonic acid) buffered HBSS. A marked increase in 
neutrophil association with both fibrinogen and BSA was noted when 
this buffer was used as illustrated in figure 9. This suggested that 
divalent cations might facilitate the association of fibrinogen and 
BSA with saturable sites on the neutrophil surface. 
The association of fibrinogen (lmg/ml) with PMA stimulated 
neutrophils (37°C, 30 minutes) in HBSS-HEPES was analysed by 
immunoelectron microscopy. As in earlier experiments using PBS 
and HBSS, fibrinogen was detected intracellularly but not on the cell 
surface. All further experiments were performed using HEPES 
buffered HBSS as the assay buffer. 
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Figure 9: The effect of divalent cations on [125/J-labelled fibrinogen and BSA 
association with PMN. (a) [1251]-labelled fibrinogen (0-500µg!ml) was incubated 
(37'C, 30 minutes) with PMA stimulated PMN (5 x 1061ml) in either PBS or HEPES 
buffered HBSS (HIHBSS). Association of [1 251]-labelled fibrinogen was measured 
and expressed as ng per 106 PMN. Each data point represents a mean of 
duplicates. An additional experiment gave similar results (appendix 3, page 232) 
(b) The association of [1 251]-labelled BSA with PMA stimulated neutrophils was tested 
under the same conditions. 
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Temperature dependence of fibrinogen uptake 
To investigate whether [1 251]-labelled fibrinogen and BSA could 
associate with the neutrophil surface, binding experiments were 
performed using cells chilled on ice (0°C). As endocytosis is 
completely inhibited at 0°C, 17 any association of [1251]-labelled 
protein detected under these conditions, would suggest surface 
binding. 
Neutrophil association with both [1251]-labelled proteins was found to 
be markedly diminished in chilled cells but not abolished, suggesting 
that these proteins can bind to the neutrophil surface (Figures 1 Oa and 
b). The association of [1 251]-labelled fibrinogen and [1251]-labelled 
BSA with chilled neutrophils was also measured over a time course 
of 0-60 minutes. As indicated in figure 11, both proteins continued to 
associate with the neutrophil over the entire time course. An 
additional experiment investigating the association of [1251]-labelled 
fibrinogen with the neutrophil at 0°C showed continued association 
over a time course of 0-90 minutes (appendix 3, page 233). These 
results suggest that this binding has a non-saturable component. 
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Figure 10a: Association of [ 1251]-/abelled fibrinogen with PMN at U'C and 31°C. 
PMA stimulated PMN (5 x 1061ml) in HEPES buffered HBSS were incubated (37'C, 
30 minutes) with [1251]-label/ed fibrinogen (0-250µg/ml). In parallel experiments, PMA 
stimulated PMN (37'C, 30 minutes) were chilled on ice for 30 minutes, after which 
they were incubated with [1 251]-label/ed fibrinogen for a further 30 minutes on ice. 
Association of [1 251]-labelled fibrinogen was measured and expressed as ng per 106 
PMN. Each data point represents the mean of duplicates. 
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Figure 10b: Association of [ 1251]-labelled BSA with PMN at D°C and 37"C. PMA 
stimulated PMN were incubated with ( 251]-labelled BSA (0-250µg!ml) at O 'C or 37'C 
as described for fibrinogen (figure 10a). Association of ( 251]-labelled BSA with PMN 
at 30 minutes was measured and expressed as ng per 106 PMN. Each data point 
represents the mean of duplicates. 
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Figure 11: Association of [1251]-label/ed fibrinogen and BSA with chilled PMN as a 
function of time. Chilled PMA stimulated PMN (prepared as described in figure 10) 
were incubated with [1 251]-labelled fibrinogen or BSA (100µglml) on ice over a time 
course of 0-60 minutes. Association of [1 251]-labelled protein was measured and 
expressed as ng per 106 PMN. Each data point represents the me.an of duplicates. 
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Neutrophil association with extensively degraded fibrinogen 
Data obtained thus far suggested that the previously reported 
neutrophil associated FDP might not necessarily reflect the selective 
binding of low molecular weight FDP to the neutrophil as was 
previously thought.2 It was equally likely that neutrophil associated 
FDP could occur through the intracellular degradation of internalised 
fibrinogen, taken up in intact and/or partially degraded forms. 
To determine whether neutrophils showed a preference for binding 
degraded forms of fibrinogen, neutrophil association with extensively 
degraded fibrinogen was compared to association with intact 
fibrinogen at 0°C. Fibrinogen digests were generated by incubating . 
[1 25I]-labelled fibrinogen with the conditioned medium of PMA 
stimulated neutrophils as described in Methods. This generated a 
preparation in which over 50% of fibrinogen products had a 
molecular weight of~ 14 kDa (i.e. were soluble in 10% TCA). 
PMA stimulated neutrophils were chilled as described earlier, after 
which they were incubated with either intact fibrinogen or fibrinogen 
digests (1 OOµg/ml) for a period of 0-30 minutes. As illustrated in 
figure 12, the quantity of [125I]-labelled product that became 
associated with the neutrophil appeared similar whether intact or 
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Figure 12: Association of [1251]-labelled fibrinogen versus an [1251]-label/ed 
fibrinogen digest with chilled PMN. Chilled PMA stimulated PMN were incubated with 
either [125/J-FBGN (1 OOµg/ml) or degraded [1251J-FDP respectively (1 OOµg/mQ over a time 
course of 0-30 minutes. Association of [12 /]-labelled product was measured and 
expressed as ng per 1 cf PMN. Each data point represents the mean of duplicates. 
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The effect of BSA on fibrinogen uptake 
Under all experimental conditions employed thus far, the pattern of 
fibrinogen uptake was consistently paralleled by BSA. This 
suggested that the mode of uptake of these proteins might be similar. 
To determine whether fibrinogen and BSA might compete for 
binding sites on the neutrophil surface, the ability of BSA to inhibit 
the uptake of [1 25I]-labelled fibrinogen was investigated. 
PMA stimulated neutrophils were incubated with [125I]-labelled 
fibrinogen (0-500µg/ml) for 30 minutes at 37°C. Parallel samples 
were pre-incubated with BSA (2mg/ml) for 10 minutes prior to the 
addition of [125I]-labelled fibrinogen (see Methods). As illustrated in 
Figure 13, pre-incubation with BSA caused marked inhibition of 
fibrinogen association with the neutrophil. This suggested that 
fibrinogen and BSA might compete for the same binding site(s) on 
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Figure 13: The effect of BSA on the association of [1251]-labelled fibrinogen 
with PMN. ( 251]-label/ed fibrinogen (0-SOOµglml) was incubated (37'C, 30 minutes) 
with PMA stimulated PMN (5 x 1061ml) in the presence and absence of BSA 
(2mglml). Association of ( 251]-labelled fibrinogen was measured and expressed as 
ng per 106 PMN. Each data point represents the mean of duplicates. An additional 
experiment gave a similar result (see appendix 3, page 233). 
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Discussion 
This study aimed to investigate the association of neutrophil derived 
FDP with 132-integrin receptors, as suggested by the results of earlier 
studies.2 The present study therefore employed similar experimental 
conditions to those used in earlier studies.2 
Immunoelectron microscopy revealed neutrophil associated FDP to 
be located within electron lucent vesicles suggesting that fibrinogen 
was being internalised by the neutrophil. Whilst the possibility that 
these "vesicles" might be external to the cell (i.e. plasma membrane 
invaginations, viewed in cross-section, see figure 14) was considered, 
several factors suggested that this was unlikely. 
The neutrophil in cross section / 
~ Gold In vesicle 
~ ~,"-"'"" ~ 





Figure 14: It is possible that gold label which appears to be intracellular in cross-
section, may, in fact, be extracellular if it is present in an invagination. This is 
illustrated in the figure above which shows the two possible locations of gold label 
which appears to be intracellular. This would become apparent if sections were cut 
in the opposite plane. 
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o Firstly, if labelled structures were invaginations rather than 
vesicles, then external labelling of these structures should have 
been observed in invaginations viewed in the . opposite plane 
(figure 14, top right). Such labelling was not observed. 
o Secondly, if FOP were binding extracellularly to integrin 
receptors, their cell surface distribution should resemble that of 
CD 11 b/CD 18 ( one of its putative receptors) in activated 
neutrophils (figure 2b).* This was not observed with FOP. 
o Thirdly, the pattern of intracellular labelling was very similar to 
that previously described for neutrophils internalising gold-
conjugated BSA by fluid phase pinocytosis. 13 
Thus, it was likely that gold labelled vesicles represented intracellular 
FOP. This is further suggested by the fact that the conditions under 
which these experiments were performed were stimulatory for 
neutrophil pinocytosis. It has been reported that activation of 
neutrophils with phorbol ester (PMA)24•25 or chemotactic peptide 
(FMLP)13 results in a rapid increase in the rate of ligand independent 
membrane internalisation, and that phorbol esters, in particular, are 
extremely potent activators of this process.25 Indeed, in the present 
study, PMA stimulated neutrophils (irrespective of whether 
fibrinogen was present) were noted to be highly vacuolated in 
comparison to non-stimulated cells. Under conditions such as these, 
surface bound ligand is often rapidly internalised, and as a result, 
studies investigating ligand binding to cell surface receptors, 
frequently employ conditions under which the endocytic apparatus is 
inhibited. This is usually accomplished by using cells that are chilled 
(0-4°C), 16,17•19 or the use of metabolic inhibitors such as sodium 
fluoride or sodium azide.26•27 However, because the present study 
aimed to further characterise observations made in previous studies, 2 
initial experiments were performed under the same conditions (i.e. 
PMA stimulation at 3 7°C) as those used previously . 
• Although expression of CD 11 b/CD 18 was measured in FMLP stimulated rather 
that PMA stimulated neutrophils, both agents are known to have a similar effect on 
the cell surface expression ofintegrin receptors.40 
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The mechanism of fibrinogen internalisation 
The next phase of this study aimed to determine the mechanism by 
which FDP accumulated intracellularly. 
The observation that FDP accumulated intracellularly in the absence 
of significant binding to the neutrophil surface, suggested initially 
that uptake might occur via fluid phase pinocytosis. If this were the 
case, then it was possible that the previously documented neutrophil 
associated FDP2 might reflect the uptake of intact fibrinogen which 
was subsequently degraded intracel/ularly. The uptake of fibrinogen 
was thus compared to that of BSA, a well described marker of fluid 
phase pinocytosis. 
BSA (unlabelled10 or tagged with fluorescein, II colloidal gold, 12•14 or 
[
125I] 15•16) has been widely used as a marker of non-specific fluid 
phase pinocytosis. Activated neutrophils have been shown to 
internalise large quantities of gold conjugated-BSA whilst showing 
minimal binding of this ligand to the neutrophil surface. 12•13 In 
addition, BSA has been used, both in monocytes16 and platelets,28•29 
as a non-specific control when investigating uptake of fibrinogen via 
integrin receptors. A comparison of the uptake of fibrinogen and 
BSA thus appeared to be a relatively simple and convenient approach 
in determining the specificity of fibrinogen uptake by the neutrophil. 
These two proteins were found to gain access to the same 
intracellular compartments, and neither ligand accumulated on the 
neutrophil surface. Further studies, using radiolabelled fibrinogen 
and BSA, revealed these two proteins to be taken up in comparable 
quantities, and a large proportion of internalised fibrinogen was 
subsequently shown to be released into the extracellular medium in a 
similar manner to that reported for other molecules internalised by 
pinocytosing neutrophils. 14 These findings initially led to the 
suggestion that fibrinogen uptake was occurring predominantly via 
fluid phase pinocytosis. However, fluid phase pinocytosis is 
characterised by uptake which varies linearly with solute 
concentration over a relatively large (mg/ml) range. 17 As the dose 
response curves for the uptake of both fibrinogen and BSA are not 
linear, a proportion of uptake may be facilitated by saturable binding 
at the neutrophil surface. Divalent cations may indeed enhance the 
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uptake of these proteins. Consistent with earlier reports,2 initial 
experiments had found the uptake of [125I]-labelled fibrinogen to be 
similar in PBS (calcium free) and HBSS (which contains lmM CaCh 
and MgCh) suggesting that uptake was not dependent on divalent 
cations. However, following the observation that the pH of HBSS 
was not stable under the experimental conditions employed, assays 
were repeated in HEPES buffered HBSS. This resulted in a marked 
increase in the association of both fibrinogen and BSA with the 
neutrophil. 
Thus the internalisation of fibrinogen and BSA might to some extent 
be preceded by binding to the neutrophil surface, particularly in the 
presence of divalent cations. To investigate this possibility, binding 
experiments (in HEPES buffered HBSS) were performed on ice to 
prevent internalisation of surface bound ligand. Whilst association of 
[
125I]-labelled fibrinogen and BSA was markedly diminished under 
these conditions, it was not abolished, suggesting that a degree of 
surface binding may occur. It thus appeared that binding of 
fibrinogen and BSA to the neutrophil surface might to some extent 
facilitate internalisation. The prior detection, by immunoelectron 
microscopy, of intracellular but not surface associated fibrinogen 
might be explained as follows: 
o Immunoelectron microscopy experiments were performed at 
37°C. At this temperature, ligands bound to the cell surface are 
rapidly internalised, 17'19 particularly in cells in which the pinocytic 
pathway is activated (such as those stimulated with PMA). Thus, 
the association of fibrinogen/FDP with the neutrophil surface may 
be transient due to its rapid internalisation, and therefore not 
detected under these conditions. In addition, at this temperature 
significant degradation of fibrinogen occurs due to release of 
proteases from PMA stimulated neutrophils which is enhanced in 
the presence of fibrinogen.2 This process may rapidly and 
efficiently clear the surface of any fibrinogen. Such proteolysis has 
previously been reported to facilitate neutrophil detachment from 
fibrinogen coated surfaces.30 
o Fibrinogen was used at a relatively high concentration (lmg/ml) 
during the electron microscopy study. The concentration of a 
ligand has a major influence on the pathway by which it is 
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* 
internalised. 14 At 1~; ·concentrations receptor-mediated uptake is 
favoured, whilst at higher concentrations internalisation via fluid 
phase pinocytosis also occurs. 14 This has been well documented 
for the chemotactic peptide fNNLP • ( see table 1 and figure 15). 14 
It is therefore possible that, at the fibrinogen concentrations used 
during electron microscopy studies, a significant proportion of 
fibrinogen/FDP is internalised via fluid phase pinocytosis without 
any prior contact with the neutrophil surface. 
Low concentration 
Receptor mediated uptake +++ 
Fluid phase pinocytosis -
High concentration 
............... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Receptor mediated uptake +++ 
Fluid phase pinocytosis ++++ 
Figure 15: The effect of ligand concentration on receptor mediated 
endocytosis versus fluid phase pinocytosis in PMA stimulated neutrophils. 
Receptor mediated endocytosis involves the selective concentration of a ligand 
at the cell surface. Thus, even at low concentrations of ligand, there is sufficient 
concentration at the cell surface to allow for uptake of significant quantities. Due 
to the low concentration of ligand in the surrounding medium, minimal uptake 
occurs via the fluid internalised during pinocytosis. As the concentration of 
ligand in the surrounding medium is increased, so the amount of ligand 
internalised in each fluid droplet during pinocytosis increases and constitutes an 
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Table 1. The influence of f HJ-N-formylnorleucylleucylphenylalanine 
(FNNLP) concentration on its pathway of uptake by neutrophils at 37 "C 
(adapted from reference 14). 
D In retrospect, the inclusion of BSA in the washing buffer (see 
Methods) may also have contributed to the failure of 
immunoelectron microscopy to demonstrate surface associated 
fibrinogen/FDP. As later experiments suggested that BSA might 
compete with fibrinogen for binding sites on the neutrophil 
surface (see below), it was possible that these washing steps 
might have removed any fibrinogen/FDP associated with the 
neutrophil surface. 
As fibrinogen and BSA displayed similar patterns of uptake under all 
conditions employed during this study, it was possible that these 
proteins were taken up via a similar process. To investigate this 
possibility, competition studies were performed testing the ability of 
BSA to inhibit [1251]-labelled fibrinogen association with the 
neutrophil. For these experiments fibrinogen was used at relatively 
low concentrations (0.05-0.5 mg/ml) which favour uptake via a 
surface mediated process. A marked decrease in the association of 
[
125I]-labelled fibrinogen with the neutrophil was noted in the 
presence of BSA suggesting that these proteins may compete for 
limited binding sites on the neutrophil surface. Since BSA is 
frequently included in incubation- and washing- buffers to block 
"non-specific binding", its ability to inhibit fibrinogen association 
with the neutrophil brings into question the specificity of this 
association. 
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The possibility that BSA inhibited fibrinogen binding due to 
competition for P2-integrin receptors was also considered. 
Neutrophils have, in fact, been reported to adhere via P2-integrin 
receptors, to surfaces coated with BSA and human serum albumin 
(HSA).31 '32 However, neutrophils are also able to adhere (P2-integrin 
dependently) to a wide variety of other protein substrates when 
immobilised on plastic surfaces, via what appear to be non-specific 
glue-like interactions.33 Included in this group, are proteins as varied 
as catalase, transferrin, soybean trypsin inhibitor, casein and 
ovalbumin.34 Whilst the soluble forms of these proteins are not 
considered ligands for P2-integrin receptors, surface bound forms of 
these proteins are. It has been suggested that partial unfolding 
following binding to plastic surfaces exposes domains which are 
recognised by P2-integrin receptors.34 
In contrast to surface adherent albumin, there is no evidence to 
suggest that soluble albumin can bind to P2-integrins.34'35 Whilst the 
specific binding of denatured albumin to neutrophils has been 
reported, native albumin does not exhibit specific binding. 35 A 
comparison of the amino acid composition of albumin to that of 
extracellular matrix proteins (fibronectin, vitronectin, von 
Willebrand's factor and fibrinogen) suggests that its interaction with 
p2-integrins is unlikely.36 Finally, the inability of soluble albumin to 
inhibit neutrophil binding to ECM protein coated surfaces, further 
suggests that it does not bind specifically to integrin receptors. 36 
Soluble HSA has, however, been shown to bind to the sialoprotein, 
sialophorin (CD43) on the neutrophil surface,36 and it is thus possible 
that BSA may bind to the neutrophil via a similar mechanism. 
Recently, rat neutrophils and murine macrophages have been shown 
to internalise gold conjugated BSA via coated pits and it was 
suggested that uptake may involve scavenger receptors.37 However, 
in a similar study using human neutrophils, it was shown that whilst 
early endocytic invaginations and small peripheral vesicles 
containing BSA-gold included coated areas of the membrane, uptake 
did not occur via a saturable, specific receptor mediated process. 13 
Moreover, BSA has been used as a control protein in studies 
investigating integrin mediated uptake of fibrinogen in platelets28'29 
and monocytes. 16 
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Interestingly, during a recent study investigating pinocytosis in rat 
hepatocytes,38 it was noted that binding of BSA to chilled 
hepatocytes was considerably higher when BSA was directly labelled 
with [1 25I]Na than when it was conjugated to tyramine cellobiose via 
its lysine residues. It was suggested that this may be due to non-
specific adsorption of [125I]-labelled BSA to the plasma membrane, 
and that conjugation of albumin to tyramine cellobiose may, in some 
way, alter the charge or hydrophobicity of the molecule, reducing its 
affinity for the plasma membrane.38 It is possible that similar charge 
related or hydrophobic interactions may have accounted for the 
binding of [125I]-labelled BSA to the neutrophil observed during the 
present study. 
In contrast to BSA, fibrinogen is a recognised ligand for P2-integrin 
receptors,3946 and the p3-integrin receptor, leukocyte response 
integrin (LRI).47'48 Most studies have characterised the binding of Pi-
integrin receptors to surface adherent fibrinogen.39,4o,4345 Although 
soluble fibrinogen has been reported to associate specifically with 
CD1lb/CD18 on neutrophils and monocytes,41 '42'46 it has been 
suggested that the affinity of P2-integrin receptors for soluble 
fibrinogen is very low.39'43 Conformational changes in fibrinogen, 
such as those which occur following binding to glass or plastic 
surfaces, may be required to unmask integrin recognition sites.42 It is 
thus thought that circulating monomeric fibrinogen will not bind to 
integrin receptors to a significant extent, and that clotted fibrinogen, 
or fibrinogen coated surfaces (in which the carboxyl terminus of the 
gamma chain is "multivalent") is the biologically relevant substrate 
for these receptors.39'43 In the context of adhesive interactions 
between cells and the extracellular matrix, these multivalent, low 
affinity interactions sum to yield the biologically important 
phenomenon of adhesion.39 
A recent study reporting the interaction of soluble FDP with P2-
integrin receptors on PMA stimulated neutrophils was the stimulus 
for the present study.2 This report was based on three sets of 
observations: 
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o Firstly, when PMA stimulated neutrophils were incubated with 
[
1251]-labelled fibrinogen, washed, and then solubilised prior to 
analysis by SOS-PAGE, only [1251]-labelled fibrinogen products of 
less than 30 kDa in size were detected on autoradiographs.2 
o Secondly, the serine protease inhibitor AEBSF, which inhibits 
neutrophil mediated fibrinogen degradation, markedly inhibited 
the association of [1251]-labelled fibrinogen (product) with the 
neutrophil under these conditions.* 
o Thirdly, monoclonal antibodies directed against the CDI la, 
CD1lb, CD11c and CD18 subunits of lh-integrin receptors 
partially inhibited the association of these [1251]-labelled products 
with neutrophils following incubation with [1251]-labelled 
fibrinogen (see Table 2).2 
Percentage inhibition of [125I]-labelled fibrinogen association with neutrophils 
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Table 2. The reported effect of monoclonal antibodies against various neutrophil 
receptors on the association of ( 251]-labelled fibrinogen /products) with PMA 
stimulated neutrophils (adapted from reference 2). [12 /]-labelled fibrinogen 
(1mglml) was incubated (37'C, 15 minutes) with PMA stimulated neutrophils in the 
presence and absence of monoclonal antibodies to various neutrophil receptors. 2 
* AEBSF has recently been reported to react rapidly and non-specifically with 
many proteins to such an extent that a blocking reagent has been specifically 
designed to address this problem.49 It is thus possible that the inhibitory effect of 
AEBSF on the neutrophil association with [1251]-fibrinogen (products) might result 
from its binding to membrane proteins rather than from its inhibition of fibrinogen 
peptide formation. 
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Whilst these findings suggest a role for integrin receptors in the 
uptake of fibrinogen/FDP under these experimental conditions, 
several factors suggest that the inhibition achieved by these 
antibodies should be interpreted cautiously. 
o Antibodies directed against the shared B-subunit of the B2-integrin 
receptors, CD 18, were relatively ineffective in blocking the 
association of [1251]-labelled fibrinogen products with neutrophils 
(10% inhibition).2 As it is well known that both the CDll and 
CD 18 subunits are required for ligand recognition by B2-
integrins, 50 the relatively minor inhibition exerted by anti-CD18 
antibodies brings into question the mechanisms by which 
antibodies to the CD 11 subunits exerted their inhibitory effects.* 
o Neither CD1 la/CD18 (which binds to ICAM-1 and -2 on 
endothelial cells) nor the lgG Fe receptor, CD16, are known 
receptors for fibrinogen.39'51 However, antibodies directed against 
these receptors caused similar levels of inhibition to those directed 
against the a-subunits of the integrin receptors CD 11 b/CD 18 and 
CD11c/CD18 (see table 1). This raises questions over the 
specificity with which the latter antibodies exerted their effects. 
o It is likely that fluid phase pinocytosis contributed significantly to 
overall association of [1251]-labelled fibrinogen products with the 
neutrophil under the conditions employed in these experiments. 
The pinocytic apparatus is highly activated in neutrophils 
stimulated with PMA at 37°C,24'25 and the high concentrations of 
fibrinogen used (lmg/ml) favour uptake via fluid phase 
pinocytosis (see explanation page 187). Such uptake may well 
have accounted for the large proportion of uptake that could not be 
inhibited in the presence of anti-integrin antibodies. 
From data acquired during the present study, it is unlikely that the 
reported association of [1251]-labelled FDP (Mr<30kDa) with 
neutrophils reflects only selective binding of FDP to the neutrophii2. 
Such association is more likely the result of uptake of both intact and 
* 
It is assumed that the two anti-CD 18 antibodies used in this study were "blocking 
antibodies". It appears that the Serotec anti-CD18 antibody, at least, has been used 
as a blocking antibody in a previous study.52 
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degraded forms of fihrinogen. Intracellular degradation then reduces 
the internalised proteins to products of less than 30 kDa size. This is 
suggested by the immunolocalisation of fibrinogen (products) within 
intracellular vesicles and by their rapid release as FDP with apparent 
molecular mass values similar to those previously reported for 
neutrophil associated FDP.2 Moreover, binding studies (performed at 
0°C) suggest that neutrophils do not show a preference for binding to 
extensively degraded fibrinogen compared to intact fibrinogen. 
Such a view is not consistent with the reported inhibitory effect of 
low Mr FDP on neutrophil adherence to immobilised fibrinogen.2 
However, a review of the experimental data from that study suggests 
that a lack of adequate controls may well have accounted for the 
observations leading to that conclusion (personal communication). 
Summary and conclusions 
It has previously been hypothesised that fibrinogen proteolysis by the 
neutrophil membrane generates low molecular weight FDP which 
associate specifically with ~2-integrin receptors, and can block 
adhesive interactions with the extracellular matrix (see figure 1, page 
161).2 
The present study, which sought morphological evidence to support 
this hypothesis, has found evidence to challenge it. On the basis of 
observations made during this study, it is postulated that FDP 
becomes associated with the neutrophil via the following mechanism 
(see figure 16). 
1. Neutrophils stimulated with PMA at 37°C, undergo ligand 
independent internalisation of their plasma membranes. Under 
these conditions fibrinogen and FDP* in the surrounding medium 
* Under the experimental conditions employed both intact and degraded fibrinogen 
are present in the surrounding medium. 1 This is due to neutrophil mediated 
fibrinogenolysis which yields both high and low molecular weight fibrinogen 
degradation products. 
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are internalised both by fluid phase pinocytosis and via association 
with the plasma membrane. The presence of divalent cations 
appears to favour the latter, whilst the former is enhanced at 
higher concentrations of ligand. The neutrophil does not appear to 
discriminate between degraded and non-degraded forms of 
fibrinogen. Data from previous studies suggests that P2-integrin 
receptors may, to some extent, be involved in this process. 
However the observation, during the present study, that BSA can 
inhibit fibrinogen association with the neutrophil, suggests 
adherence to cell surface molecules other than P2~integrin 







FOP are degraded 
intracellularly 
3 
Partial release of 
low molecular 
weight FDP 
Figure 16: The proposed mechanism whereby FOP become neutrophil 
associated during incubation of PMA stimulated neutrophils with fibrinogen. 
2. Internalised fibrinogen (products) are rapidly degraded 
intracellularly into low molecular weight FDP. This degradation 
may be mediated by HNE and cathepsin G which afe known to be 
expressed on the neutrophil plasma membrane ( and therefore on 
membranes of pinocytic vesicles) under these conditions. 
3. A proportion of these products are released back into the 
surrounding medium. Those that remain cell associated most 
likely account for the low molecular weight fibrinogen peptides 
previously reported in association with the neutrophil.2 It is 
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therefore unlikely that these products modulate neutrophil p2-
integrin dependent adhesive interactions as has previously been 
suggested. 2 
Finally, despite the widespread use of BSA as a marker of fluid phase 
pinocytosis, this study suggests that [1251]-BSA, due to its propensity 
to bind to the neutrophil surface, is not a suitable marker of fluid 
phase pinocytosis in this setting. As a result the use of BSA did not 
allow for the elucidation of the pathway of fibrinogen uptake as was 
originally intended. 
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Chapter Seven 
Neutrophil mediated clot lysis 
Once a fibrin clot has achieved haemostasis it needs to be -
dismantled - failure to do so will result in life-threatening 
thromboembolic events. Whilst the plasminolytic system serves as 
the primary pathway for fibrin dissolution, the neutrophil provides an 
alternative pathway and recent evidence suggests that neutrophil 
proteases may act synergistically with plasmin to aid clot lysis1 (see 
chapter 3, pages 81-85). 
Neutrophils have long been known to degrade· fibrin via their 
azurophil granule proteases, HNE and cathepsin G.2•3 More recently, 
the neutrophil membrane has been reported to be an important source 
of fibrinolytic activity.4•7 This activity was ascribed to a 600 kDa 
protease which also degrades fibrinogen5 and CRP6 (see chapter 4). 
In studies using intact neutrophils, this fibrinolytic activity was 
shown to be constitutively present on the neutrophil membrane and 
was only marginally upregulated following stimulation with low dose 
PMA.7 
Whilst the fibrinolysis observed during these studies appeared to be 
due to the neutrophil membrane,4,7 it was possible that intracellular 
digestion might also contribute to this process. This possibility was 
entertained during the present study for several reasons: 
o Firstly, the ability of the neutrophil to internalise and digest 
material in the pericellular environment was highlighted by the 
findings presented in the previous chapter. 
o Secondly, neutrophil internalisation of partially digested fibrin 
particles had been shown, under certain conditions, to contribute 
significantly to the process of fibrin dissolution. 8•9 
o Finally, an immunostaining technique capable of detecting 
fibrinogen degradation products had recently been established 
(see previous chapter). This technique had the potential to detect 
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intracellularly degraded fibrin which is often not identifiable 
morphologically followitig degradation. 8 
The present study aimed to determine whether the neutrophil 
mediated fibrinolysis reported previously was exclusively due to the 
neutrophil membrane, or whether intracellular degradation also 
contributed to this process. 
Several observations made during the course of this study raised 
questions over the nature of the membrane associated proteolytic 
activity - in particular the extent to which it was constitutively 
present on the membrane of resting neutrophils, as well as its origin. 
Additional studies were thus undertaken to further characterise this 
membrane associated fibrinolytic activity. 
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Methods 
Chemicals and Reagents 
The sources of chemicals and reagents used in this study are listed in 
Appendix 1, page 225-226. 
Neutrophil isolation and fibrinogen purification & iodination 
These procedures were performed as described previously (see 
chapter 4, Methods page 107). Purified neutrophils were resuspended 
in HEPES buffered HBSS, and kept on ice until the beginning of 
experimental procedures. 
Incorporation of neutrophils into fibrin clots 
Neutrophils were incorporated into fibrin matrices using adaptations 
of previously described procedures.4•7 Neutrophils (20 x 106/ml) in 
HEPES buffered HBSS) were warmed (37°C, 10 minutes), and 
following the addition of bovine thrombin (0.25units/ml, final 
concentration), were mixed with fibrinogen (lmg/ml, final 
concentration) in a final reaction volume of 200µ1. Where neutrophils 
were stimulated with PMA (lOng/ml, final concentration), this was 
added immediately prior to the addition of fibrinogen. The reaction 
was allowed to proceed at 3 7°C for various durations of time. At 
selected time points samples were removed from the waterbath, and 
fixed (3.5% paraformaldehyde and 0.2% glutaraldehyde, O.lM 
phosphate buffer, pH=7.4) on ice for 90 minutes. 
Gelatin embedding 
Following fixation, fibrin clots were rinsed and incubated with 
0.05M glycine in PBS to quench free aldehydes, before embedding in 
gelatin. This involved the infiltration of fibrin clots with increasing 
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concentrations of gelatin (37°C, rotating end-on-end) according to 
the following protocol: 2% gelatin in PBS x 20 minutes; 6% gelatin 
in PBS x 20 minutes; 10% gelatin in PBS x 20 minutes. In order to 
avoid any fibrinolytic activity that might be reactivated following the 
removal of fixative, the serine protease inhibitor AEBSF (final 
concentration lmM) was added to the 2% gelatin mixture. Following 
gelatin infiltration fibrin clots were gently removed, placed on a glass 
slide and cooled to 4 °C, to solidify the gelatin. The clot was 
transferred into a tube containing fixative (same as above) and kept at 
4 °C overnight in order to crosslink the infiltrated gelatin. The next 
morning the gelatin infiltrated clots were removed from fixative, 
rinsed with PBS, and cut into small blocks (approximately lmm3) 
with a scalpel blade. 
Ultracryotomy and immunostai,:iing 
Blocks were sucrose infiltrated and cryosectioned, and sections 
immunostained (with antifibrinogen antibody) as described earlier. 
(see chapter 6 pages 164-166). Sections were then analysed by 
transmission electron microscopy. 
lmmunohistochemistry 
For the preparation of sections for light microscopy, the same 
procedure was followed with the exception that the gelatin infiltrated 
clots were not cut into blocks, but instead embedded in paraffin prior 
to microtomy. Thin sections were dewaxed and pretreated with 0.3% 
hydrogen peroxide in methanol (30 minutes, room temperature) to 
quench endogenous peroxidase activity. Sections were incubated 
with normal swine serum ( diluted 1 :20 in PBS) for 15 minutes, prior 
to exposure (30 minutes, room temperature) to rabbit antihuman 
fibrinogen antibody (1 Oµg/ml) in PBS. Slides were then washed with 
PBS and incubated (30 minutes, room temperature) with biotinylated 
swine antirabbit IgG diluted 1 :250 in PBS. After washing with PBS 
slides were incubated for a further 30 minutes with horseradish 
peroxidase linked streptavadin (diluted 1 :500 in PBS). Slides were 
then developed using the chromogenic substrate 3-3 1 diamino-
benzidine (0.5mg/ml) in the presence of 0.01 % hydrogen peroxide. 
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Slides were then stained with Meyer's haematoxylin, dehydrated and 
mounted. Controls were included in which rabbit antihuman 
fibrinogen antibody was substituted with non-immune rabbit IgG. 
Scanning electron microscopy 
Following fixation clots were washed and then post-fixed in osmium 
tetroxide for two hours. Clots were then washed with distilled water 
and dehydrated through a graded series of ethanol concentrations 
before undergoing critical point drying. Clots were then sputter coated 
with gold palladium and analysed by scanning electron microscopy. 
Neutrophil solubilisation of [1251]-labelled fibrin clots 
Neutrophils were incorporated into fibrin matrices as described 
above with the exceptions that neutrophils were used at a 
concentration of 10 x 106/ ml and [125I]-labelled fibrinogen was used 
to generate the clots. At selected time points, tubes containing fibrin 
clots were placed on ice, the clots squeezed and the supernatant 
collected and microfuged (11000 x g for 1 minute) to remove cellular 
debris. A 50µ1 aliquot was then removed and its radioactivity 
counted, and used as a measure of clot solubilisation. Radioactivity 
not incorporated into fibrin formed from [125I]-labelled fibrinogen (in 
the absence of cells) was used as the measure of baseline soluble 
radioactivity in the reaction. 
Analysis of [1251]-labelled fibrin degradation products 
[
125I]-labelled fibrin clots were generated by incubating fibrinogen 
(l.25mg/ml) with thrombin (0.6units/ml) in a final volume of 100µ1 
HBSS-HEPES at 37°C for 2 hours. Clots were squeezed and added to 
either conditioned medium or granule enzymes (prepared as 
described in chapter 5, page 128) used at various concentrations (see 
results) and the reaction was allowed to proceed at 3 7°C for 20 hours. 
The proteolytic products were analysed by SDS-PAGE (10%, 
reducing) and autoradiography. 
Chapter 7 202 
Results 
Neutrophil mediated fibrinolysis is predominantly extracellular 
PMA-stimulated neutrophils usually achieved complete dissolution 
of fibrin clots within 60-90 minutes (as judged macroscopically), 
whereas non-stimulated neutrophils induced no discernible alterations 
in the macroscopic appearance of the clot over the same period of 
time (figure 1). 
Time (minutes) 
15 30 45 60 90 
No neutrophils 
Figure 1: Fibrin clots were generated in the absence of neutrophils or around 
non-stimulated or PMA (10nglml) stimulated neutrophils (20 x 1061ml) (see 
Methods). At 90 minutes, fibrin clots containing PMA stimulated neutrophils (right) 
showed near complete dissolution whilst those containing non-stimulated 
neutrophils (left) showed no decrease in size or density compared to clots formed in 
the absence of neutrophils. 
Immunoelectron microscopy revealed no evidence of fibrin 
internalisation by non-stimulated neutrophils over a time course of 0-
90 minutes. A small percentage of PMA stimulated neutrophils (less 
than 5%) showed evidence of fibrin internalisation (figure 2 a-d). In 
a few cases, fibrin was detected within endocytic vesicles, mainly at 
later time points (30-90 minutes). Degraded fibrin, not identifiable 
~~-~------- --- - - --
Figure 2: Transmission electron micrographs of PMA stimulated neutrophils showing evidence of 
fibrin internalisation. PMA (10ng/ml) stimulated neutrophils (20 million/ml), incorporated within polymerising 
fibrin (1 mg/ml) clots, were incubated for 30 minutes at 37 degrees C. Samples were fixed, cryosectioned and 
immunostained using rabbit antihuman fibrinogen antibody followed by 5nm-gold conjugated goat antirabbit 
lgG (see Methods) . A small percentage (< 5%) of neutrophils showed evidence of fibrin internalisation with 
fibrin strands located within plasma membrane (Pm) invaginations (figures 2a-c) - arrows indicate the 
direction of the plasma membrane invaginations. Figure 2d shows the immunodetection of extensively 
degraded fibrin (no longer identifiable morphologically) within an intracellular vesicle containing cytoplasmic 
granules (G) . 
Figure 3: lmmunohistochemistry of PMA stimulated neutrophils within fibrin clots. PMA stimulated 
neutrophils were incorporated within polymerising fibrin clots under the same conditions as described above. 
Sections were immunostained with rabbit antihuman fibrinogen antibody which was detected using the biotin-
streptavadin-HRP system (see Methods) . (a) Fibrin (stained brown) was detected extracellularly but not 
intracellularly. (b) A negative control, in which antifibrinogen antibody was substituted with non-immune 
rabbit lgG, confirmed the specificity of fibrin staining. 
Chapter 7 204 
morphologically, could be detected immunologically (figure 2d) 
confirming the ability of this procedure to detect degraded fibrin 
which was no longer identifiable morphologically. These findings 
were consistent over a series of 5 experiments in which at least 250 
neutrophils were viewed, and were supported by immuno-
histochemistry which showed a lack of cytoplasmic staining for fibrin 
(see figure 3a). 
As minimal intracellular accumulation of fibrin was detected during 
the period in which complete fibrin dissolution was observed 
(macroscopically), it appears that neutrophil mediated fibrinolysis, 
under these conditions, is predominantly an extracellular event. 
The effect of PMA on neutrophil mediated fibrinolysis 
During this series of experiments, PMA stimulated neutrophils were 
noted to effect complete fibrin dissolution within 60-90 minutes, 
whilst over the same time period, non-stimulated neutrophils induced 
no noticeable changes in the size of the clot (figure 1 ). This 
suggested that the constitutive fibrinolytic activity of non-stimulated 
neutrophils was relatively low, and that neutrophil activation was 
required for this process. Previous studies had, however, reported 
only marginal upregulation of neutrophil mediated [1 25I]-fibrinolysis 
following stimulation with PMA.4•7 Further experiments were thus 
performed to investigate the effect of neutrophil activation on its 
capacity to degrade fibrin. 
Quantification of [1 251]-labelled fibrin solubilisation 
Solubilisation of [125I]-labelled fibrin clots in which either non-
stimulated or PMA stimulated neutrophils were incorporated was 
investigated as described previously4•7 (figure 4). Control samples 
(fibrin clots without neutrophils) were included for each time point 
(figure 4a), and the soluble radioactivity in these samples was 
subtracted from experimental samples to estimate the rate of 
fibrinolysis (figure 4b ). [125I]-labelled fibrin solubilisation was 
found to be far faster for neutrophils stimulated with PMA than for 
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Figure 4: Comparison of [1 251]-labelled fibrin solubilisation by non-stimulated 
and PMA stimulated neutrophils. (a) Non-stimulated or PMA stimulated 
neutrophils (10 x 106! ml) were incorporated (37'C, 10-90 minutes) into 1mg!ml 
[1 251)-labelled fibrin clots. At selected time points solubilised radioactivity was 
measured and expressed as cpm released. The soluble radioactivity associated 
with cell free control clots was also measured at each time point. The progressive 
decrease in the soluble radioactivity seen in cell free control clots reflects 
fibrinogen polymerisation. (b) This figure shows the radioactivity released by 
stimulated and non-stimulated neutrophils experimental samples following the 
subtraction of radioactivity associated with the cell free control at each time point. 
Data points represent means of duplicates. Two additional experiments gave 
similar results (see appendix 3, pages 234-235). 
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non-stimulated neutrophils. At 90 minutes PMA stimulated 
neutrophils achieved full solubilisation of the fibrin clot whereas 
non-stimulated neutrophils achieved less than 50% solubilisation. 
Scanning electron microscopy 
Scanning electron microscopy revealed marked differences in the rate 
of fibrin solubilisation by PMA stimulated neutrophils compared to 
non-stimulated neutrophils. Non-stimulated neutrophils caused little 
appreciable change in the structure of the fibrin matrix over a period 
of 15 to 60 minutes (figure 5, right panel). These cells did not appear 
to undergo major morphological changes and remained rounded 
throughout the period of observation. In contrast, PMA stimulated 
neutrophils induced marked changes in the appearance of the fibrin 
matrix over the same time period (figure 5, left panel). At 15 
minutes, the fibrin matrix appeared relatively dense with few visible 
neutrophils, but by 30 minutes the matrix had thinned substantially 
and more neutrophils had become exposed. The cells appeared far 
more concentrated due to collapse of the fibrin architecture, and 
many neutrophil aggregates were present. PMA stimulated cells 
underwent dramatic shape changes, exhibiting extensive pseudopod 
formation as well as vacuolation. By 60 minutes, hardly any fibrin 
was present in the vicinity of neutrophils and disintegration of the 
clot resulted in a highly concentrated mass of neutrophils, most of 
which were in aggregates. These findings suggest that neutrophil 
mediated fibrinolysis is markedly upregulated following stimulation 
with PMA. 
Figure 5 (Opposite): Scanning electron micrographs showing fibrin 
solubilisation by PMA stimulated and non-stimulated neutrophils. PMA 
(10ng/ml) stimulated or non-stimulated neutrophils (20 x 1061ml) were incorporated 
within polymerising fibrin clots (1mg!ml) for 15-60 minutes at 37'C. Samples were 
then fixed and analysed by scanning electron microscopy. Clots containing PMA 
stimulated neutrophils are shown in the left hand panel and those containing 
resting neutrophils are shown on the right (Magnification x 5000). These samples 
are shown at higher magnification (x 10 000) on the following page. 
PMA stimulated Non-stimulated 
15 minutes 15 minutes 
30 minutes 30 minutes 
60 minutes 60 minutes 
PMA stimulated Non-stimulated 
15 minutes 15 minutes 
30 minutes 30 minutes 
60 minutes 60 minutes 
Figure 5. Scanning electron micrographs showing fibrin internalisation by PMA stimulated and 
non-stimulated neutrophils. See previous page (Magnification x 10000). 
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The role of granule proteases in fibrin dissolution 
The possibility that PMA upregulated neutrophil mediated 
fibrinolysis by inducing release of azurophil granules was considered. 
Indeed, concurrent experiments (see chapters 4 and 5) revealed 
biochemical evidence to suggest that low dose PMA is capable of 
inducing azurophil granule release. Moreover, during the present 
study PMA stimulated neutrophils were noted to have a less granular 
cytoplasm than non-stimulated neutrophils and occasional granules 
were noted on the neutrophil surface (figure 6). It was possible, 
however, that these observations were due to processing steps during 
cryoultramicrotomy, which can result in extraction of cytoplasmic 
organelles. As a result, resin embedded sections of PMA stimulated-
and non-stimulated neutrophils incorporated within fibrin matrices 
(37°C, 30 minutes) were used for a comparison of cytoplasmic 
granule content. This revealed the cytoplasm of non-stimulated 
neutrophils to be densely packed with granules whilst the majority of 
PMA stimulated neutrophils showed a decrease in granule content 
(figure 7). • The distribution of granules appeared to be altered in 
PMA stimulated neutrophils; there was a tendency for granules to 
redistribute towards the periphery of the cytoplasm with a relative 
depletion in the perinuclear area. These findings suggest that PMA is 
capable of inducing significant release of cytoplasmic granules under 
these conditions. 
Analysis of fibrin degradation products: SDS-PAGE 
To determine whether the release of neutrophil granules contributed 
to the fibrinolytic activity of the neutrophil membrane, membrane-
• Although attempts were made to quantify these differences, a quantitative comparison 
was precluded by a number of technical factors: Cell to cell comparisons could not be 
made because the diameters of cells differed depending upon which part of the cells 
were sectioned. Granule density per unit area was also not reliable due to distortions in 
the shape of PMA stimulated neutrophils as well as extensive vacuolation, which 
necessitated the selection of specific areas to examine, thereby introducing an element of 
subjectivity. As a result the comparison was made purely qualitatively. The differences 
between non-stimulated and stimulated neutrophils (figure 7) were clearly visible and 
were confirmed by an unbiased observer. 
Figure 6: Transmission electron micrographs showing granules on the surface of a cryosectioned 
neutrophil. (a) Cytoplasmic granules (G) were occassional/y seen on the plasma membranes (Pm) of 
PMA stimulated neutrophils incorporated within fibrin (Fn) matrices during the experiments described in 
figure 2. (b) The same granules seen at higher magnification. 
Figure 7: Transmission electron mlcrographs showing the cytoplasmic granule content of PMA 
stimulated and non-stimulated neutrophils. PMA (1 0nglml) stimulated and non-stimulated neutrophils 
(20 million/ml) were incorporated within fibrin matrices for 30 minutes at 37 degrees C. Samples were 
fixed, resin embedded and analysed by transmission electron microscopy. Representative micrographs 
show: (a) A non-stimulated neutrophil with densely packed cytoplasmic granules; (b) A higher magnific-
ation view of the cytoplasm of a non-stimulated neutrophil; (c) A PMA stimulated neutrophil with a lower 
density of cytoplasmic granules and vacuolation (Va) of the cytoplasm (Fn = fibrin, Nu = nucleus); (d) A 
higher magnification view of the cytoplasm of a PMA stimulated neutrophil. 
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associated fibrinolytic activity was compared to that of granule 
proteases· with respect to the [1251]-labelled degradation products that 
it generated. The conditioned medium of PMA (5ng/ml) stimulated 
neutrophils was used as a source of the membrane associated 
protease.4,7 Degradation reactions were performed over a range of 
different protease concentrations and products were analysed by 
SDS-PAGE and autoradiography. 
When sufficiently diluted, preparations of granule proteases 
generated identical appearing fibrin degradation products to those 
generated by the conditioned medium (figure 8). This suggests that 
the fibrinolytic activity of the conditioned medium (and therefore the 
neutrophil membrane) is due to proteases of the azurophil granule. 
Conditioned Granule 






1 2 3 1 2 3 
• Prepared as in Chapter 5, Methods, page 128. 
Figure 8: A comparison of fibrin 
products generated by PMA 
stimulated neutrophil conditioned 
medium versus granule 
enzymes. [1251]-labelled fibrin 
clots (125µg, 100µ1) were 
incubated with either conditioned 
medium or granule enzymes 
(37'C, 20 hours). The proteolytic 
products generated were 
analysed by SOS-PAGE (10%, 
reducing) and autoradiography. 
Left panel lanes 1-3 show fibrin 
degradation products generated 
by conditioned medium from 3-, 
3.5-, and 4 x 106 PMA stimulated 
neutrophils, whilst the right panel 
shows fibrin degradation 
products generated by granule 
enzymes (see Methods} from 
1.6-, 2- and 2.4 x 1a5 neutrophils 
respectively. 
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Discussion 
The initial purpose of this study was to determine the extent to which 
intracellular fibrin degradation contributed to neutrophil mediated 
fibrinolysis reported in earlier studies.4'7 
Over the period in which complete fibrin dissolution was observed 
(macroscopically), immunoelectron microscopy revealed only a small 
percentage (<5%) of neutrophils to contain intracellular fibrin, 
suggesting that the neutrophil mediated fibrinolysis described m 
previous studies,4'7 is predominantly an extracellular event. 
Whilst other studies have reported neutrophil internalisation of 
fibrin,8'9 these studies differed in experimental design from the 
present study. Riddle and Barnhart8 studied fibrin clots infiltrated 
with canine neutrophils. These were generated by placing fibrin 
coated glass coverslips over denuded areas of skin created by 
Rebuck's skin window technique. An inflammatory infiltrate, 
consisting almost entirely of neutrophil and eosinophil granulocytes, 
was present in the fibrin matrix. 8 Indirect immunofluorescence 
microscopy revealed diffuse intracytoplasmic staining for fibrinogen 
in these neutrophils, whilst electron microscopy, demonstrated 
neutrophil internalisation of fibrin via extrusion of pseudopodia into 
the fibrin mass isolating smaller fibrin particles.8 Lewis et al,9 studied 
neutrophil mediated fibrinolysis in glycogen stimulated dog 
peritoneal neutrophils incubated with particulate fibrin and, using 
electron microscopy, demonstrated internalisation and degradation of 
fibrin particles.9 The present study, based on that of Adams et al,4'7 
studied fibrinolysis by purified human neutrophils incorporated into 
polymerising fibrin clots. Only a very small percentage of neutrophils 
were demonstrated to internalise fibrin over a period in which 
complete dissolution of fibrin was achieved. Thus, whilst fibrin 
internalisation may contribute to neutrophil mediated fibrinolysis 
under certain experimental conditions, &,9 this does not appear to 
occur under the conditions employed in the present study. 
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During the course of this study, PMA stimulated neutrophils were 
noted to achieve complete fibrin dissolution over a time period in 
which no appreciable changes were observed in the appearance of 
clots containing non-stimulated neutrophils. These observations were 
confirmed at an ultrastructural level by scanning electron microscopy 
which showed PMA stimulated neutrophils to cause complete 
destruction of the fibrin matrix at 60 minutes whilst non-stimulated 
neutrophils had little appreciable effect. 
Studies measuring the rate of [125I]-labelled fibrin solubilisation also 
revealed neutrophil mediated fibrinolysis to be upregulated following 
stimulation with PMA. At 90 minutes PMA stimulated neutrophils 
achieved full solubilisation of the fibrin clot whereas non-stimulated 
neutrophils achieved less than ·so% solubilisation. The solubilisation 
of [125I]-labelled fibrin by non-stimulated neutrophils was far higher 
than suggested by macroscopic observations and scanning electron 
microscopy. A closer consideration of the experimental design used 
to quantify [125I]-labelled clot solubilisation may explain this 
discrepancy. The design is such that [125I]-labelled fibrinogen (under 
the action of thrombin) is allowed to polymerise around neutrophils 
in the reaction mixture. It has been assumed that a measure of clot 
solubilisation can be made by subtracting the radioactivity not 
incorporated into a cell free ( control) clot from the radioactivity 
released from a clot by incorporated neutrophils. However this may 
not represent an accurate measure of the neutrophil mediated clot 
solubilisation since neutrophils (non-stimulated and stimulated) 
cleave fibrinogen to a non-clottable form. 1° Fibrinogenolysis occurs 
very quickly and minor alterations in molecular weight profoundly 
affect fibrinogen clottability.* Thus in the presence of neutrophils, 
both clot formation and the generation of non-clottable fibrinogen are 
competing. The generation of non-clottable fibrinogen is impossible 
to quantify but the soluble radioactivity monitored during clot 
• Degradation of fibrinogen (340 kDa) to a 330 kDa fragment is reported to be 
associated with 60% increase in the thrombin clotting time (a measure of the time 
required for fibrin formation), whilst further proteolysis to a 310 kDa fragment 
increases the thrombin clotting time by over 700%. 10 Analysis of earlier data, 
suggests that, under the conditions employed in the current study, neutrophil 
mediated proteolysis (by both non-stimulated and PMA stimulated neutrophils) 
may have a significant effect on fibrinogen clottability as early as 5-10 minutes 
following its exposure to neutrophils.5•10 
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dissolution by neutrophils is a composite of (1) non-incorporated 
fibrinogen, (2) non-clottable fibrinogen products and (3) solubilised 
fibrin. Thus, merely subtracting the soluble radioactivity of the cell 
free control clot may provide a falsely high measure of fibrin · 
dissolution by incorporated neutrophils. 
As PMA stimulated neutrophils have been shown to generate non-
clottable fibrinogen degradation products more quickly than non-
stimulated neutrophils,9 the accuracy of quantification of [I25I]-
labelled fibrinolysis might be worse affected in the case of PMA 
stimulated cells. It might therefore be argued that the lower density of 
clot around PMA stimulated neutrophils (observed macroscopically 
and by scanning EM) at 60 minutes may, in part, reflect an initial 
decreased availability of clottable fibrinogen rather than digestion of 
the fibrin clot. The initial density of the clot might also affect the 
speed of fibrin dissolution but the experiments conducted in this 
study could not assess this. Recent reports suggest that release of 
HNE in response to low dose PMA is time dependent. I I Therefore 
the HNE content in the extracellular medium of PMA stimulated and 
non-stimulated neutrophils may not be that different during the 
period in which the rate of fibrin polymerisation is maximal (0-10 
minutes - see figure 4b stippled line). Moreover, it is also known that 
ligation of integrin receptors on activated neutrophils by ECM 
proteins is a powerful stimulus for granule release. I2 Therefore the 
stimulatory effect of PMA on azurophil granule release might only be 
maximal once the fibrin matrix has formed. The extensive clot 
formation seen around neutrophils at 15 minutes (both 
macroscopically and by scanning EM) which was similar for PMA 
stimulated and non-stimulated neutrophils, would support this 
suggestion. 
Whatever the mechanisms involved, it is clear that fibrin clots 
formed around PMA stimulated neutrophils are dissolved far more 
rapidly than those formed around non-stimulated neutrophils. These 
findings suggest the importance of neutrophil activation in 
fibrin(ogen)olysis under these conditions. It should be mentioned, 
however, that whilst non-stimulated neutrophils had little effect on 
fibrin clot size or structure during the period under investigation (90 
minutes), these cells were eventually able to effect fibrin dissolution, 
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usually after 3-4 hours (as judged macroscopically). This fibrinolysis 
was most likely the consequence of neutrophil activation which is 
known to occur in isolated neutrophils during prolonged incubation 
at 37°C.13 In addition, it is also possible that fibrinopeptide B (a 
known chemotactic factor for neutrophils)14 released by thrombin, 
may contribute to neutrophil activation over time, as may thrombin 
itself. 15 Moreover, any neutrophil activation that does occur is likely 
to be amplified by ligation of integrin receptors following interaction 
with the fibrin matrix, a process known to trigger neutrophil 
activation responses. 12' 16' 17 Such activation may trigger the 
mobilisation and release of azurophil granules with an associated 
increase in fibrin degrading activity. Indeed, the periodic release of 
individual azurophil granules (with accompanying bursts of 
proteolytic activity) has recently been documented in neutrophils 
incubated at 3 7°C in fibronectin coated wells, in the absence of any 
exogenous stimuli. 18 It is possible that similar events may account 
for the fibrinolytic activity of non-stimulated neutrophils 
incorporated within fibrin matrices. 
The relatively low capacity of non-stimulated neutrophils to effect 
fibrinolysis compared to that reported in previous studies4' 7 may 
reflect differences in the neutrophil activation state following 
isolation procedures. In the present study, a number of adaptations 
were made to neutrophil isolation procedures employed in previous 
studies in order to minimise the neutrophil activation that can occur 
during these procedures. 13' 19 These included the use of autoclaved 
glassware and pipette tips as well as sterile filtered buffers.· In 
addition, all steps following Ficoll centrifugation and dextran 
sedimentation, were performed at 4 °C to minimise neutrophil 
activation. 
It was possible that the mechanism by which neutrophil activation 
accelerated clot lysis was through the release of azurophil granule 
proteases. Concurrent studies had just revealed that stimulation with 
a low dose of PMA was capable of inducing release of azurophil 
granule proteases ( chapters 4 and 5), and that these proteases were 
most likely responsible for the proteolytic activity of the neutrophil 
conditioned medium previously ascribed to a novel membrane 
associated protease.4-6 Transmission electron microscopy was thus 
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undertaken to compare the granule content of fibrin entrapped 
neutrophils in the presence and absence of PMA. This revealed a 
marked decrease in the density of cytoplasmic granules in PMA 
stimulated compared to non-stimulated neutrophils. The present 
study did not attempt to distinguish between the various granule 
subsets, and therefore cannot conclude that the granules released 
necessarily included azurophil granules. These findings are, however, 
in conflict with earlier studies reporting no morphological evidence 
of degranulation under these conditions. 7 This is important, as these 
observations had been used to exclude the release of azurophil 
granule proteases under these conditions, allowing neutrophil mediated 
fibrinolysis to be solely ascribed to a membrane associated protease.4'7 
This membrane associated proteolytic activity had been further 
distinguished froin that of azurophil granule proteases on the basis of 
the fibrin degradation products that it generated, which had distinctly 
different apparent molecular mass values to those generated by 
preparations of granule proteases. 4' 7 The present study showed, 
however, that when sufficiently diluted, preparations of granule 
proteases generated fibrin degradation products with identical 
apparent molecular mass values to those produced by a frequently 
used source of the membrane associated protease. It thus appears that 
the previously reported neutrophil mediated fibrinolysis,4'7 is due to 
azurophil granule proteases released as a result of neutrophil 
activation. 
Finally, it has been reported that egress of proteolytic activity from 
PMA stimulated neutrophils is enhanced in the presence of fibrin, 
and that this effect can be blocked by monoclonal antibodies directed 
against the integrin receptor CD11c/CD18.7 The present study 
suggests that these findings most likely reflect the enhanced 
mobilisation and release of azurophil granules from PMA stimulated 
neutrophils following ligation of P2-integrin receptors by the fibrin 
matrix. 
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Summary and conclusions 
Neutrophil mediated fibrinolysis, under the conditions employed in 
this study, is predominantly an extracellular event occurring both at 
the neutrophil membrane and in the surrounding medium. It is 
markedly upregulated following activation with PMA, most likely on 
the basis of azurophil granule protease release. Fibrinolysis by non-
stimulated neutrophils is far slower than with PMA stimulated cells, 
and is most likely due to partial activation of these cells during 
isolation procedures and during prolonged incubation at 3 7°C. Such 
activation, may be augmented via interactions with the fibrin matrix 
and can result in release of azurophil granules with subsequent 
degradation of the fibrin matrix. These findings are in keeping with 
biochemical evidence presented in chapter 5 suggesting that the 
fibrinogen degrading activity of the neutrophil membrane is due to 
azurophil granule proteases. 
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Chapter Eight 
Summary and conclusions 
This study aim~d to purify a 600 kDa membrane associated 
protease reported to degrade fibrinogen, fibrin and C-reactive 
protein. 1•3 This protease, which had been implicated in a variety of 
biological processes, i-s appeared to be distinct from proteases of the 
azurophil granule on the basis of its molecular weight, its inhibitor 
profile and the nature of the products that it generated. 1 •3 
The present study explored various avenues whereby this protease 
could be purified and further characterised. Although unsuccessful, 
several observations made during purification attempts led to the 
realisation that this proteolytic activity had similar properties to that 
of proteases of the azurophil granule. 
o AEBSF affinity chromatography isolated proteolytic activity 
from soluble neutrophil cytoskeleton proteins that was identified 
by SDS-PAGE to contain proteins that had a mobility 
corresponding to that of proteases of azurophil granules. 
o The conditioned medium from neutrophils stimulated with a low 
dose of PMA contained proteins with similar electrophoretic 
mobility to those of a conditioned medium known to contain 
azurophil granule proteases. 
o The conditioned medium from neutrophils stimulated with a low 
dose of PMA generated products from plasminogen with a 
similar electrophoretic mobility to those generated by HNE. 
When these results were considered together with reports on the 
existence of catalytically active, membrane-bound forms of HNE, 
cathepsin G, and proteinase 3,9-13 the possibility that these proteases 
might be part of the proteolytic activity of the 600 kDa protease was 
considered. In this study poor solubility of lyophilised enzyme 
preparations was noted and this may account for the poor 
reproducibility of the migration of bands to regions of the gel 
previously reported to contain the proteolytically active subunits of 
the 600 kDa protease. This prompted the consideration that the 
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proteolytic activity in these preparations might represent aggregates 
of proteases of azurophil granule origin. It is known that the 
azurophil granule proteases are highly cationic and have a tendency 
to form heteroaggregates with negatively charged proteoglycans. 14 
Results from this study show quite clearly that the proteolytic activity 
previously ascribed to a 600 kDa protease is of azurophil granule 
origin. This conclusion is based on results of inhibitor profiles, the 
molecular size and hydrophobicity of the generated degradation 
products and peptides, and the molecular size of the proteolytic 
activity. The use of zymography as well as extensive experiments 
involving enzyme/substrate dose response studies and enzyme-
inhibitor investigations were fundamental in obtaining the results that 
allowed this conclusion to be made. Previous studies analysed the 
molecular size of the protease by eluting the proteolytic activity from 
polyacrylamide gels after separation of concentrated enzyme 
preparations by SDS-PAGE.1•3 In contrast, the present study 
employed zymography to determine the molecular mass of this 
proteolytic activity. 15 Due to the sensitivity of this technique, 
concentrating steps are not required prior to electrophoresis and 
therefore problems with aggregation of the enzyme species are 
overcome. 
Fibrinogenolysis has been shown in this study to be predominantly 
due to HNE, with cathepsin G playing a lesser role and proteinase 3 
also possibly involved. It is clear that the concentration of azurophil 
granule proteases determines the extent of fibrinogenolysis - i.e. the 
molecular size of the terminal degradation products is enzyme 
concentration dependent. In previous studies, where high 
concentrations of HNE were employed to degrade fibrinogen, it was 
concluded that since the electrophoretic mobility of the generated 
products was different from that of products generated by the 
proteolytic activity of the neutrophil membrane, membrane 
associated HNE was not responsible for fibrin( ogen)olysis.2•3 Thus 
the size of the generated degradation products is not conclusive in 
deciding the nature of the protease involved until extensive enzyme-
substrate dose response curves have been analysed. The low 
concentration of proteolytic activity in PMA stimulated neutrophil 
conditioned medium also accounts for the reported presence of HNE 
sensitive sites in what appeared to be the terminal fibrinogen 
degradation products generated by the conditioned medium.2 
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From this study it has also become apparent that the concentration of 
azurophil granule proteases determines the process of 
fibrinogenolysis. PMA stimulated neutrophil conditioned medium 
has been shown, in a previous study, to cleave fibrinogen from the N-
terminus of the Aa chain and the C-terminal regions of BP and y 
chains. 2 Other studies have reported the cleavage of fibrinogen from 
the N-terminus of all three chains by neutrophil lysates and pure 
HNE. 16"19 These apparent discrepancies in the process of 
fibrinogenolysis may well reflect the concentration of enzyme being 
used. 
Concurrent with purification attempts, studies were undertaken to 
investigate one of the reported consequences of this membrane 
associated proteolytic activity. A previous study suggested that low 
molecular weight fibrinogen products (FDP) generated by the 
membrane protease could associate with neutrophil P2-integrin 
receptors blocking subsequent adhesion to fibrinogen coated 
surfaces.4 Thus it seemed that FDP might, through blockade· of P2-
integrin receptors, modulate neutrophil responses at sites of 
inflammation. The present study aimed to confirm the association of 
FDP with integrin receptors. 
Irnmunoelectron microscopy detected fibrinogen within the 
neutrophil and not on the membrane. This uptake process in the 
presence of high doses of fibrinogen (as used in previous studies 
investigating intact neutrophil processing of fibrinogen) is facilitated 
to a large extent by a non-specific pinocytic process. However an 
initial specific interaction with the neutrophil surface cannot be ruled 
out. The receptors involved in the putative interaction of fibrinogen 
with the neutrophil were not investigated in this study. However, 
fibrinogen has been shown in previous studies to effect the release of 
proteolytic activity (shown in this study to be azurophil granule 
proteases) from neutrophils which promotes its degradation in the 
extracellular medium.4 It has been suggested that this interaction 
occurs near the CD 11 c/CD 18 receptor as monoclonal antibodies 
directed against this receptor were found to cause marked inhibition 
of fibrin(ogen)olysis. 4 It is interesting to note that ligation of Pr 
integrin receptors by soluble ICAM-1 has recently been reported to 
induce release of HNE from neutrophils.20 This suggests that other 
soluble ligands for P2-integrin receptors may also have the ability to 
induce azurophil granule release. 
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The inability to detect surface associated fibrinogen by 
immunoelectron microscopy might be due to a combination of its 
rapid internalisation and its rapid degradation by membrane 
associated azurophil granule proteases following its interaction with 
the surface. Such a notion is supported by previous reports that HNE 
proteolysis facilitates detachment of neutrophils bound to fibrinogen 
coated surfaces.21 
It appears that neutrophils internalise both intact and degraded forms 
of fibrinogen. Degradation of these internalised proteins and partial 
release of low molecular weight fibrinogen degradation products into 
the extracellular medium then takes place. This route of 
fibrinogenolysis contributes minimally to the overall extent of the 
degradation process during incubation of fibrinogen with neutrophils 
as only a fraction of a percent of the fibrinogen in the surrounding 
medium is internalised by neutrophils under these conditions. The 
majority of neutrophil mediated fibrinogenolysis occurs thus via 
extracellular proteolysis, shown during this study to be due to 
azurophil granule proteases. 
In view of the ability of PMA stimulated neutrophils to internalise 
and digest material in the pericellular environment, it was possible 
that similar endocytic activity might contribute to the process of 
fibrin clot lysis previously ascribed solely to the neutrophil 
membrane. 3 Having recently established techniques for the 
immunolocalisation of fibrinogen, these were applied to determine 
whether internalisation of fibrin played a significant role in 
neutrophil mediated fibrinolysis under these conditions. 
Immunoelectron microscopy revealed minimal evidence of fibrin 
internalisation during the period in which complete fibrinolysis 
occurred, supporting the earlier suggestion that neutrophil mediated 
fibrinolysis, under these conditions, is an extracellular event. 
During this study it was noted that PMA stimulated neutrophils were 
able to achieve complete fibrin dissolution over a time period in 
which no appreciable changes were observed in the appearance of 
clots containing non-stimulated neutrophils. These macroscopic 
observations were supported both by studies measuring [1251]-labelled 
fibrin solubilisation and by scanning electron microscopy. Scanning 
electron microscopy revealed morphological features of activation in 
' ,• .... ,f 
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neutrophils stimulated . with PMA, whilst transmission electron 
microscopy showed a decrease in the density of cytoplasmic granules 
in these cells with a redistribution of granules towards the periphery 
of the cytoplasm. This raised the possibility that clot lysis by PMA 
stimulated neutrophils might be mediated by the mobilisation of 
azurophil granules. Further studies revealed that, when used at 
sufficiently low concentrations, granule proteases generated fibrin 
degradation products with apparent molecular mass values identical 
to those generated by the conditioned medium of PMA stimulated 
neutrophils. Thus both morphological and biochemical evidence 
support a conclusion that the previously documented 
fibrin( ogen)olytic activity of the neutrophil membrane2-5 is mediated 
by proteases of granule origin. 
Previous studies have drawn attention to the important role played by 
the proteolytic activity of the neutrophil membrane which, through its 
ability to degrade fibrinogen, fibrin and C-reactive protein, may 
influence a number of biological processes.1-8 The ability of 
membrane associated proteolytic activity to degrade fibrinogen and 
fibrin has emphasised the close relationship between the coagulation 
and inflammation pathways. The present study confirms the ability of 
the neutrophil to degrade fibrin( ogen), and provides biochemical and 
morphological evidence to suggest that this proteolytic activity is due 
to proteases of the azurophil granule. It has become increasingly 
apparent-that membrane bound forms of azurophil granule proteases, 
through their ability to evade inhibition by naturally occurring 
protease inhibitors, may represent the biologically relevant forms of 
these proteases.9-13 Therefore, taken together with studies which first 
identified the fibrinogen-, fibrin- and CRP-degrading activity of the 
neutrophil membrane, this study adds to the growing body of 
evidence that membrane bound forms of azurophil granule proteases 
may influence a variety of important biological processes. 
Chapter 8 224 
References 
1. Shephard EG, Kelly SL, Anderson R, Fridkin M. (1992) Clin. Exp. Immunol. 87, 
509. 
2. Kelly SL, Adams SA, Robson SC, Kirsch RE, Shephard EG. (1994) Biochem. J. 
298,689. 
3. Adams SA, Kelly SL, Kirsch RE, Robson SC, Shephard EG. (1995) Blood Coag. 
Fibrinol. 6, 693. 
4. Kelly SL. (1995) A neutral protease of the neutrophil surface: Role in the proteolyis 
ofC-reactive protein and fibrinogen.(PhD Thesis, University of Cape Town) 
5. Adams SA. (1996) Proteases of the neutrophil membrane represent an alternative 
fibrinolytic pathway to that mediated by plasmin. (PhD Thesis, University of Cape 
Town). 
6. Shephard EG, De Beer SM, Anderson R, Strachan AF, Nel AE, De Beer FC. (1989) 
J. Immunol. 143, 2974. 
7. Shephard EG, Anderson RA, , Rosen 0, Myer MS, Fridkin M, Strachan AF, De 
Beer FC. (1990) J. Immunol. 145, 1469. 
8. Shephard EG, Anderson RA, Rosen 0, Fridkin M. (1992) Immunology. 76, 79. 
9. Bangalore N, Travis J. (1994) Biol. Chem. Hoppe Seyler. 375,659. 
10. Owen CA, Campbell MA, Sannes PL, Boukedes SS, Campbell EJ. (1995) J. Cell 
Biol. 131, 775. 
11. Owen CA, Campbell MA, Boukedes SS, Campbell EJ. (1997) Amer. J. Physiol. 
272, L385. 
12. Gaudin P, Berthier S, Barro C, Zaoui P, Morel F. (1997) Eur. J. Cell. Biol. 72,345. 
13. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. (1994) Clin. Exp. 
Immunol. 95, 244. 
14. Gullberg U, Andersson E, Garwicz D, Lindmark A, Ohlsson I. (1997) Eur. J. 
Haematol. 58, 137. 
15. Lantz MS, Ciborowski P. (1994) Meth. Enzymol. 235(A) Chapter 45. 
16. Plow EF, Edgington TS. (1975) J. Clin. Invest. 56, 30. 
17. Gramse M, Bingenheimer C, Schmidt W, Egbring R, Havemann K. (1978) J. Clin. 
Invest. 61, 1027. 
18. Bilezikian SB, Nossel HL. (1977) Blood. 50, 21. 
19. Gramse M, Bingenheimer C, Havemann K. (1980) Thromb. Res. 19,201. 
20. Barnett CC, Moore EE, Mierau GW, Partrick DA, Biffl WL, Elzi DJ, Silliman CC. 
(1998) Am. J. Physiol. 274, Cl 634. 
21. Cai T-Q, Wright SD. (1996) J. Exp. Med. 184, 1213. 
Appendices 225 
Appendix 1: Chemicals & Reagents 
An chemicals and reagents were obtained from Sigma Chemical 
Co. (St. Louis, MO) except for those listed below. 
Iodination 
[1 251]-Na was purchased from Amersham (Buckinghamshire, UK), 
and iodogen from Pierce and Warinner (Cheshire, UK). 
Neutrophil isolation 
Dextran T-500 was obtained from Pharmacia (Uppsala, Sweden). 
Hanks balanced salt solution (HBSS) was obtained from Gibco/Life 
Technologies (Paisley, Scotland) and HEPES buffered HBSS was 
obtained fromHighveld Biological (Johannesburg, South Africa). 
Affinity chromatography 
Tosylactivated superparamagetic polystyrene beads (Dynabeads®) 
were obtained from Dynal (Oslo, Norway). Affigel 10 affinity matrix 
was obtained from Biorad (California, USA). AEBSF ([2-
aminoethyl]-benzenesulphonyl fluoride) was obtained from 
Boehringer Mannheim (Mannheim, Germany). · 
Molecular biology 
Oligonucleotide probes for the screening of cDNA libraries were 
synthesised by Genosys Biotechnologies (Cambridgeshire, UK). A 
human bone marrow cDNA library, together with the E. Coli strain 
K802, were purchased from Clontech laboratories (California, USA). 
Hybond-N™ nylon membranes, [y-32P]ATP and T4 polynucleotide 
kinase were obtained from Amersham (Buckinghamshire, UK). 
Sephadex PD-50 was obtained from Pharmacia (Uppsala, Sweden), 
Formamide was from Merck (Darmstadt, Germany). 
Polyacrylamide gel electrophoresis and transblotting 
A kit containing pre-stained molecular weight markers for use in 
SDS-PAGE was purchased from Amersham (Buckinghamshire, UK). 
This kit contained myosin (200 kDa), phosphorylase b (97 kDa), 
bovine serum albumin (69 kDa), ovalbumin (46 kDa), carbonic 
anhydrase (30 kDa), trypsin inhibitor (21 kDa) and lysozyme (14 
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kDa). For autoradiography, Kodak XAR-5 film (Eastman Kodak, 
Rochester, NY) was used. Silver staining was performed using a 
silver staining kit obtained from Amersham (Buckinghamshire, UK). 
Polyvinylidene difluoride (PVDF) protein sequencing membrane 
(lmmobilion™-PSQ) was purchased from Millipore Corporation 
(Bedford, USA). 
Fibrinogen proteolysis 
The cathepsin G inhibitor, Z-Gly-Leu-Phe-CMK was purchased from 
Enzymes Systems Products (Livermore, USA). Chymostatin was 
obtained from Boehringer Mannheim (Mannheim, Germany). Human 
neutrophil elastase was purchased from Calbiochem (San Diego, 
USA). Acetonitrile was from Baxter Healthcare Corporation 
(Michigan, USA). Diethyl ether and LiChrosorb RP-18 were 
obtained from (Merck). 
lmmunoelectron microscopy and immunohistochemistry 
Rabbit anti-human fibrinogen antibody (purified IgG fraction) and 
non-immune rabbit lgG were a kind gift from Brent Jennings 
(MRC/UCT Liver Research Centre, Cape Town, South Africa). 
Mouse monoclonal anti-CDllb and anti-CD18 were obtained from 
Sanbio (Uden, Netherlands). 30nm-gold conjugated antimouse lgG 
antibody and 1 Onm-gold conjugated streptavadin were obtained from 
Amersham (Buckinghamshire, UK), 15nm-gold conjugated goat 
antibiotin antibody was from Nanoprobes (New York, USA), 5nm-
gold conjugated goat antirabbit lgG antibody was from Zymed (San 
Fransisco, USA). Streptavadin, biotinylated swine antirabbit lgG and 
horseraddish peroxidase conjugated streptavadin were obtained from 
Dako (Glostrup, Denmark). Bovine serum albumin was obtained 
from Seravac (Cape Town, South Africa). Hydrogen peroxide, 
sucrose, gelatin (microbiology grade), glutaraldehyde 25% (electron 
microscopy grade) and paraformaldehyde ( electron microscopy 
grade) were obtained from Merck (Darmstadt, Germany). Spurr's 
resin was obtained from Agar Scientific Limited (Stanstead, UK). 
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bovine serum albumin 
biotinylated bovine serum albumin 
C-reactive protein 
3rd component of complement, fragment b 
3rd component of complement fragment b (inactivated) 
5th complement component, fragment a 
complement receptor 1 




epidermal growth factor 
electron microscopy 
fibrinogen 
fibrin( ogen) degradation product 
N-formyl-methionyl-leucyl-phenylalanine 
N-formyl-norleucyl-leucyl-phenylalanine 
Hanks balanced salt solution 
N-[2-Hydroxyethyl]piperazine-N' -[2-ethanesulphonic 
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lymphocyte function associated antigen 1 






nicotinamide adenine dinucleotide phosphate 
superoxide anion 
platelet activating factor 
plasminogen activator inhibitor 
phosphate buffered saline 
phosphate buffered saline containing BSA 
phorbol 12-myristate 13-acetate 
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Appendix 3: Additional experimental data 
Chapter 4 - Proteolysis of plasminogen 
Proteolytic modification of plasminogen by pancreatic elastase has 
been reported to generate proteolytic fragments which have anti-
angiogenic effects. 1'2 As part of the further characterisation of the 
proteolytic potential of the 600 kDa neutrophil membrane protease, 
studies were undertaken to investigate whether it was capable of 
similar proteolytic modification. Preliminary experiments revealed 
the neutrophil conditioned medium to generate several products 
within the 45 kDa region of the gel. N-terminal sequencing of these 
products identified a fragment containing the kringle 5 domain of 
plasminogen, which is known to have anti-angiogenic activity.2 In 
one experiment, the pattern of plasminogen degradation by the 
conditioned medium was compared to that of purified HNE. Human 
plasminogen (62.5µg) was 
incubated (37°C, 3-8 hours) 
with either the conditioned 
medium from 106 PMA 
( 5ng/ml) stimulated neutrophils, 
in a final volume of 200µ1 (left 
hand panel in gel opposite) or 
with purified HNE (0.3µg) in a 
final volume of 100µ1 (right 
hand panel). As a control, 
plasminogen was incubated at 
3 7°C for 8 hours in the absence 
of proteases (far right hand 
lane). It can be seen that the 
products generated by these two 
sources had similar apparent 
molecular mass values. 
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Chapter 5 - Additional experimental data 
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Fiflure 1 (see page 132): The effect of MeO-Suc-(Ala)2-Pro-Val-CH2CI on the 
£1 /J-labelled-fibrinog(!n degrading activity of the conditioned medium. (a) 
[1 251]-labelled fibrinogen (10µg) was incubated (37°C, 1-5 hours) with the 
conditioned medium from 106 PMA (Sng/ml) stimulated neutrophils in a final volume 
of 100µ1. Reactions were performed in the absence (-0-) and presence (-~) of 
MeO-Suc-(Ala)2"Pro-Val-CH2CI (1mM). Degradation was measured as 10% (wlv) 
TCA soluble peptide formation. Each data point represents a single measurement. 
This data is also presented in figure 6b page 139. 
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Chapter 6 - Additional experimental data 
'2 .E 
600 0 
I:'.? z 500 ~ BSA 
a.. 
~ 400 ..... 
Cl 







0 0 a::: 
9:. 0 0.1 0.2 0.3 0.4 0.5 ;;, 
r... [1251]-PROTEIN ADDED {mg/ml) 
Figure 5a (see page174) : Association of [1251]-labelled fibrinogen and BSA with 
PMA stimulated neutrophils (PMN), as a function of concentration. { 251]-label/ed 
fibrinogen (FBGN) or { 251]-label/ed BSA (100-SOOµglml) were incubated (37~ 30 
minutes) with PMA stimulated PMN (5 x 1061ml) in PBS. Association of [ 251]-
labelled protein was measured and expressed as ng { 251]-labelled protein per 106 
PMN. Each data point represents a mean of duplicates. 
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Figure 9a (see page 178): The effect of divalent cations on [1251]-labelled 
fibrinogen association with PMN. (a) { 251]-labelled fibrinogen (100-500µg/ml) was 
incubated (37'C, 30 minutes) with PMA stimulated PMN (5 x 1061ml) in either PBS 
or HEPES buffered HBSS (HIHBSS). Association of [1 251]-labelled fibrinogen was 
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Figure 11 (see page 180): Association of [1251)-labelled fibrinogen with chilled 
PMN as a function of time. Chilled PMA stimulated PMN (prepared as described in 
figure 10) were incubated with [1251]-labelled fibrinogen (100µglml) on ice over a 
time course of 0-90 minutes. Association of [1251]-label/ed fibrinogen was measured 
and expressed as ng per 106 PMN. Each data point represents the mean of 
duplicates. 
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Figure 13 (see page 182): The effect of BSA on the association of {1251)-
labelled fibrinogen with PMN. [1251]-labelled fibrinogen (100 and 250µglml) was 
incubated (37'C, 30 minutes) with PMA stimulated PMN (5 x 1061ml) in the 
presence and absence of BSA (2mglml). Association of [1 251]-label/ed fibrinogen 
was measured and expressed as ng per 106 PMN. Each data point represents the 
mean of duplicates. 
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Figure 4 (see page 205): Comparison of [1 251]-labelled fibrin solubilisation by non-
stimulated and PMA stimulated neutrophils. (Additional experiments 1 and 2) (a) 
Non-stimulated or PMA (Bnglml) stimulated neutrophils (10 x 1061 ml) were 
incorporated (37"C, 10-90 minutes) into 1mg/ml [1 251}-labelled fibrin clots. At 
selected time points solubilised radioactivity was measured and expressed as cpm 
released. The soluble radioactivity associated with cell free control clots was also 
measured at each time point. The progressive decrease in the soluble radioactivity 
seen in cell free control clots reflects fibrinogen polymerisation. (b) This figure 
shows the radioactivity released by stimulated and non-stimulated neutrophils 
experimental samples following the subtraction of radioactivity associated with the 
cell free control at each time point. Data points represent means of duplicates. 
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